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Skeletal mineralisation is dependent on the generation of inorganic phosphate 
(Pi), which has traditionally been attributed to tissue non-specific alkaline 
phosphatase (TNAP). However, evidence exists to suggest the presence of other Pi 
generating phosphatases in bone, with the most compelling being that initial bone 
mineralisation events in newborn TNAP knockout mice appear to be normal, 
although abnormalities of the skeleton and dentition appear later. PHOSPHOl is a 
phosphatase, which belongs to the haloacid dehalogenase (HAD) superfamily of 
magnesium-dependent hydrolases. The work of this thesis has shown that 
PHOSPHOl is able to catalyse the hydrolysis of phosphoethanolamine (PEA) and 
phosphocholine (PCho), which displays favourable kinetics under optimal conditions 
indicating that these reactions would occur in vivo.
Site directed mutagenesis of active site residues, along with molecular 
modelling, confirm this enzyme as a member of the HAD superfamily as well as 
implicating residues in substrate specific interactions. PHOSPHOl protein is 
localised to the mineralising sites of the skeleton and cells of bone and cartilage in 
the mouse model. Further to this PHOSPHOl is present in an active state within 
matrix vesicles, the epicentre of mineral formation. Modulation of PHOSPHOl 
activity through siRNA gene knockdown studies and specific PHOSPHOl inhibitors 
leads to a decrease in the mineralisation potential of cells and matrix vesicles 
respectively. These data further support the hypothesis that PHOSPHOl plays a 
central role in matrix mineralisation, and indicates that the function of PHOSPHOl is 
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Chapter 1 _________________________________________Introduction
Preface
The biochemistry surrounding bone formation is relatively poorly understood 
with proteins that contribute to the initial events of bone formation being suggested 
through hypothesis and speculation. Indeed PHOSPHO1 is a completely novel 
protein which is concentrated at sites of bone formation. This protein could 
conceivably be one of the missing links in unravelling the mechanisms by which 
bones grow and develop. It is amazing that a process such as growth is so poorly 
understood; yes we know that the length of your bones determines your final height 
but the molecular and biochemical processes surrounding growth remains to leave 
biologists scratching their heads. Understanding these mechanisms will give rise to 
novel strategies aimed at therapeutics for bone and soft tissue abnormalities that 
include diseases of great public health concern.
1.1 Skeleton
The skeleton is a highly complex organ with a range of functions spanning 
from support and locomotion to ion homeostasis. The skeleton itself is comprised of 
two different tissues - cartilage and bone (Karsenty, 2003). The bones, which form 
the skeletal frame, are held together by tendons thus providing a scaffold to which 
muscles can attach. The protective role that the skeleton provides cannot be 
understated with the most important organs such as the brain and lungs/heart being 
shielded from physical forces by the skull and ribcage, respectively. In addition to 
this the skeleton has an important role to play in ion homeostasis with large amounts 
of calcium and phosphate stored as hydroxyapatite crystals. Phosphate homeostasis is 
highly important as phosphate forms a major component of all glycolytic compounds
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such as ATP and creatine phosphate due to the intrinsic high energy nature of the
phosphate bond, as well as being used as both an extracellular and intracellular pH 
buffering system. Calcium also has many important roles including acting as a co- 
factor for cellular, enzyme mediated reactions, secondary messengers and also 
regulating blood clotting. Disruption of phosphate or calcium homeostasis can lead 
to hypocalcaemia, osteomalacia and rickets or hypercalcaemia.
1.2 Bone
Two types of bone structure exist; cortical (compact) and cancellous 
(trabecular) bones. Cortical bone makes up approximately 80% of the total skeletal 
mass (Sambrook et al, 1993). This bone type is also known as compact bone due to 
its unporous (2-5%), dense and highly organised nature. It is located along the shafts 
of long bones (figure 1.1 A), such as the tibia and ulna and forms the primary 
constituent of flat bones such as the skull. Cortical bone intrinsically has a high 
resistance to tensile forces due to its compact structure (Skedros et al, 1996), which 
is particularly advantageous in central regions of long bones where bending is likely. 
Compact bones have very few internal spaces, those that do exist are arranged in 
structures called osteons with their Haversian canals and central blood capillaries 
(Havers, 1691). Between each osteon interstitial lamellae are found as shown in 
figure 1.1C. Lamellar bone is made up from parallel deposits of mineralised bone, 
the orientation of which gives the bone a complex rotated plywood-like structure and 
allows the formation of a very strong tissue (Weiner et al, 1999).
Cancellous bone, represents around 20% of the total skeletal mass. 
Cancellous, otherwise known as trabecular or spongy, bone is less dense (porosity
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50-90%), more elastic and has a higher turnover rate than cortical bone. This bone is 
arranged as a scaffold of trabeculae found within the epiphyseal space of long bones 
as shown in figure LIB. Trabecular bone is also found within bones of the skull, ribs 
and spine. The main function of trabecular bone is to allow bones to withstand 
compressive forces felt during movement. For example the force felt during weight 
bearing on the proximal femur is redistributed by the trabecular bone to the cortical 


















Figure 1.1 Structure and components of long bone. (A) The medullary cavity is 
shown which houses the bone marrow. In addition the spongy or trabecular bone is 
shown (within the epiphysis) (www.sirinet.net/~jgjohnso/skeletonorg.html). A 3D 
representation of structure and organisation of trabecular bone is shown in (B). Note 
the organisation of the trabeculae to allow the resistance of compressive forces by 
filling the epiphyseal space (www.gcarlson.com/anatomical_trabecularbone.htm). 
(C) Structure of compact bone found at the diaphyseal region of long bones. Note the 
unporous nature of this bone type when compared to trabecular bone with laminar 
sheets making up the plywood like structure. The central region is the osteon with a 
central Haversian canal and blood capillary (www.histology- 
world.com/audioslides/bone.htm).
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As stated previously mineralised bone is characterised by vast amounts of
hydroxyapatite (calcium phosphate) Caio(PO4)6(OH)2, formed as a result of calcium 
and inorganic phosphate (Pi) precipitation. This mineral forms around 70% of the 
total bone mass and the majority of the inorganic content. The mineral crystals are 
deposited along, and in close relation to bone collagen fibrils. A balanced diet is 
essential for a healthy skeleton as calcium and phosphate are derived from nutritional 
sources, however phosphate can also be produced through the actions of enzymes 
such as alkaline phosphatase. Vitamin D metabolites and parathyroid hormone (PTH) 
are key mediators of calcium regulation, and lack of the former or excess of the latter 
leads to bone mineral depletion.
1.3 Bone Cells
Bone contains three main cell types osteoblasts, osteoclasts and osteocytes. 
Osteocytes are terminally differentiated osteoblasts, which are immobilised within 
mature bone. Osteoblasts are responsible for bone formation and osteoclasts for bone 
resorption thus these two cell types function in a synchronised manner to regulate 
bone turnover.
1.3.1 Osteoblasts
Osteoblasts are derived from multipotent mesenchymal stem cells (stromal 
stem cells) found in the bone marrow and have been described as complex 
fibroblasts, other cell types that can descend from this stem cell include chondrocytes 
(cartilage cells) and adipocytes (fat cells) (Ducy et al, 2000; Aubin et al, 2002). 
Morphologically osteoblasts are cuboidal in shape and are found very close to the
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bone surface and along with their precursors form a very tight layer of cells. The
gene expression profile of the osteoblast is very similar to that of a fibroblast with 
very few bone specific transcripts being produced. The main difference in cell 
function is that osteoblasts have the ability to form an extracellular matrix (osteoid) 
which they can subsequently mineralise (Ducy et al, 2000). The un-mineralised 
matrix is formed mainly from collagen type 1 (approximately 94%) which is laid 
down early in bone formation, with the remainder being taken up with embedded 
proteins such as osteocalcin, osteonectin, osteopontin and bone sialoprotein 
(Sommerfeldt and Rubin, 2001). This stage of matrix production is under strict 
control of growth factors such as fibroblast growth factor (FGF) and insulin like 
growth factor (IGF). IGF-I and IGF-II can stimulate the production of type I collagen 
and decrease its degradation though the inhibition of collagenase expression 
(McCarthy et al, 1989). FGF functions in a complex manner, signalling through the 
FGF receptor can cause inhibition of matrix development through the down 
regulation of collagen type I expression and also stimulation of osteoblastic 
precursors (Hurley and Florkiewicz, 1996). It was originally thought that the 
osteoblast specific transcripts were restricted to Runx2, which is a gene transcription 
factor and osteocalcin, which is a secreted protein with the ability to inhibit 
osteoblastic function (Ducy et al, 1996, 1997), however more recently several other 
osteoblast specific genes including osterix have been described.
Runx2, otherwise known as osteoblast specific factor-2 (OSF2) or core 
binding factor alphal (Cbfal), has the characteristics of a differentiation factor, 
which functions by pushing the cell from a mesenchymal stem cell to one with an 
osteoblast phenotype. During embryonic development Runx2 expression is limited to
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cells which are intended to become osteoblasts (Ducy et al, 1997). In addition, the
expression of this transcription factor in vivo inhibits the differentiation of 
mesenchymal cells into either adipocytes or chondrocytes (Komori, 2006). The Runx 
proteins are homologues of Drosophila gene products known as Runt (Gergen and 
Wieschaus 1985), with particularly high identity within their 128 amino acid DNA 
binding domain motif known as the Runt domain (Kagoshima et al, 1993). In 
addition, a C-terminal proline-serine-threonine-rich (PST) domain is present within 
all Runt proteins and is thought to act as the transcription activation domain 
(Thirunavukkarasu et al, 1998). This protein only binds to DNA in its monomeric 
form, which differs from other members of the Runt family. This is directly due to an 
extra domain known as the AD2 or QA domain. In total three novel domains are 
present in the Runx protein compared with other members of the family thus perhaps 
accounting for its osteoblast specific functions (Thirunavukkarasu et al, 1998). 
Runx2 knockout mice (Runx''') display no bone formation (either endochondral or 
intramembranous) due to the lack of differentiated osteoblasts (Komori et al, 1997).
Osterix is another osteoblast specific transcription factor which belongs to the 
SP family and contains three zinc finger, DNA binding domains. Studies on this 
protein using a knockout mouse model revealed that Osterix^' animals had no 
osteoblasts thus identifying its function as a key transcription factor in osteoblast 
differentiation (Nakashima et al, 2002). It is known that osterix activates gene 
transcription downstream of Runx2 as Runx2 is expressed in mesenchymal stem 
cells of Osterix''' mice but osterix is not expressed in these cells of Runx2~/' mice. 
Overexpression of osterix in mesenchymal stem cells causes an increase in cellular
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proliferation, alkaline phosphatase activity, and ability to form bone nodules further
indicating its importance in osteoblast differentiation (Tu et at, 2006).
A further signalling pathway which directs differentiation into an osteoblast 
phenotype is the canonical Wnt signalling pathway. This pathway is involved in the 
differentiation of mesenchymal stem cells into the cells of the skeletal system, 
stimulation of which is a positive regulator of osteoblastic differentiation. This 
pathway induces cellular differentiation and a post mitotic state by increasing the 
intracellular level of non-phosphorylated (stable) p-catenin through the inhibition of 
glycogen synthase kinase 3 p (GSK3 P) thus promoting the transcription of cell 
specific genes. A natural inhibitor of this pathway Dickkopf-1 (Dkkl), inhibits the 
differentiation of mesenchymal cells into specific cell types by the down regulation 
of nuclear P-catenin and thus gene transcription and also cytoskeletal p-catenin 
inhibiting the formation of adherens junctions, which is a key regulator of 
mesenchymal stem cell differentiation (Gregory et al, 2003).
The Wnt pathway as shown in figure 1.2 functions through the binding of the 
Wnt ligand to a receptor complex consisting of the transmembrane protein frizzled 
(Frz) and lipoprotein-related protein 5 and 6 (LRP-5/6). Stimulation of Frz induces 
the recruitment of the cytoplasmic bridging molecule, disheveled (Dsh), which acts 
to inhibit glycogen synthetase kinase 3p (GSK3P). The function of GSK3p is to 
phosphorylate P-catenin which induces its degradation through the ubiquitin 
mediated pathway, inhibition of which causes an increase in intracellular p-catenin 
which acts in the nucleus causing the activation of the lymphoid enhancer factor 
(LEF)/TCF family of DNA-binding proteins resulting in LEF/TCF-mediated 
transcription (Huelsken and Birchmeier, 2001). This pathway is inhibited naturally
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through the binding of Dkkl to the LRP-5/6 thus antagonising the action of the Wnt
ligand. Simulation of the Wnt pathway through GSK3P inhibition results in the 
upregulation of bone specific transcripts such as osteopontin, collagen type I and V, 
osteocalcin, alkaline phosphatase and Runx2 (Kulkarni et al, 2006). In addition to 
this mesenchymal stem cells from p-catenin^ mice maintain their ability to 
differentiate into chondrocytes, indicating that this pathway is essential for 
osteoblastic differentiation but not to all cell types of the mesenchymal lineage (Hill 
et al, 2005). Runx2 and not osterix is expressed in fi-cateniri1' mice suggesting that 
P-catenin functions on an osteoblast progenitor cell during mesenchymal 
differentiation. Thus Runx2 directs mesenchymal stem cells to a preosteoblast 
phenotype and osterix and P-catenin function to promote differentiation into an 
immature osteoblast (Komori, 2006).
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Figure 1.2 Major components of the canonical Wnt pathway. Stimulation of the 
pathway causes the inhibition of GSK3P thus resulting in an increase of un- 
phosphorylated (stable) P-catenin which results in gene transcription. The inhibitor 
Dkkl inhibits this pathway causing GSK3P to phosphorylate P-catenin thus targeting 
it for ubiquitin mediated degradation (Gregory et al, 2003).
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1.3.2 Osteoclasts
Osteoclasts are multi-nucleated cells, derived from haematopoietic stem cells, 
which resorb mineralised bone at sites known as Howships lacunae (Sommerfeldt 
and Rubin, 2001). This is an essential process (pathway shown in figure 1.3) as it 
allows bone repair as well as allowing sequestration of calcium into the blood to 
maintain ion homeostasis. Bone modelling and re-modelling is a crucial event in 
skeletal development and repair which is strictly controlled by Osteoclasts. Defects in 
these processes lead to diseases such as hypercalcemia of malignancy and 
postmenopausal osteoporosis where an increase in bone resorption is the main 
pathological episode (Vaananen et al, 2000). Osteoclasts are closely related to 
macrophages and dendritic cells with only the final stage of differentiation altering 
for each cell type. This differentiation is dependent on whether the cell is stimulated 
by exposure to a particular receptor activator of NF-kB ligand i.e. osteoclast 
differentiation factor, macrophage colony-stimulating factor (M-CSF) or 
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Figure 1.3 The bone remodelling cycle showing the interplay between all the 
major cell types. Osteoclasts create a cavity at the remodelling site through the 
secretion of enzymes and acids, osteoblasts are then recruited to this site where they 
lay down a matrix which is subsequently mineralised. Osteocytes are embedded in 




The osteoclast can degrade both the inorganic and the organic components of
bone matrix. To initiate resorption of bone the osteoclast is firstly recruited to the site 
of damage by cytokines such as M-CSF and vascular endothelial growth factor 
(VEGF) (Niida, 1999). Following recruitment, the osteoclast attaches to the 
resorption site through a membrane domain called the sealing zone (Vaananen et al, 
2000). It has been hypothesised that integrins play a vital role in this stage of the 
resorption, with at least four being expressed in osteoclasts (avp3, avps, a2pl, avpl) 
(Nesbitt et al, 1993). It is unclear how these integrins help coordinate bone resorption 
however it is thought that they may bind to collagen type I and also matrix proteins 
such as osteopontin (OPN) (Horton et al, 1995; Helfrich et al, 1996). Adhesion to the 
bone surface causes the osteoclast to become polarised and form specific membrane 
domains known as the ruffled border, a secretory domain and a basolateral 
membrane. The ruffled border is formed by the fusion of intracellular lysosomal 
vesicles with the membrane region in contact with the bone. This initiates the 
secretion of hydrochloric acid by the vacuolar H+-ATPase (proton pump), along with 
this acid proteases are also secreted. At this stage the plasma membrane in contact 
with the matrix becomes convoluted due to an increase in membrane surface area 
thus giving it a ruffled appearance (Mulari et al, 2003). Secreted enzymes, such as 
matrix metalloproteases and tartrate resistant acid phosphatase (TRAP), cause the 
breakdown of the extracellular matrix thus allowing the release of hydroxyapatite 
crystal, which is subsequently dissolved due to the high pH of the secreted acid. The 
digested bone matrix is phagocytosed and degradation products such as the collagen 
fragments, along with TRAP, are then passed through the secretory domain in the 
basolateral membrane. Thus, the amount of TRAP released into the circulation
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should reflect the rate of bone resorption and is hence used as a diagnostic marker of
bone resorption (Mostov and Werb, 1997; Halleen and Ranta, 2001).
1.4 Cartilage
Cartilage is a tough, elastic and flexible connective tissue which has many pre 
and postnatal functions and is found in the body in three main types. Hyaline, or 
articular cartilage, functions to disperse forces on joints caused by movement, acts as 
a template for long bone growth, and is involved in the repair of fractured bones 
(Shum and Nuckolls, 2001). Within this type of cartilage, chondrocytes (cartilage 
cells) are embedded in a matrix, composed mainly of collagen type II and 
proteoglycans. A second type, elastic cartilage gives support to external structures, 
and is composed of chondrocytes embedded in a matrix of collagen and elastic 
fibres. Fibrocartilage aids in transferring loads between tendons and bone. It 
consists of an outer layer of collagen and fibroblasts that provide support and an 
inner layer of chondrocytes that synthesise type II collagen fibres. Surrounding all 
cartilage, bar hyaline cartilage in joints, is a dense layer of fibrous connective tissue, 
known as the perichondrium, which is closely involved with the ability of the 
chondrocytes to produce the aforementioned matrix (Colnot et al, 2004).
1.4.1 Chondrocytes
Chondrocytes are derived from the same progenitor cells as osteoblasts and, 
in many manners, function very similarly. Terminal differentiation of chondrocytes 
gives rise to the three different types of cartilage, as discussed earlier. The actual 
phenotype of the cartilage is very much under the control of various transcription
12
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factors, DNA binding proteins and adhesion molecules (Shum and Nuckolls, 2001).
Sox9 is a transcription factor, which is expressed in prechondrocytic, and 
chondrocytic cells during embryonic development. Interestingly its expression 
mirrors that of collagen type II indicating a possible involvement in chondrocyte 
development. Indeed cells lacking Sox9 fail to differentiate to a chondrocyte 
phenotype due to decreased activation of COL2A1 (collagen type II gene), which is 
an important element of differentiation (Lefebvre et al, 1997). This results in 
campomelic dischondroplasia through decreased production of collagen type II. 
Mesenchymal cells from Sox9~f~ knockout mice cannot differentiate into 
chondrocytes and cartilage cannot be formed from teratomas derived from Sox9~f~ 
embryonic stem (ES) cells. (Bi et al, 1999). In addition to this when Sox9 is 
inactivated following mesenchymal condensations during embryonic development 
the phenotype displayed was that of chrondodysplaysia with a severe decrease in 
differentiated chondrocytes (Akiyama et «/, 2002). Sox9 is a critical transcriptional 
regulator of chondrocyte differentiation and in essence functions as Runx2 in 
osteoblasts. Additional transcription factors such as Runx2 and c-fos also seem to be 
involved in chondrogenesis. Runx2 although involved in osteogenesis also has a 
significant role in chondrogenesis with knockout mice showing over expression of 
type II and IX collagens, aggrecan (a proteoglycan involved in cartilage shock 
resistance), and chondromodulin (Inada et al, 1999). Interestingly Runx2'A mice 
show no ossification due to the maturational arrest of osteoblasts (Komori et al, 
1997) however chondrocytes are found indicating perhaps a more crucial role in 
osteoblast generation (Inada et al, 1999). It has however been reported that Runx2 
might function synergistically with Runx3 as Runx2'/~3~/~ mice showed a complete
13
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absence of chondrocyte maturation (Yoshida et al, 2004). C-fos is a proto-oncogene,
which interferes with proteoglycan synthesis in chondrocytes and inhibits the 
production of an extracellular matrix and chondrocyte differentiation (Tsuji et al, 
1996).
The chondrocytes of most importance, with regard to bone growth, are those 
of the growth plate, which are involved in the manufacture of a template for 
endochondral ossification. Within the growth plate, chondrocytes go through various 
stages of proliferation and differentiation, which is accompanied by a hypertrophic 
phenotype (increased cellular volume) (Beier et al, 1999). This is strictly controlled 
by growth factors and hormones, shown through the knockout of receptors for 
parathyroid hormone/parathyroid hormone-related peptide receptor (Lanske et al, 
1996), FGF receptor 3 (Deng et al, 1996), transforming growth factor p (TGF-P) 
(Serra et al, 1997) and many more, all of which cause defects in bone growth. Bone 
morphogenic proteins, retinoic acid and steroids are also involved in the function of 
the growth plate. Bone morphogenic proteins are extracellular ligands which are 
members of the TGF-P super-family and can induce both bone and cartilage 
formation by signalling through serine threonine kinase receptors (Miyazono et al, 
2000). Initial investigations on these factors noted their propensity to induce bone 
formation when injected subcutaneously in mice (Urist et al, 1965). During 
mesenchymal stem cell differentiation the BMP receptor antagonist, Noggin, inhibits 
the formation of precartilaginous condensations, the stage preceding cellular 
differentiation (Pizette and Niswander, 2000) and mutations in the BMP5 gene cause 




Bones can grow by two distinct mechanisms; flat bones of the skull grow by 
intramembranous ossification while all long bones grow by endrochondral 
ossification. Endochondral ossification is the process whereby a mineralised cartilage 
template (growth plate), produced by chondrocytes is resorbed by osteoclasts and 
replaced with bone from osteoblasts. The growth plate is located between the 
epiphysis and diaphysis and is the centre for bone growth. As mentioned before, 
chondrocytes at varying stages of proliferation and differentiation are located in this 
region, with several distinct zones consisting of resting, proliferating and terminally 
differentiated hypertrophic cells, as shown in figure 1.4. These zones are arranged in 
columns with resting at one end and hypertrophic at the other in parallel to the 
direction of bone growth, separated by longitudinal and transverse septa consisting of 
collagen and proteoglycans (Farquharson, 2003). As the chondrocytes become 
hypertrophic and increase their size they begin to produce type X collagen and cease 
to produce collagen type II (Kronenberg, 2003). A further marker of chondrocyte 
differentiation is the expression of alkaline phosphatase, which is characteristic of 
cells within the hypertrophic zone (Matsuzawa and Anderson, 1971). Chondrocytes 
which reach this terminally differentiated state mineralise the surrounding matrix 
before progressing to programmed cell death or apoptosis.
Following growth plate matrix mineralisation blood vessels from the bone 
marrow invade the hypertrophic region; these are attracted to this site through the 
production of vascular endothelial growth factor by chondrocytes (Kronenberg, 
2003). These vessels bring with them osteoclasts which results in compete resorption 
of the transverse septa along with the terminally differentiated chondrocytes and
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approximately half of the longitudinal septa. This forms a scaffold for bone 
formation, with osteoblasts laying down an un-mineralised matrix (osteoid) 
consisting of collagen type I and matrix proteins such as osteocalcin. This matrix is 
mineralised forming a network of immature trabeculae termed the primary spongiosa 
which is eventually replaced with secondary spongiosa before being converted into 
primary cortical bone by filling of spaces between the trabeculae (Howell and Dean, 
1992). This ultimately leads to the longitudinal growth of the bone. The growth plate 
exists as this dynamic structure of constant bone formation (distal femur in humans 
extends by 0.04mm/day; Farquharson, 2003) from the cartilage template until 
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Figure 1.4 Schematic diagram showing the position of the growth plate at end of 
the long bone contained within the epiphysis. Chondrocytes within this region go 
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1.6 Matrix Mineralisation
1.6.1 The History of Mineralisation
The process of mineralisation or calcification was first documented by Rudolf 
Virchow in 1855 upon describing pathological metastatic calcification, when he 
concluded that "calcium salts dissolved from bone were carried in the blood and 
deposited at some distant site to form calcium metastases, a process analogous to the 
dissemination of cells from a primary neoplasm." The initial research on 
calcification was based on case studies from calcification disorders. This gave rise to 
information regarding the extracellular nature of calcification, the crystalline form of 
calcium phosphate and also that the extracellular Ca2+ and PO43 " ions are maintained 
by homeostasis (Pommer, 1885 - cited in Anderson, 1992; Shipley et al, 1926). 
However perhaps the most important discovery with regard to understanding the 
process of mineralisation was that of alkaline phosphatase in 1923 by Robert 
Robison this was accompanied by his theory of local phosphatase derived Pi driving 
cell mediated mineralisation (Robison, 1923).
However it was not until 1970-71 that the actual mechanism of mineralisation 
was hypothesised. At this point it was known that the initiation of mineral crystals 
required a local nucleator through the discovery that the extracellular fluid at the 
calcification front is metastable (the concentrations of Ca and PO4 are less than that 
required to allow calcium phosphate precipitation) (Howell et al, 1968). In addition 
to this Irving (1963) and Wuthier (1968) demonstrated that lipids were concentrated 
at the mineralisation front thus hypothesising that the local nucleator should consist 
of lipids or have a high lipid element. In 1970-71 pioneering work by Anderson et al, 
Matsuzawa et al and Ali et al illustrated the presence of matrix vesicles (MVs) which
17
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were shown to be membrane derived packages found at the mineralisation front and
were characterised by intense phosphatase activity.
1.6.2 The Chemistry of Hydroxyapatite
Hydroxyapatite is a double salt of tricalcium phosphate and calcium 
hydroxide and has theoretical calcium to phosphate ratio of 1.67:1. The calcium 
phosphate which makes up the inorganic constituent of bone can be divided into two 
separate phases, the amorphous phase which consists of tricalcium phosphate and the 
crystalline phase which exists as hydroxyapatite. The amphorous phase is 
predominately found in younger immature bones and is subsequently turned into 
hydroxyapatite crystal, which forms around 40% of adult bone (Narasaraju and 
Phebe 1996).
It was originally postulated that the major mineral constituent of bone was a 
very small apatite, a finding from X ray diffraction by DeJong in 1926. However it 
was not until the crystal structure of hydroxyapatite was first resolved in 1964 by 
Kay et al that more clues on bone mineral were identified. It was found that the 
structure of hydroxyapatite consisted of a hexagonal arrangement of calcium and 
phosphate that surrounded a column of monovalent hydroxide. When these findings 
were compared with X ray diffraction patterns of apatite found in bones it was 
discovered that teeth and bone did actually contain natural hydroxyapatite (Eanes and
9-1-Posner, 1970). The crystal lattice of hydroxyapatite is formed from the ions Ca , 
PO43', and OH" with their arrangement in the unit cell reflecting two phases which 
are a mirror image of each other, with each cell measuring 9.432 A by 6.881 A 
(Posner et al, 1958). The needle like crystals of hydroxyapatite reach a length of up
18
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to 300 A in bone tissue (Duming, 1958). The crystalline structure of hydroxyapatite
lends itself to isomorphous substitution, where an ion can be replaced within the 
structure without disrupting the structure itself (Narasaraju and Phebe 1996). These 
substitutions include the replacement of OH" with F" (Narasaraja, 1972), and can 
provide an explanation of the integration of carbonate ions in both bones and teeth.
1.6.3 The Mineralisation Process
1.6.3.1 The Role of Matrix Vesicles (MVs)
Matrix mineralisation is a controlled process exhibited by both osteoblasts and 
mineralising chondrocytes of the growth plate. It is widely regarded that the initial 
stages of mineral formation occurs within the previously described packages known 
as MVs. MVs bud from distinct areas of the membrane on the surface of all 
mineralising cells, these areas usually lie adjacent to the matrix which will be 
mineralised. The region of the hypertrophic chondrocyte that the MVs bleb from is 
the lateral membrane that lies adjacent to the longitudinal septal matrix. Developing 
bone MVs are restricted to the freshly formed osteoid that is located at the basal 
plasma membrane of mineralising osteoblasts (Morris et al, 1992). Inside the MV 
lumen, calcium phosphate accumulates within the matrix vesicle sap until sufficient 
amounts are present for precipitation to occur. This is then converted to an 
intermediate, octa-calcium phosphate, crystals of which are transformed into the less 
soluble hydroxyapatite (Sauer and Wuthier, 1988). The first hydroxyapatite crystals 
are visible by EM and are often found closely aligned to the MVs trilaminar 
membrane as seen in figure 1.5 (Anderson, 1995). Calcium accumulation is
o_i_
controlled by Ca -binding molecules such as annexin I and phosphatidylserine (Wu
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et al, 1995; Anderson, 2003). Pi accumulation is associated with the action of
alkaline and acid phosphatases (Wu et al, 1995; Anderson 2003). The most abundant 
of these being tissue non-specific alkaline phosphatase (TNAP), an isoenzyme of 
alkaline phosphatase expressed in bone, liver and kidney (Anderson, 1996). It is 
thought that the mineralisation process is divided into two phases; phase one 
concerns the intravesicular precipitation of calcium phosphate and the initial 
production of hydroxyapatite crystals. This phase is predominantly regulated by 
enzymes and the membrane embedded proteins such as annexin. Phase two occurs 
when the crystal grows to an extent that it pierces the vesicle membrane, causing it to 
collapse, allowing the egress of mineral into the extracellular space. This mineral 
serves as a template for the epitaxial proliferation of the HA crystal (Anderson, 
1995). The crystal, at this point, proliferates radially around the edge of the matrix 
vesicle to form a sphere or spherule of hydroxyapatite, these continue to grow until 
they fuse forming a mineralisation front. The rate of mineral growth at this stage is
s\ ,
dependent upon the ionic conditions of the extracellular fluid (Ca and Pi), the pH 
and also presence of inhibitory molecules such as inorganic pyrophosphate (PPi), 
anionic proteoglycans and calcium binding noncollagenous proteins (Bohn et al, 
1984; Dziewiatkowski and Majznerski, 1985; Campo and Romano, 1986). Three 
molecules present in osteoblasts have so far been identified as affecting the 
controlled deposition of bone mineral by regulating the extracellular levels of PPi 
i.e., tissue-non-specific alkaline phosphatase (TNAP); NPP1 (a nucleotide 
pyrophosphatase/phosphodiesterase isozyme) and the ANK gene product (which 
forms a PPi channel on the surface of mineralising cells). Hydroxyapatite crystals 
form structures around the triple helix of the collagen fibril, which has been
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described as a "rotating plywood structure" by Anderson (1995) and has been 
attributed to the reason why mineralised bone matrix has both hard and flexible 
properties.
Ca binding










Figure 1.5 Electron micrographs showing the process of mineral formation.
Note the two phases; phase 1 is very much enzymatically controlled, whereas phase 
2 is more a biochemical reaction (Anderson, 1995).
1.6.3.2 Apoptosis and Apoptotic Bodies
Following growth plate cartilage mineralisation hypertrophic chondrocytes 
undergo programmed cell death, or apoptosis, leaving behind a mineralised cartilage- 
bone template. During the process of chondrocytic apoptosis the cell phenotype and 
morphology undergoes rapid change beginning with DNA fragmentation, nuclear 
alterations and chromatin condensations. This progresses to the loss of membrane 
stability which is preceded by the exteriorisation of phosphatidylserine, resulting in 
the release of phospholipid membrane fragments (Kirsch et at, 2003). These 
membrane fragments progress to form apoptotic bodies which characterise the end 
point of cellular death (Zhang et al, 1998). This chondrocyte apoptotic process also 
occurs in articular chondrocytes, which do not normally adopt a hypertrophic 
phenotype, as found in osteoarthritic cartilage. Interestingly these areas are
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characterised by pathological mineralisation leading to the theory that apoptosis is an
important step in the mineralisation process (Hashimoto et al, 1998). In addition, 
apoptotic bodies can be induced to mineralise in vitro though a similar mechanism to 
MVs (Proudfoot et al, 2000), this initially led to the hypothesis that MVs were 
closely related to apoptotic bodies and perhaps apoptosis mediated matrix vesicle 
release. This is however not the case as matrix vesicle production precedes the 
apoptotic process and mineralisation of the growth plate cartilage occurs in a wider 
region than that of apoptosis (Kirsch et al, 2003). Also several structural differences 
exist between MVs and apoptotic bodies including, particle size (MVs are bigger, as 
shown in figure 1.6), however perhaps more importantly MVs contain all of the 
necessary machinery to create an environment conducive to mineralisation (alkaline 
phosphatase activity and annexins) whereas apoptotic bodies do not (Kirsch et al, 
2003). It is more likely therefore that mineralisation can occur upon apoptotic bodies 
due to the capture of calcium during the exteriorisation of phosphatidylserine, this is 
in concordance with the findings that detergent treatment of apoptotic bodies causes 
inhibition of calcium uptake through membrane solubilisation (Proudfoot et al, 
2000), however an identical treatment of MVs only serves to release the mineral 
from the lumen where it can continue to grow as per phase 2 of crystal growth 
(Kirsch et al, 1994). These findings indicate that mineral is produced on the outer 
membrane of apoptotic bodies whereas it is produced in the lumen of MVs 
(Anderson, 1995). It is not clear what the precise function of these apoptotic bodies 
are in growth plate cartilage as mineralisation of this area is mediated before 
apoptosis occurs, through the production of MVs. At the point of apoptosis a 
vascular network is present thus it is possible these bodies will be phagocytosed
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along with cellular debris by macrophages. However in areas where vascularisation
is not present, such as articular cartilage, it is possible that this mechanism mediates 
pathological calcification (Kirsch et al, 1994).
Figure 1.6 Comparison of MVs and apoptotic bodies by electron microscopy.
From (A) Chondrocytes induced to release MVs by the addition of retinoic acid and 
(B) apoptotic chondrocytes. MVs from A measure approximately 200 to 500 mM 
whereas the apoptotic bodies from C were approximately 100 to 200nM (Adapted 
from Kirsch et al, 2003).
1.6.4 Regulatory Factors of Matrix Mineralisation 
1.6.4.1 Tissue Non-Specific Alkaline Phosphatase
TNAP, an isoenzyme of alkaline phosphatise, is the only tissue-nonrestricted 
isozyme of a family of four homologous alkaline phosphatase genes (EC 3.1.3.1). 
TNAP is a dimeric ecto-enzyme which is attached to the cell membrane via a 
glycosylphosphatidylinisotol anchor (GPI) and also to collagen through a crown 
region (shown in figure 1.7) and has been has been shown to play a pivotal role in 
matrix mineralisation. This is clear as deficiency in this enzyme leads to 
hypomineralisation (hypophosphatasia), manifesting itself as rickets in children and 
osteomalacia in adults (Anderson et al, 2004). The severity of hypophosphatasia is 
variable and modulated by the nature of the TNAP mutation (Henthom et al, 1992; 
Shibata et al, 1998; Zurutuza et al, 1999). Unlike common types of rickets and
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osteomalacia the serum levels of calcium and Pi are not subnormal in 
hypophosphatasia. The clinical severity in hypophosphatasia patients varies widely. 
The different syndromes, listed from the most severe to the mildest forms, are: 
perinatal hypophosphatasia, infantile hypophosphatasia, childhood 
hypophosphatasia, adult hypophosphatasia, odontohypophosphatasia and 
pseudohypophosphatasia (Whyte, 1995). The symptoms of these diseases range from 
complete absence of a mineralised skeleton and stillbirth to spontaneous fractures 
and premature loss of teeth in adult life. Inactivation of the mouse TNAP gene 
mimics the infantile form of human hypophosphatasia (Narisawa et at, 1991 \ Fedde 
etal, 1999).
Figure 1.7 Structural model of human TNAP. The model is based on the crystal 
structure of human placental alkaline phosphatase (shares 74% identity). Black 
circles depict the active sites of the enzyme and the blue circle depicts the 'crown' or 
collagen binding domain (Mornet et al, 2001).
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As seen in figure 1.8A TNAP is localised on the outer membrane of
hypertrophic chondrocytes and MVs. It is also found on the surface of mineralising 
osteoblasts and MVs derived from this cell type. TNAP is more concentrated on the 
surface of MVs compared to their parent cells, the mechanism by which this occurs, 
however is unknown. It has been advocated that the role of TNAP in bone formation 
is to generate the Pi needed to facilitate calcium phosphate precipitation and 
therefore hydroxyapatite deposition, however this is not the whole story regarding 
TNAP function (Robison, 1923; Majeska and Wuthier, 1975). Perhaps the most 
important role that TNAP plays in mineralisation is by hydrolysing PPi, its natural 
substrate since PPi is a potent inhibitor of hydroxyapatite crystal formation, 
elimination of the molecule from mineralising sites is critical to the mineralisation 
process. This has in part been proven by examination of TNAP knockout mice 
where hypomineralisation of the skeleton is evident. Electron microscopic analysis of 
MVs from TNAP-deficient mice, demonstrate that crystals of calcium phosphate are 
present within the vesicle lumen (as shown in figures 1.8B and C), however 
extravesicular crystal propagation is retarded (Anderson et al, 1997; 2004). Indeed it 
has recently been hypothesised that the actual function of TNAP is to decrease the 
PPi/Pi ratio thus forming an environment conductive for hydroxyapatite deposition. 
This hypothesis has been formed due to the finding that TNAP knockout mice have 
an abnormally high bone PPi concentration whereas the Pi concentration remains 
constant (Harmey et al, 2004). It has previously been hypothesised that TNAP can 
also function as a Pi transporter (Parley et al, 1980) due to its apparent affinity for 
free phosphate however more recently the specific Pi transporters Pit-1 and Pit-2
25
Chapter 1 Introduction
have been attributed to Pi handling in osteogenic cells (Montessuit et al, 1991; 
Palmer etal, 1997).
Figure 1.8 (A) MVs of hypertrophic growth plate chondrocytes, which have been 
stained for alkaline phosphatase. Black colouration denotes areas of alkaline 
phosphatase activity (Anderson, 1995). Analysis of uncalcified osteoid layers from 
wildtype mice (B) and osteoid layer in TNAP-deficient tibial metaphyseal bone (C). 
MVs are visible (indicated by arrows and shown at higher magnification in inserts) 
in both bone sections. Note both contain apatite like needles M, mineralized bone 
matrix; Obi, osteoblast; Ost, osteoid. (Anderson et al, 2004)
1.6.4.2 Clues from NPP1 and Auk
Further studies with NPP1 and TNAP double knockout animals provides 
insights into TNAP function. NPP1 or PCI (plasma cell membrane glycoprotein 1) 
as it is alternatively known is a membrane protein that acts as a phosphodiesterase 
(pyrophosphatase) and is an isozyme of the NPP family of pyrophosphatases (Oda et 
al, 1991). Two other members, autotoxin (NPP2) is secreted and BIO (NPP3) is 
found within intracellular compartments, with all three being found within 
mineralising tissues (Bachner et al, 1999; Bollen et al, 2000). NPP1 has a large 
extracellular domain that contains the catalytic site and one or possibly two calcium- 
binding motifs (Belli et al, 1994). The main function of this enzyme is to cleave 
nucleotide tri phosphates (NTP's) to produce pyrophosphate (most commonly CTP 
to CMP and PPi) thus functioning to increase both intra and extracellular
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concentrations of PPi. NPPs have been implicated in several cellular pathways
including bone mineralisation, cell signalling by insulin and nucleotides and cell 
differentiation and motility (Bollen et al, 2000). NPP1 localisation mirrors that of 
TNAP, with high concentrations being found on the surface of osteoblasts and 
chondrocytes as well as MVs derived from these cell types (Johnson et al, 1999). 
The main role of NPP1 seems to be its mineralisation inhibiting properties through 
the production of the mineralisation inhibitor PPi. This has been shown in osteoblasts 
engineered to over express NPP1, the result of which is an elevated intravesicular 
concentration of PPi accompanied by a decrease in hydroxyapatite precipitation 
(Johnson et al, 1999). NPP1 knockout mice, however are characterised by 
hypermineralisation defects such as mineralisation of the posterior longitudinal 
ligament of the spine diffuse idiopathic skeletal hyperostosis, ankylosing spinal 
hyperostosis and pathological soft-tissue ossification, including arterial calcification 
(Okawa et al, 1998; Sali et al, 2000). Conversely when NPP1 expression is elevated, 
MV-mediated calcium pyrophosphate dihydrate (CPPD) matrix calcification of the 
knee meniscal cartilage during aging is observed (Johnson et al, 2001; Masuda et al, 
2001). This pathological CPPD precipitation has also been observed in association 
with TNAP deficiency which, as with elevated NPP1 levels is characterised by high 
PPi concentrations. When TNAP was knocked out alone, PPi would build up within 
the matrix thus inhibiting crystal formation, however when NPP1 and TNAP were 
knocked out in tandem a normally mineralised skeleton was seen at birth (Hessle et 
al, 2002). A schematic pathway is shown in figure 1.9. Thus these two enzymes have 
an antagonistic effect on each other and loss of TNAP can be corrected by knocking 
out NPP1 thus decreasing the production of PPi. Interestingly PPi negatively
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regulates both NPP1 and ankylosis protein (ANK) which also plays a central role in 
PPi homeostasis through the mediation of intracellular and extracellular PPi levels.
The ank gene encodes a protein containing 492 amino acids with a molecular 
mass of 54.3 kD. The protein contains three N-linked glycosylation sites and multiple 
potential phosphorylation sites (Ho et al, 2000). ANK functions as a transmembrane 
PPi channel allowing intracellular PPi to traverse the membrane into the extracellular 
space (Numberg et al, 2001). ANK is expressed in many tissues, however its 
expression seems to be upregulated in osteoblasts and chondrocytes where the 
protein is abundant in the cellular membrane (Sohn et al, 2002), it is however not 
present upon the surface of MVs (Harmey et al, 2004). Mice lacking the ANK 
protein are characterised by pathological calcification of articular cartilage and the 
synovial fluid surrounding these regions (Hakim et al, 1984). These mice mimic 
severe arthritic diseases including ectopic calcification, cartilage erosion and 
vertebral fusion (Sampson, 1988; Johnson et al, 2005).
Phosphatase X
Figure 1.9 Schematic diagram showing how TNAP and NPP-1 work in tandem 
to allow mineralisation, however if both these enzymes are knocked out 
mineralisation still occurs giving rise to the potential for additional phosphatases.
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An interesting finding from these studies is that the Pi to allow mineralisation
of the double knockout skeleton must be produced or sourced from another location 
hinting that TNAP is not the only enzyme supplying Pi for mineralisation. Indeed, 
recently it has been suggested that other phosphatases contributing to the Pi pool are 
present (Anderson et al, 2004).
1.6.4.3 Other Phosphatases Contributing to Pi Accumulation
MVs contain many other phosphatases which have the potential to raise the 
intravesicular concentration of Pi to allow the initiation of mineralisation. Adenosine 
monophosphoesterase (AMPase) is one such phosphatase which is enriched in MVs 
(Ali et at, 1970). Interestingly it has recently been shown that adenosine 
monophosphate (AMP) can induce, and indeed was one of the best substrates for the 
deposition of calcium phosphate within isolated rat MVs (Garimella et al, 2004). In 
addition to this inorganic pyrophosphatase (PPiase) has also been shown to be 
concentrated within matrix vesicle preparations, this enzyme functions in a similar 
fashion to TNAP by hydrolysing the mineralisation inhibitor PPi (Ali et al, 1970). It 
is however not known what the relative contribution is of TNAP vs PPiase in 
contributing Pi for calcium phosphate precipitation. Another phosphatase known to 
be present within MVs is ATPases (Matsuzawa and Anderson, 1971), it has also 
been shown that ATP hydrolysis increases the potential for MVs to mineralise in 
vitro (Hsu and Anderson, 1996). However, much evidence to suggest that this 
enzyme is not responsible for the induction of mineralisation in vivo is present. 
Perhaps the most compelling of this evidence comes from the analysis of the action 
of matrix vesicle ATPase and its hydrolysis products. This enzyme acts as a tri 
phosphate pyrophosphatase, producing AMP and the mineralisation inhibitor PPi
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(Hsu, 1983), and as stated previously AMP is a potent inducer of mineralisation. In
addition when using ATP as a substrate for in vitro MV calcification the mineral 
formed is mostly calcium pyrophosphate dihydrate, which is of a non-crystaline 
nature (Derfus et al, 1995). This would suggest that the role of ATPases are in fact to 
modulate the mineralisation process through the production of PPi.
1.6.4.4 Osteopontin
Osteopontin (OPN) is a negatively charged, acidic and hydrophilic protein of 
around 300 amino acids (44KDa) in size (Mazzali et al, 2002). It is secreted by both 
osteoblasts and osteoclasts, but not exclusively, and mediates the attachment of cells 
to hydroxyapatite crystals through polyaspartic acid motifs as well as arginine- 
glycine-aspartic acid (RGD) motifs (Young et al, 1990). Osteopontin also potentially 
contains calcium binding motifs and two heparin binding domains thus perhaps 
accounting for its affinity for hydroxyapatite (Prince, 1989). In addition to this it is 
also thought that it can attach to collagen through transglutamination (Beninati et al, 
1994). OPN was first recognised in bone matrix by Franzen and Heinegard in 1985 
and at that time it was called bone sialoprotein 1. A specific function for this gene 
product is not known, which is in part due to Opri1' mice displaying a normal 
skeleton with the only phenotypic differences being greater crystal size and 
crystallinity (Boskey et al, 2002). These mice however, when challenged with 
parathyroid hormone, which signals indirectly via osteoblasts for osteoclast 
differentiation through production of RANKL and therefore bone resorption, show 
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Figure 1.10 The roles of TNAP, ANK, NPP1, PPi and OPN in the mineralisation 
process. The role of NPP1 and ANK is to raise the extracellular PPi pool whereas 
TNAP depletes it thus eliminating it from sites of mineralisation. PPi is also a 
regulator of transcription from the NPP1 (Enppl) and Ank genes thus a negative 
feedback loop is present to mediate transcription. In addition to this PPi induces OPN 
transcription which further inhibits mineralisation. Thus when TNAP is not 
functional PPi serves to inhibit mineralisation both directly and through the 
production of OPN causing hypomineralisation (Harmey et al, 2004).
Osteopontin is thought to be involved in the mineralisation process through 
inhibition of formation and more importantly the propagation of hydroxyapatite 
crystals (Hunter et al, 1996). This inhibition of crystal growth is thought to involve 
both carboxylate and phosphate groups on the protein, the poly-aspartic acid motif 
may also play an important role in the inhibition of mineralisation (Hunter et al, 
1994). Other functions of OPN include inhibition of apoptosis, stimulation of cellular 
attachment and migration in tumour formation, wound healing and modulation of 
immune responses (Xuan et al, 1995; Rollo and Denhardt, 1996; Noti, 2000).
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Osteopontin expression is also promoted in the presence of PPi, thus providing a link
between this protein, NPP1, ANK and TNAP in mineralising cells, as shown in 
figure 1.10 (Harmey et al, 2004).
1.6.4.5 Osteocalcin
Osteocalcin, or BGP (bone gla protein), is exclusively found in bone tissue, 
and accounts for 10-20% of the non-collagenous protein in bone. This protein has 
been the subject of investigation by knockout mouse technology, and functionally it 
was found to be able to negatively regulate bone formation. Newborn knockout mice 
have a normal bone phenotype at birth but after a period of 6 months an increased 
bone density and thickness is observed. This was hypothesised to be due to 
osteoblasts depositing more bone matrix than those of wild-type mice, which led to 
the conclusion that Osteocalcin was a negative regulator of bone formation (Wolf, 
1996). Osteocalcins' regulatory function is due to the structure of the protein; it 
consists of a single chain approximately 50 amino acids in length and contains three 
vitamin K-dependent gamma-carboxyglutamic acid residues (GLA). These are 
closely involved in its ability to bind both calcium and hydroxyapatite, shown in 
figure 1.11. This protein is largely unstructured when calcium is not present, 
however when calcium is in the vicinity of the protein it is transformed into a folded 
state (Hoang et al, 2003). This allows calcium sequestering thus inhibiting mineral 
formation and matrix mineralisation (Chenu et al, 1994). In addition to osteocalcins 
ability to regulate bone formation it has also been implicated in bone remodelling by 
acting as a chemo-attractant for monocytes which are part of the osteoclast cell 
linage (Malone et al, 1982).
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Figure 1.11 Structure of porcine 
osteocalcin showing the residues 
involved in calcium binding. Each 
osteocalcin molecule can co-ordinate 
to calcium ions sequestered in a 
hydroxyapatite crystal lattice thus 
attributing to its affinity of mineralised 
bone matrix.
ASP34
1.6.4.6 Matrix Gla Protein (MGP)
Matrix gla protein (MGP) was originally isolated from bone by Price 
et al in 1983 and like osteocalcin contains 5 vitamin K dependent y-carboxyglutamic 
acid (GLA) residues (Price and Williamson, 1985). MGP is a 14-kD extracellular 
matrix protein which, although expressed in many tissues only appreciably 
accumulates in the matrix of bone, cartilage, and dentin (Hale et al, 1988). As with 
osteocalcin, the GLA residues found within this protein function to promote the 
binding of hydroxyapatite through their affinity to calcium ions. Due to this the 
protein is closely associated to the mineralisation process, indeed mice lacking this 
gene product are severely compromised and fatality is observed within two months. 
This is primarily due to the presence of arterial calcification, through the action of 
chondrocytes, which leads to the rupture of blood vessels (Luo et al, 1997). The 
chondrocytes, which have replaced the smooth muscle cells that normally reside in 
this region, undergo the process of enochondral ossification, hence it is likely that 
MGP also plays a pivotal role in the mediation of cell differentiation. In addition to 
this pathological calcification of the growth plate is also observed which leads to 
fractures and osteopenia, thus it has been hypothesised that this primary function of
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this protein is to inhibit or, in the case of the growth plate, modulate the
mineralisation process (Luo et al, 1997). This hypothesis has been furthered through 
the demonstration that overexpression of MGP in hypertrophic chondrocytes reduces 
their mineralisation potential (Newman et al, 2001). The human disease Keutel 
syndrome is triggered by mutations in the MGP gene, and is characterised by 
excessive cartilage calcification (Munroe et al, 1999).
1.6.4.7 Osteonectin
Osteonectin, otherwise known as SPARC (secreted protein acidic and rich in 
cysteine) or BM-40 is an osteoblast expressed, phosphorylated glycoprotein of 
approximately 32KDa (Termine et al, 1981). Osteonectin is known as a matricellular 
protein as it does not function as a structural component of matrix but does act as 
regulator of cell behaviour and can account for up to 15% of non collagenous protein 
in bone (Bradshaw and Sage, 2001). This protein has been implicated in many 
cellular pathways in nonskeletal systems including the stimulation of 
metalloproteinase expression, modulation of angiogenesis and inhibition of cell 
proliferation. It can also inhibit the function of growth factors such as platelet- 
derived growth factor, TGFB, and vascular endothelial growth factor (Bradshaw and 
Sage, 2001). Its precise function in bone remains unclear, however osteonectin null 
mice display an imbalance in bone turnover. This primarily affects trabecular bone 
where a decrease in both osteoblast and osteoclast numbers are present, this results in 
a negative effect on bone mass (Delaney et al, 2000). It is thought that this is directly 
due to osteopontin acting as matrix embedded differentiation factor for osteogenesis 
(Delany et al, 2003).
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Osteonectin can bind collagen within the matrix and when complexed can
bind apatite. It has therefore been hypothesised that this protein may initiate 
mineralisation in normal bone by acting as a local nucleator for hydroxyapatite 
formation (Termine et al, 1981). Human osteonectin is found on chromosome five 
and spans 10 exons containing domains attributing to its calcium binding 
characteristic. The two domains involved in calcium binding are the N-terminal 
acidic region containing clusters rich in glutamic acid residues and the EF-hand 
domains which are helices connected with a calcium binding loop. The N terminal 
region is negatively charged thus attributing to its affinity for Ca2+ whereas the 
helices of the EF hand domain are co-ordinated to allow calcium binding, as found in 
other intracellular binding proteins such as calmodulin. When the protein is fully
<•> .
loaded with several Ca ions a structural change is educed resulting in an increased 
helix content of the protein (Engel et al, 1987). It has also been reported that 
osteonectin has the ability to inhibit hydroxyapatite crystal growth in vitro (Romberg 
etal, 1986).
1.6.4.8 Bone Sialoprotein
Bone sialoprotein (BSP-II) is one of the major phosphorylated proteins in 
bone and protein localisation reflects sites of mineralisation. These sites are 
associated with both chondrocytes and osteoblasts and have been linked to an 
involvement in hydroxyapatite crystal formation (Chen et al, 1991). BSP-II is highly 
glycosylated and has a molecular weight of approximately 57KDa and contains 
approximately 50% carbohydrate (small O-linked oligosaccharides) with around 
15% sialic acid (Fisher et al, 1983). The protein also contains a RGD cell attachment
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sequence, three regions of acidic ammo acids (glutamic acid) and three regions of
tyrosine residues throughout its sequence (Fisher et al, 1990). The tyrosine residues 
are likely to undergo sulphation, however the importance of this process is yet 
unknown.
BSP-II has been shown to act as a local nucleator for hydroxyapatite 
production (Hunter and Goldberg, 1994). It is thought that this function is due to 
glutamic acid rich sequences as polypeptides of L-Glu induced the formation of 
hydroxyapatite similar to that seen with bone sialoprotein (Hunter and Goldberg, 
1994). It has been suggested in this study that this nucleation of hydroxyapatite 
growth may be directly due to the specific conformation of the helical polyglutamate 
stretches in the bone sialoprotein at mineralisation sites. In addition it has been 
reported that in a case of bovine osteoporosis a significant reduction in BSP-II is 
present within the bone matrix thus strengthening its role in mineral formation 
(Fisher et al, 1990).
1.6.4.8 Potential Mediators of Mineralisation - PHOSPHO1?
Although the eradication of the potent mineralisation inhibitor, PPi has been 
shown to be of utmost importance for the propagation of hydroxyapatite crystals, 
examination of MVs from TNAP knockout mice by electron microscopy indicate 
that they contain mineral (figure 1.8C) (Anderson et al, 2004). As TNAP is localised 
on the outer leaflet of the MV thus controlling the extra-vesicular PPi/Pi ratio it 
would have no influence on the mineralisation occurring in the vesicle lumen. 
Although other phosphatase enzymes have been identified within MVs their 
relevance to the mineralisation process remains to be questioned. Undoubtedly
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enzymes causing the hydrolysis of intra-vesicular PPi or elevating Pi thus creating an
environment permissive for hydroxyapatite formation are present. It has been 
suggested that PHOSPHO1, a novel enzyme thought to belong to the haloacid 
dehalogenase superfamily of hydrolases could be involved in this stage of 
mineralisation.
1.7 On the Origin of PHOSPHO1
PHOSPHO1, or 3X11A as it was originally known, was discovered at the 
Roslin Institute during a scheme of work that was attempting to characterise the gene 
expression profile of both proliferating and hypertrophic chondrocytes. In particular 
it was trying to identify factors that may regulate chondrocyte differentiation and/or 
matrix resorption. By separating chondrocytes into populations depending on their 
stage of differentiation a novel transcript that was highly expressed in differentiated 
chondrocytes was identified. Analysis of gene expression by RT-PCR showed that 
this phosphatase was up regulated 5-fold during terminal differentiation of 
chondrocytes and expressed around 100-fold higher in growth plate chondrocytes 
compared to various non-skeletal tissues including heart, lung and brain (figure 
1.12A) (Houston et al, 1999). Upon sequence analysis three motifs were identified 
which were found to be conserved at the active sites of members of the haloacid 
dehalogenase (HAD) superfamily. The HAD superfamily is a group of magnesium- 
dependent hydrolases, including dehalogenases, P-type ATPases, phosphatases and 
phosphomutases (Aravind et al, 1998; Collet et al, 1998). Following analysis of the 
active site motifs it was suggested that this protein was a phosphatase and it has 
subsequently been shown to have the ability to cleave p-nitrophenyl phosphate
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(pNPP) (Farquharson et al, 2002). PHOSPHO1 is also expressed in human 
osteoblast-like cells (SaOS-2) along with TNAP, but not in the MG-63 cell line 
(figure 1.12B). This finding furthers the initial hypothesis that PHOSPHO1 is 
involved and perhaps critical to the mineralisation process as SaOS-2 cells are 
widely regarded as a good model cell type for a well differentiated osteoblast, 
through expression of TNAP and the ability to form a mineralised matrix in culture 
(McQuillan et al, 1995). Conversely MG-63 cells do not have the ability to form a 










Figure 1.12 (A) Semi-quantitative PCR showing expression of PHOSPHOl is 
approximately 100 times more in chondrocytes than in other soft tissues. (Houston et 
al, 1999) (B) Semi quantitative PCR showing PHOSPHOl expression in SaOS-2 
cells (do mineralise) and MG-63 cells (don't mineralise) (Houston et al, 2004).
The initial study on PHOSPHOl gene expression profile was done in 
chickens, however since then EST sequence database entries have been identified 
corresponding to human and murine PHOSPHOl which have been subsequently 
amplified and cloned (Houston et al, 2002). These transcripts have a 94% identity to 











Figure 1.13 Genetic Organisation and chromosomal localisation of human
PHOSPHOl. (A) Organisation of PHOSPHOl and neighbouring genes. Arrows 
depict the direction of transcription. (B) Chromosomal localisation of PHOSPHOl, 
which maps between GNGT2 and SGC35087 on HSA17.
The human and murine PHOSPHOl genes lie within approximately 7.4Kb 
regions on HSA17q21.32 and distal MMU11 respectively and are flanked by the 
ACLY and GH1 loci, and which exhibit conservation of synteny with part of 
GGA27. Using genetic linkage analysis, chick PHOSPHOl was mapped to the 
syntenic region on GGA27 (Houston et al, 2002). This strongly suggests that the 
PHOSPHOl loci on HSA17 and MMU11 are orthologous to the PHOSPHOl gene 
originally identified in the chick. Figure 1.13 shows the genomic organisation of 
PHOSPHOl including its flanking genes, in addition the chromosomal localisation 
of this gene is also displayed.
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1.7.1 PHOSPHO1 Localisation
PHOSPHO1 protein has been localised to all regions of mineralising bone 
and cartilage in the avian model (Houston et at, 2004). As seen in figure 1.14A, 
PHOSPHO1 is found in early hypertrophic chondrocytes, which are the sites of the 
first stages of hydroxyapatite mineral production. It is not found in the hypertrophic 
chondrocytes suggesting that PHOSPHO1 is required for the initiation of 
mineralisation but not for its maintenance. The perichondral ring, as shown in figure 
1.14B, is also intensely stained for the presence of PHOSPHO1. The function of the 
mineralised perichondral ring is to provide protection to the growth plate. 
PHOSPHO1 protein was also identified, in both cortical and trabecular bone. As 
shown in figure 1.14C strong PHOSPHO1 staining is evident in the periosteum and 
on the mineralising surfaces of the primary osteons, upon analysis of diaphyseal 
cross sections. Houston and colleagues (2004) reported that the staining within the 
periosteum was limited to the osteoid with fibroblast or osteogenic layers found to be 
PHOSPHO1 negative, however these cellular layers would also be found negative 
for mineralisation. PHOSPHO1 was also localised to the surfaces of 17 day old 
embryonic calvaria, osteoid found on both the intramembranous and periosteal bone 
surfaces stained positively for PHOSPHO1 (figure 1.14D). The investigators also 
reported its presence on the surfaces of mature trabecular bone. No PHOSPHO1 
staining was found on the surface of cartilage spicules directly distal to the growth 
plate, interestingly this area is characterised by an absence of osteoid and 
mineralisation. All soft tissues examined for PHOSPHO1 localisation were negative 






Figure 1.14 Immunocytochemistry of growth plate cartilage and bone showing 
regions of PHOSPHO1 localisation. Protein localisation is identified through areas 
of intense brown colourisation. (A) localisation of PHOSPHO1 within chondrocytes 
of the growth plate, note intense staining of those with a pre-hypertrophic phenotype 
(B) PHOSPHO1 staining of the perichondrol ring as indicated by arrows. (C) 
PHOSPHO1 staining of diaphyseal cross section, note intense staining of infilling 
osteons (black arrow) whereas closed osteons are negative (red arrow) (D) Staining 
of embryonic calvaria showing positive staining on all mineralising surfaces (Inset: 
staining of the periosteal (black arrows) and intramembranous (grey arrows) bone 
surfaces (Houston et at, 2004).
In addition to the protein localisation studies, PHOSPHO1 transcript has also 
been localised in developing embryonic bones of the chick by in situ hybridisation 
(Stewart et al, 2006). In this study the transcript of PHOSPHO1 has been found to be 
expressed at sites destined for mineralisation as shown in figure 1.15. Interestingly 
the transcript is present at these sites prior to overt signs of mineralisation thus
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furthering the theory that perhaps PHOSPHOl is involved in the initial stages of 
mineralisation, which as discussed previously are TNAP independent.
Figure 1.15 Comparison of PHOSPHOl expression with mineral deposition as 
assigned by alizarin red staining. (A) PHOSPHOl transcript localisation in a day 
10 embryonic front limb, when compared to an alcian blue/alizarin red stained limb 
(B) it is evident that PHOSPHOl is spread throughout the shaft that is destined for 
mineralisation, which contrasts with the more restricted distribution of mineral. (C) 
PHOSPHOl transcript is present only in the diaphysis of the hind limb phalange, 
however no mineralisation is present in these bones, as shown by the absence of 
alizarin red staining (D). (Stewart et al, 2006)
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1.7.2 Molecular Modelling of PHOSPHO1
A homology model has been constructed of human PHOSPHO1 based upon 
the crystal structure of phosphoserine phosphatase (PSP) from Methanococcus 
jannaschii to which it shares approximately 20% identity (Stewart et al, 2003). In the 
PHOSPHO1 model, amino acid side-chains involved in magnesium binding and PSP 
catalysis are conserved between the template and PHOSPHO1. However, residues 
involved in substrate-specific interactions are not. This suggests that PHOSPHO1 is 
not a member of the phosphoserine phosphatase subfamily but belongs to a novel, 
closely related enzyme group within the HAD superfamily. The residues which 
facilitate hydrolysis of the phosphate group (GlylOO, Lysl44 and AsnlTO) (Wang et 
al, 2002) are fully conserved in PHOSPHO1 with the exception of GlylOO, which is 
replaced with Asp 123. In addition three Asp residues (11, 13 and 167) involved in 
catalysis are also conserved between the two proteins (Stewart et al, 2003). This 
implies that the catalytic site in PHOSPHO1 is very closely related to that of PSP 
thus suggesting that phosphocompound hydrolysis by PHOSPHO1 occurs by the 
stepwise Mg2+-dependent mechanism, as with PSP. Analysis, however, of the 
binding pocket of PSP compared to PHOSPHO1 reveals that PHOSPHO1 is likely to 
be able to hydrolyse larger substrates than PSP due to alterations in amino acid 
composition (Stewart et al, 2003). A diagrammatic representation of the PHOSPHO1 




Figure 1.16 (A) Ribbon diagram of the human PHOSPHOl model (B) Active 
site/binding pocket of PHOSPHOl showing the conserved amino acids involved in 
Mg2+ binding (Stewart et al, 2003).
1.8 Aims and Strategy
The main aim this project was to characterise, as fully as possible, 
mammalian PHOSPHOl, a phosphatase belonging to the haloacid dehalogenase 
superfamily. This will take the take the form of a both biochemical and a 
cellular/molecular study. The purpose of the biochemical study is to investigate 
possible substrates for the enzyme and hence implicate PHOSPHOl in certain 
cellular pathways. I intend to define the substrate of PHOSPHOl by generating the 
recombinant human protein and utilising it in a biochemical in vitro assay.
PHOSPHOl is obviously linked closely to the mineralisation process due its 
presence at every mineralising surface and therefore perhaps the most likely cellular 
pathway that it could be involved with is the generation of phosphate for 
hydroxyapatite production. For this to be true the enzyme would have to be
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associated with MVs in a similar fashion to TNAP as these are widely regarded as
the sites of mineral initiation and the only part of hydroxyapatite deposition that is 
enzyme restricted. This recombinant protein produced will be used for the production 
of an antibody to allow the immunolocalisation of PHOSPHO1.
To assign function I intend to both over express PHOSPHO1 and attempt to 
knock down gene transcription in cell lines. The overexpession work will take the 
form of driving the expression of human PHOSPHO1 in a non-mineralising cell to 
investigate whether this protein is potent enough to induce mineralisation. To knock 
PHOSPHO1 expression down I will attempt to use short hairpin (sh)RNA vectors to 
stably transfect both chondrocytes and osteoblasts to investigate gene function in 
each of these cell types.
I also intend to modulate protein activity; however this is more difficult to do 
than genetically manipulating cells to modify gene expression. To tackle this aim I 
intend to find small molecule inhibitors of PHOSPHO1 and investigate their effect 
on the mineralisation process in vitro. This will be achieved by high throughput 
chemical screening of compounds and assessing their effect of PHOSPHO1 mediated 
hydrolysis of phosphoesters.
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Chapter 2______________________________________Materials and Methods
2.1 Reagents and Solutions
2.1.1 Materials
All chemicals were purchased from Sigma Aldrich (Dorset, 
UK) unless otherwise stated. PCR oligonucleotides were purchased from MWG 
Biotech (Ebersberg, Germany), shRNA oligonucleotides were purchased from 




Phosphate Buffered Saline (PBS)
140 mM NaCl, 2.5 mM KCI, 10 mM Na2HPO4, 1.8 mM KH2PO4
Cell Freezing Buffer
60% DMEM, 30% FBS, 10% Dimethyl sulfoxide (DMSO)
Hanks Buffered Saline Solution (HBSS)
1.26 mM CaCl2, 0.493 mM MgCl2, 0.407 mM MgSO4, 5.33 mM KCI, 0.441 mM
KH2PO4, 4.17 mM NaHCO3 , 137.93 mM NaCl, 0.338 mM Na2HPO4, 5.56 mM D-
Glucose
Bacterial Culture
Lvsogenv Broth (LB) media
1% bacto-tryptone, 0.5% bacto-yeast extract, 150 mM NaCl, adjusted to pH 7.5
LB agar
LB supplemented with 1.5% bactoagar
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Super Optimal Broth with Catobolite repression (SOC) Media 
2% bacto-tryptone, 0.5% bacto-yeast extract, 10 mM NaCl, 2.5 mM KCI, 10 mM 
MgCl2, 10 mM MgSO4, 20 mM glucose
Gel Electrophoresis
Tris-Acteric Acid-EDTA (TAB)
40 mM Tris, 1 mM EDTA, 0.1 % Acetic Acid
Tris-Boric Acid-EDTA (TBE)
(90 mM Tris, 2 mM EDTA, 90 mM boric acid
Agarose Gel Loading Buffer
1.2 mM bromophenol blue, 50% (w/v) glycerol, 10% (v/v) lOx TBE
Qiagen Kit Buffer Compositions
Re-suspension Buffer PI
50 mM Tris-HCl, pH 8.0; 10 mM EDTA; 100 ug/ml RNase A
Bacterial Lysis BufferP2 
200 mM NaOH, 1% SDS
Elution Buffer EB 
lOmM Tris-HCl, pH 8.5
Neutralisation Buffer P3
3 M Potassium Acetate, pH 5.5
Equilibration Buffer QBT
750 mM NaCl; 50 mM 3-[N-morpholino] propanesulfonic acid (MOPS), pH 7.0;
15% isopropanol (v/v); 0.15% Triton X-100 (v/v)
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Column Wash Buffer QC
IM NaCl, 50 mM MOPS pHT.O, 15% isopropanol (v/v) and 0.15% Triton X-100 
(v/v)
Elution Buffer ON
1.6 M NaCl, 50 mM MOPS, pH 7.0, 15 % isopropanol (v/v)
DNA Re-suspension Buffer TE
10 mM Tris HCI, pH 8.0, 1 mM EDTA
PolyAcrylamide Gel Running and Staining Buffers
MOPS Running Buffer
50 mM MOPS pH 7.7, 50 mM Tris, 0.1% SDS, 1 mM EDTA
NuPAGE Transfer Buffer
25 mM Bicine pH 7.2 , 25 mM Bis-tris , 1 mM EDTA, 0.05 mM Chlorobutanol
LDS Sample Buffer
10% Glycerol, 141 mM Tris Base, 106 mM Tris HCI, 2% LDS, 0.51 mM EDTA,
0.22 mM SERVA® Blue G250, 0.175 mM Phenol Red, pH 8.5
Coomassie Stain Solution
50% (v/v) methanol, 10% (v/v) acetic acid, 1.5 mM coomassie brilliant blue
Coomassie Fixing Solution
50% (v/v) ethanol, 10% (v/v) acetic acid
Coomassie De-stain Solution
50% (v/v) methanol, 5% (v/v) acetic acid
Silver Stain Developing Solution
0.003% (w/v) citric acid, 0.012% (v/v) formaldehyde
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Silver Stain Staining Solution
175 mM AgNO3 , 780 mM NH4OH 0.36% (v/v) NaOH
Western Blotting
Tris-Bufferd Saline with Tween 20 (TEST)
10 mM Tris HCI pHS.O, 150 mM NaCl, 0.1% Tween-20
Blocking Solution
5% (w/v) dried milk protein (Marvel) in TEST
Immobilised Metal Chromatography Buffers
NiNTA Lysis Buffer
20 mM Tris-HCl pH 8.0, 500 mM NaCl, 10 mM imidazole and 1.6 mg/ml of
Complete® protease inhibitor cocktail
NiNTA Wash Buffer
20 mM Tris-HCl pH 8.0, 500 mM NaCl, 20 mM imidazole
NiNTA Elution Buffer
20 mM Tris-HCl pH 8.0, 500 mM NaCl, 250 mM imidazole
Biochemical Assay Buffers
Calcification Buffer
50 mM Tris-HCl pH 7.6, ImM MgCl2, 85mM NaCl, 15mM KCI, 2.2 mM CaCl2, 1.6
mM KH2PO4, lOmM NaHCO3
Tris-Buffered Saline (TBS)
10 mM Tris HCI pH7.2, 500 mM NaCl
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2.2 Cell Culture
2.2.1 Cell Culture Reagents
Dulbecco's Modified Eagle Medium (DMEM), containing 4500g/L glucose 
and L-glutamine, was purchased from Gibco (Gibco BRL, Paisley, UK). All tissue 
culture reagents were prepared in a sterile category 2 hood. DMEM was 
supplemented with 0.5% of the broad spectrum antibiotic gentomycin (Gibco) and 
10% heat inactivated foetal bovine serum (FBS) (Gibco) before use. All media was 
filter-sterilised through a 0.22 uM filter and stored at 4°C.
2.2.2 Cell Lines and Primary Cells
For over expression and knockdown experiments SaOS-2 and SW1353 cells 
were used. SaOS-2 cells were obtained from the European Collection of Cell 
Cultures (Sailsbury, Wiltshire, UK), while SW1353 cells were a kind gift from Dr 
Simon Tew, University of Manchester. HeLa cells were obtained from European 
Collection of Cell Cultures (Sailsbury, Wiltshire, UK). MLOA5 cells were a kind gift 
from Lynda F Bonewald, University of Missouri-Kansas City. Primary chick 
chondrocytes were extracted from 3-week-old broiler chicks (as described in 2.2.7). 
Primary mouse TNAP null/heterozygous/wild type calvarial osteoblasts were a kind 
gift from Professor JL Millan, Burnham Institute, La Jolla, CA.
2.2.3 Maintenance and Passaging of Cells
Adherent cells were passaged (split) by trypsinisation at sub-confluence. The 
cell culture media was removed and the monolayer washed with sterile phosphate 
buffered saline (PBS), the cells were then covered with trypsin/EDTA solution and
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incubated at 37 °C until cells become detached. Growth media containing serum was
then added to the cell suspension to neutralise the trypsin, this was pipetted 
repeatedly to create a single cell solution and split into fresh flasks. The ratio each 
cell line was split at differed, however it was usually between 1:3 and 1:8. The cells 
were then allowed to attach to the plastic and propagate in 37°C, humidified 
incubator in the presence of 5% CO2 .
2.2.4 Freezing/Thawing cells
To freeze cells a monolayer was stripped as described in 2.2.3 and counted. 
The cells were centrifuged at 2000 rpm for 5 minutes and resuspended in the 
appropriate volume of cell freezing buffer to give a cell concentration of between 2-4 
x 106 cells per ml. The cells within a cryovial (Corning, Surrey, UK) were then 
transferred to a temperature of-80°C for between 4-7 days and then to -150°C for 
longer term storage.
Cells were thawed at 37°C and added drop wise to 10ml complete media. The 
cell suspension was then mixed and spun at 2000 rpm for 5 minutes to remove the 
DMSO. The cell pellet was resuspended in complete media and transferred to a T75 
tissue culture flask.
2.2.5 Cell Counts
To allow accurate plating density the cells were counted using an Improved 
Neubauer haemocytometer. This device has a counting chamber that is 0.1 mm deep 
and divided into nine large squares. Following trypsinisation an aliquot of diluted 
cells was mixed with trypan blue to allow quick detection of viable cells under the
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microscope. The viable cells in four of the large squares were counted and an
average taken. That figure was then multiplied 104 (as one square = 0.1 ul) and then 
by the appropriate dilution factor to get number of cells/ml.
2.2.6 Transfection of Mammalian Cells with Vector DNA
SW1353/SaOS-2/Hela cells were seeded in T25 flasks in complete DMEM so 
as to reach approximately 70% confluence the following day. For each T25 to be 
transfected 100 ul Opti-MEM (Gibco) serum free medium was placed into a sterile 
tube, 3 ul Gene Juice (Novagen, Madison, USA) was then added drop-wise directly to 
the serum-free medium and vortexed. The solution was incubated at room 
temperature for 5 min. 1 ug of plasmid DNA was added to GeneJuice/serum-free 
medium mixture for each T25 to be transfected and mixed. The GeneJuice/DNA 
mixture was incubated at room temperature for 15 min. The entire volume of 
GeneJuice/DNA mixture was added drop-wise to the cells in complete growth 
medium (4ml). The flask was rocked to ensure good distribution of the 
genejuice/DNA complexes. The cells were incubated for 24 h at 37°C (5% CC^) 
before the growth medium was removed and replaced with fresh DMEM. At this 
point selective pressure with the appropriate antibiotic (G418 or Puromycin) was put 
on the cells and cultured. Cell growth was observed every day and medium changed 
with selection drug every 2 days. The stable line was usually produced after 4 weeks 
of selection pressure.
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2.2.7 Isolation of Chondrocytes and Matrix Vesicles from Chick Growth Plate
Cartilage
Under sterile conditions, growth plate cartilage from 3-week-old broiler 
chickens was collected and diced. Matrix vesicles were released from this according 
to the collagenase method as previously described (McLean et al, 1987). With the 
following adjustments; diced cartilage was incubated at 37 °C in Hanks buffered 
saline solution (HBSS) (Gibco) containing 0.1% trypsin type II at a ratio of 0.2g 
tissue/ml solution for 30mins. The cartilage was then washed in fresh HBSS and 
incubated in 0.07% collagenase (Worthington, type II) for three hrs with constant 
agitation at 37 °C. The partially digested tissue was passed through a 40 |jM sieve to 
remove mineral and undigested material. The flow through was checked for the 
presence of chondrocytes by microscopy. Chondrocytes and matrix vesicles were 
harvested from the digest by differential centrifugation. Briefly, the digest was spun 
for 30 min at 1500 g to collect chondrocytes, then at 30,000g to remove sub - 
cellular debris and finally at 250,000g to pellet matrix vesicles. Isolated chondrocytes
__ /: f\
were seeded in T25 flasks at an initial density of 1x10 cells/cm in DMEM 
containing 10% FBS. Following cellular attachment the cells were treated with 50 
jig/ml ascorbic acid 2-phosphate (AA) and 10 mM (3-glycerophosphate (POP) to 
induce matrix mineralisation. A media only control was always included. Cells 
reached confluence in approximately seven days.
2.2.8 Isolation of Matrix Vesicles from Cultured Chick Chondrocytes
The cell monolayer was washed with HBSS, and then incubated at 37°C in 
the presence of 0.1% trypsin type II in HBSS for 30min. This was removed, cells
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washed and a 0.07% collagenase (Worthington, type II) solution added, This was
allowed to incubate at 37°C for 10 minutes before scraping into a universal container 
and incubating for a further 90 minutes at 37°C. The cell suspension was subjected to 
differential centrifugation as described in 2.2.7 to isolate both cells and matrix 
vesicles.
2.2.9 Staining of Cell Monolayers 
2.2.9.1 Alizarin Red Staining
This stain is used to detect the presence of calcium deposits on cell 
monolayers and hence is ideal for the detection of hydroxyapatite (calcium 
phosphate) deposits. Calcium forms an alizarin red S-calcium complex in a chelation 
reaction thus areas containing calcium deposits stain red. The growth media was 
removed from the cell monolayer and the cells washed 3x with PBS. The monolayer 
was then fixed in 2% para-formaldehyde (PFA) for 15 minutes at 4°C, washed in 
PBS and stored in PBS until required at 4°C. A solution of 2% Alizarin-S stain was 
made in H2O and pH set at 4.2 with NaOH, this is critical to the staining procedure. 
The monolayer was overlaid with the stain for 5 minutes with constant agitation and 
repeatedly washed with distilled H2O until no stain was present in the wash. To 
quantify dye incorporation the dye was leached from the monolayer by the addition 
of a 10% cetylpyridinium chloride (CPC) solution for 5 minutes (or until all of dye 
had been drawn from the monolayer). The OD of the dye solution was then measured 
at 570nm, calibrating the spectrophotometer to 10% CPC.
55
Chapter 2_____________________________________Materials and Methods 
2.2.9.2 Von Kossa Staining
This stain is used to detect the presence of calcium salt deposits in cell 
monolayers. It utilises silver nitrate in the staining solution (silver ion carries a 
positive charge) binding with the anionic (negative charge) region of the salt (in this 
case phosphate). As the major calcium salt found in mineralising cells is calcium 
phosphate this stain will show regions where crystals of calcium phosphate 
(hydroxyapatite) are present. The growth media was removed from the cell 
monolayer and the cells washed 3x with distilled H2O. The cell monolayer was then 
immersed in 5% silver nitrate for 30 minutes under strong light, this actively reduces 
the calcium and replaces it with silver thus creating black deposits. The monolayer 
was then washed 3x in distilled t^O and incubated with 2.5% sodium thiosulphate 
for 5 minutes to remove unreacted silver ions. The monolayer was then stored under 
distilled H^O until a digital image was taken.
2.2.9.3 Alkaline Phosphatase
This procedure is a simultaneous coupling azo dye method utilising sodium 
a-naphthyl phosphate as substrate for alkaline phosphatase in the presence of fast 
blue RR (a diazonium salt). When the a-naphthyl phosphate is hydrolysed by 
alkaline phosphatase the a-naphthyl couples with the diazonium salt, forming an 
insoluble, visible pigment at sites of phosphatase activity. The growth media was 
removed from the monolayer and the cells washed 3x with distilled H^O. The cells 
were then overlaid with 2 nM a-naphthyl acid phosphate, 2 mM MgC^, Img/ml fast 
blue RR in 0.1 M barbitone buffer pH9.4 (set with HC1) and incubated at 37°C for 6
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minutes. The cells were then rinsed with ice cold 0.1M acetic acid to stop the
reaction and washed 3x in distilled H2O.
2.3 DNA Methods
2.3.1 Transformation of Competent Bacteria
Three stains of Escherichia coll (E. coli) were used in this study, JM109 
(Stratagene, the Netherlands) for routine cloning, TOP 10 (Invitrogen, Paisley, UK) 
for protein expression, and SURE-2 (Stratagene, the Netherlands) cells for pSUPER 
cloning. SURE-2 (Stops Unwanted Recombination Events) were selected due to the 
homologous regions of the pSUPER plasmid having a propensity for recombination, 
when using JM109 this phenomenon is observed. The transformation procedures for 
all three are very similar, the main differences are the length of heat shock. When 
using SURE-2 cells and JM109 cells, 2 ul and 0.8 ul p-mercaptoethanol was added 
respectively to 100 ul of cells and was incubated on ice for 10 minutes (Note this 
step was not necessary with TOP 10 cells). Approximately 20ng of plasmid DNA was 
added to the cells, mixed and allowed to incubate on ice for 30 minutes. Both JM109 
and TOP 10 cells were subjected to heat shock at 42°C for 30 seconds, whereas for 
SURE-2 cells this was 45 seconds thereafter the cells were returned to ice for 2 
minutes. 900 ul SOC (Super Optimal Broth with Catobolite repression; Hanahan, 
1983) media (Invitrogen, Paisley, UK) was added to the cells and incubated at 37°C 
for 1 hr with constant agitation. Aliquots of the transformation mixture were spread 
on LB (Lysogeny Broth; Bertani, 2004) agar plates containing 100 ug/ml ampicillin 
and incubated overnight at 37°C.
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2.3.2 Liquid Culture of Bacterial Clones
Individual colonies were picked from the agar plates of transformed bacteria 
into a 10ml LB culture media containing 100 ug/ml ampicillin. This was incubated 
overnight at 37°C with constant agitation. 2ml of the bacterial culture was spun at 
6,000g and pelleted bacteria resuspended in 1ml LB containing 50% glycerol. These 
glycerol stocks were stored at -20°C until required.
2.3.3 Minipreparation of Plasmid DNA
The remaining 8ml of bacterial culture was used for plasmid DNA production 
utilising the Qiagen miniprep spin kit (West Sussex, UK). Briefly the 8ml of culture 
was spun at 6,000 rpm for 15 minutes and resuspended in 250 ul buffer PI. The cells 
were then lysed by addition of 250 ul buffer P2, and incubated at room temperature 
for 5 minutes. The genomic DNA and proteins were precipitated from the lysate by 
addition of 350 ul buffer N3 and centrifuged at 13,000 rpm for 15 minutes to clear 
the lysate. The supernatant was centrifuged through a Qiagen column containing a 
silica membrane to selectively adsorb plasmid DNA in the high salt buffer. The 
membrane was the washed with buffer PE and plasmid DNA eluted by centrifugation 
at 13,000 rpm with 50 ul buffer EB or distilled water.
2.3.4 Endofree Maxipreparation (Qiagen) of Plasmid DNA
Endofree Maxi Prep kits remove endotoxin generated from gram-negative 
bacteria such as E. coli. Endotoxin-free DNA improves the efficiency of transfection 
into sensitive or immunologically active cells. A 10ml liquid culture was set up as 
detailed above and grown for 9 hrs at 37°C with vigorous shaking (-300 rpm). The
58
Chapter 2 _______^__________________________Materials and Methods 
10ml E. coli culture was then transferred into a flask containing 200ml LB (with 100
ug/ml ampicillin) and grown overnight at 37°C with vigorous shaking (-300 rpm). 
The bacterial cells were harvested by centrifugation at 6000 x g for 15 min at 4°C. 
The supernatant was removed and bacterial pellet resuspended in 10ml buffer PI, the 
cells were then lysed through addition of 10 ml buffer P2 which was mixed 
thoroughly by inverting and incubated at room temperature for 5 minutes. The 
genomic DNA, proteins, cell debris, and SDS were precipitated by addition of 10 ml 
chilled buffer P3, which was mixed by inverting 4 6 times. The lysate was poured 
into the barrel of the QIAfilter cartridge and incubated at room temperature for 10 
min. The lysate was then passed into a sterile tube and 2.5 ml buffer ER was added to 
remove endotoxin and incubated on ice for 30 minutes. The filtered lysate was then 
applied to a QIAGEN-tip equilibrated with buffer QBT and allowed to enter the resin 
by gravity flow. The QIAGEN-tip was washed with 2 x 30 ml buffer QC. The DNA 
was eluted by addition of 15 ml buffer QN and precipitated through the addition of 
0.7 volumes of room temperature isopropanol. This was mixed and centrifuged at 
15,000 x g for 30 min at 4°C to pellet the plasmid DNA. The supernatant was 
decanted and pellet washed with 5 ml of endotoxin-free 70% ethanol and centrifuged 
at 15,000 x g for a further 10 min. The supernatant was decanted and the pellet left 
to air dry for 10 min. The DNA pellet was then re-dissolved in 100 ul endotoxin-free 
buffer TE and stored at -20°C until required.
2.3.5 Agarose Gel Electrophoresis
DNA fragments were separated by horizontal agarose gel electrophoresis. 
Agarose concentrations from 0.75% to 2% were used depending on fragment size
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(higher concentrations for smaller fragments). The gels were produced by dissolving
powdered agarose in TBE buffer by heating to the point of boiling. Ethidium 
bromide (EtBr) was added to a final concentration of 0.5jLig/ml to allow visualisation 
of the DNA under UV light. The gel was then poured into a cassette with slot former 
and allowed to set. The DNA samples were mixed with loading buffer and loaded 
onto the submerged gel. The fragments were separated according to size by applying 
a voltage of 100V across the gel for 1-2 hrs. DNA bands were visualised using a UV 
transilluminator and photographed using attached camera.
2.3.6 Isolation of DNA Fragments from Agarose gel
DNA was separated as detailed in section 2.3.5. The DNA band was 
visualised over UV light (due to EtBr intercalation) and excised using a scalpel 
blade, taking care to trim all unstained gel from the slice. The agarose gel slice was 
weighed and then subjected to the DNA extraction protocol set out in the Quiquick 
gel extraction kit (Qiagen). Briefly 300 jjl of QG buffer was added per lOOmg of 
agarose and heated to 50°C for 10 minutes to dissolve the gel. 100 jiil isopropanol per 
lOOmg agarose was added to the mixture to help increase the DNA yield. The 
mixture was then applied to a spin column and centrifuged at 13,000 rpm for 1 
minute. This allows the DNA to bind to the silica membrane of the column. The 
DNA was then washed with 750 |ul wash buffer (PE) by applying it to the spin 
column and centrifuging at 13,000 rpm for 1 minute. The empty spin column was 
then spun for an additional minute to remove traces of ethanol. The DNA was eluted 
by the addition of 50 |il buffer EB or nuclease free F^O and centrifuging at 13,000 
rpm for 1 minute. The DNA was stored at -20°C until needed.
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2.3.7 Quantification of DNA Concentration
DNA concentration was calculated by UV spectroscopy. Readings were taken 
at 260nm and 280nm. The concentration of DNA was automatically calculated by the 
biowave reader using the following equation: A26o x 50 x dilution factor. The ratio 
of: A26o/ A28o gives an indication to how pure the DNA is, proteins have an 
absorbance at around A28o therefore the lower the number the less pure the DNA 
prep is.
2.3.8 Restriction Endonuclease Digestion of DNA
Digestion of DNA using restriction endonucleases was carried out both as a
diagnostic tool and to allow the formation of a DNA fragment to engineer into other 
DNA i.e. plasmids. Roche restriction endonucleases were used for this process along 
with their optimised buffer. A typical 20 JLL! digest would contain 1 jig DNA, 1 unit 
of the restriction enzyme, 2 jil 1 Ox reaction buffer, the volume was made up with 
distilled H2O. The restriction reaction was carried out at 37°C for 1-2 hrs. If a double 
digest is to be carried out the manufacturers technical data was consulted to find a 
suitable reaction buffer that both enzymes are able to operate in. Usually 1 unit of 
each enzyme would be used per 1 |Lig of DNA in a 20|il reaction.
2.3.9 DNA Ligation into Linearised Vectors 
2.3.9.1 Ligation into the pBAD-TOPO Vector
The pBAD-TOPO vector (Invitrogen, appendix 1) is an expression vector 
which utilises topoisomerase technology to allow direct cloning of PCR fragments in 
front of an arabinose inducible bacterial promoter. Taq polymerase has a non- 
template-dependent terminal transferase activity that adds a single deoxyadenosine
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(A) to the 3' ends of PCR products. This allows ligation directly to overhanging 3'
deoxythymidine (T) residues at the cloning site of the vector. The covalently bound 
topoisomerase 1 enzyme allows the PCR product to be ligated without the enzyme 
DNA ligase. lOOng of PCR product was mixed with 1 jil vector and 1 |ul salt 
solution, this was incubated at room temperature for 5 minutes. This ligation mixture 
was used directly for transformation of competent cells.
2.3.9.2 Ligation into Vectors Linerarised by Restriction Digestion
The vector of choice was linerarised by restriction enzyme digestion using 
enzyme sites contained within the vector multiple cloning site. The insert will also 
have complimentary sites at either terminus making "sticky ends" for ligation. A 
molar ratio of 3:1 insert to plasmid was used for all ligations of this nature. The 
Roche rapid ligation kit was used and manufacturers instructions followed. Briefly 
both insert and vector were diluted in DNA dilution buffer so that the final volume 
equalled 10 \jl, reaction buffer (10 Jill) was then added and mixed. Finally 1 |Lil DNA 
ligase was added to the reaction which was incubated at room temperature for 15 
minutes. This ligation mixture was used directly for transformation of competent 
cells.
2.3.10 DNA Sequencing
DNA sequencing was carried out commercially at either ARK Genomics 
(Roslin) or through the DNA sequencing facility at Dundee University.
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2.4 RNA Methods
2.4.1 Isolation of Total RNA from Cells and Tissues
Ultraspec RNA isolation reagent was used to isolate RNA from both cell
monolayers and tissues. When isolating RNA from a cell monolayer the cells were 
scraped directly in ultraspec (1ml per 25cm2) and transferred to a nuclease free 
universal. Similarly for tissue the dissected organ was immersed in ultraspec (approx 
Iml/g tissue). The tissue/cells were homogenised using an electric homogeniser in 
five 10-second bursts. The universal was returned to ice between each of the bursts to 
prevent heat build up. The homogenised lysate was then passed though a 25G needle 
ten times to ensure the production of a uniform lysate. Chloroform (200 \\\ per ml) 
was added and vortexed for 15 seconds, the sample was then incubated on ice for 5 
minutes, before centrifuging at 12,000g (4°C) for 15 minutes; this separates the 
sample into two phases - the upper, aqueous phase and the lower organic phase. The 
RNA is contained in the aqueous phase and proteins/DNA in the organic phase. The 
aqueous phase was removed and transferred to a sterile tube, and 0.5x the volume of 
isopropanol added to the RNA. 50 |ul RNA Tack resin was added to the RNA and 
vortexed for 30 seconds. The mixture was spun for 1 minute at 12,000g and 
supernatant discarded. The pellet was then washed twice with 75% ethanol by serial 
vortexing and centrifugation. The pellet was then left to air dry for 30 minutes. The 
RNA was eluted from the resin pellet by the addition of 100 |il nuclease free H2O.
2.4.2 DNase Treatment of RNA
To each 100 jol of RNA, 10 |il lOx DNase 1 Buffer (Ambion, Huntingdon, 
UK) was added along with 2.5 jul RNase inhibitors (Promega, Southampton, UK).
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This was vortexed before 5 |jl DNase (Ambion) was added. The RNA was mixed
and incubated at 37°C for 60 minutes. The DNase was inactivated using 0.2 x the 
volume of inactivation reagent (Ambion).
2.4.3 Reverse Transcription Polymerase Chain Reaction (RT PCR)
Reverse transcriptase is a RNA-dependent DNA polymerase which is 
encoded by retroviruses. Their viral function is to copy the viral RNA genome into 
DNA prior to its integration into host cells. This can be exploited to allow production 
of DNA (cDNA) from any RNA template and is known as reverse transcription PCR.
The SUPERSCRIPT - First Strand synthesis system for RT-PCR was used 
for reverse transcription (Invitrogen) along with Oligo dT (Roche, East Sussex, UK).
5 jig RNA sample and 500 ng Oligo dT were mixed and incubated at 70°C for 10 
min to denature the RNA, this was subsequently incubated on ice for 1 minute. 2 ul 
10 x RT buffer, 2 mM MgCl2, 10 mM DTT and 0.5 mM dNTP's were added to each 
RNA sample and mixed, finally 200units (u) Superscript enzyme was added and
mixed. The following PCR cycle was used; 25°C for 10 min, 42°C for 50 min and 
70°C for 15 min for annealing, elongation and termination respectively. The cDNA 
was stored at -20°C until required.
2.4.4 Polymerase Chain Reaction (PCR)
PCR was performed on either cDNA produced from reverse transcription or
on genomic DNA, as a diagnostic tool or to allow the amplification of a gene for 
functional studies. In a typical 50 jil PCR reaction the following quantities of 
reactants were used; 0.2 mM dNTP mix (Promega), 5 (il lOx PCR Buffer (Roche), 5
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units Taq polymerase (Roche), 0.5 |iM of the forward and reverse primers, 4 |ul DNA
(at appropriate concentration) and nuclease free t^O up to 50 |il. This was then 
cycled in a ThermoHybaid Px2 Thermal Cycler under the following conditions: 94°C 
for 5 minutes for one cycle, thirty cycles of 94°C for 30 seconds 55-60°C (depending 
on the melting temperature of the primers) for 30 seconds and 72°C for 1 minute and 
finally one step of 72°C for 10 minutes. The PCR products were then run on an 
agarose gel, as outlined in section 2.3.5.
2.4.5 Real Time (Quantitative) Polymerase Chain Reaction (qPCR)
Tissues from several mice were pooled and RNA was isolated by 
phenol/chloroform extraction and used directly in a quantitative RT-PCR reaction 
The Brilliant® SYBR® Green QRT-PCR Master Mix Kit (Stratagene) method was 
utilised to allow quantification by fluorescence during the PCR reaction. Briefly 25 
|il SYBR green mastermix was added to 10 ng RNA along with 0.2 (iM forward and 
reverse primers for Phosphol (forward: GACAATGAGCGGGTGTTTTC reverse: 
GGGGATGGTCTCGTAGACAG). The RT-PCR reaction was cycled in a Perkin- 
Elmer Applied Biosystems Prism 7700 sequence detector as follows: 50°C for 30 
minutes (RT step), 95°C for 10 minutes, 40 cycles of 95°C for 30 seconds 57°C for 
30 seconds and 72°C for 1 minute. Each tissue sample was tested in triplicate and 
compared to 18S RNA (classic II primers; Ambion) as an external control which 
allowed normalisation of results. An identical PCR was carried out on a dilution 
series of RNA using both gene of interest and external to allow estimation of PCR 
efficiency.
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The raw data is in the form of a Ct value which is the cycle number at which
the fluorescence in the tube passed above a predefined threshold. This Ct value is 
used in the calculations to show relative differences in gene expression in different 
samples. Briefly the difference in Ct values between the gene of interest and the 
control was calculated and used to determine relative quantification by expressing 
the values as 2"ACT.
2.5 Protein Methods
2.5.1 SDS Polyacrylamide Gel Electrophoresis
Mammalian cells and MVs were disrupted by sonication in PBS containing 
1.6 mg/ml of Complete® protease inhibitor cocktail (Roche). Proteins were separated 
according to weight on Novex Bis-Tris gels (Invitrogen) based on the discontinuous 
method of Laemmli (1970). The comb was removed from the pre-cast gel and the 
wells rinsed with distilled water. This gel was then placed in to a tank filled with Ix 
MOPS running buffer (Invitrogen), the central portion of buffer contained an anti- 
oxidant to help keep reduced proteins in a reduced state.
Protein samples in Ix LDS sample buffer (containing DTT reducing agent) 
were heated to 70°C for 15 minutes and cooled on ice. The samples were then 
centrifuged at 13,000 rpm for 30 seconds. The samples (containing approximately 50 
jig lysate protein or 50 ng purified protein) were loaded onto the gel, a pre-stained 
molecular weight marker (See Blue plus 2; Invitrogen) was also loaded into one of 
the wells. The gel was run at 200V for 60 minutes.
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2.5.2 Coomassie Staining of Polyacrylamide Gel
The gel was removed from its cassette and immersed in fixing solution for 
approximately 60 minutes. The gel was then immersed in Coomassie Blue staining 
solution for 60 minutes which served to stain the entire gel blue. This was 
subsequently destained by washing overnight in 500ml destain solution in a sealed 
container at room temperature. This allowed the visualisation of protein as a blue 
band on the gel, however this technique is only sensitive down to 50ng^and and 
therefore other detection systems were used.
2.5.3 Silver Staining of Polyacrylamide Gel
To allow the detection of less protein in a direct method, a silver staining 
protocol is used which is sensitive down to approximately lOng/band. The gel was 
removed from its cassette and immersed in 7% acetic acid for 7 minutes. The gel was 
then immersed in two changes of 200ml 50% methanol for 20 minutes, followed by 
two rinses in 200ml distilled water for 10 minutes. The gel was then submerged in 
staining solution for 15 minutes and rinsed twice in 200ml distilled water for 5 
minutes. The gel was subsequently immersed in developing solution for a maximum 
of 15 minutes, or until bands become visible. The development was stopped by 
rinsing the gel in 3 changes of distilled water.
2.5.4 Western Blotting
The gel was removed from the cassette and immersed in transfer buffer. The 
nitrocellulose membrane that the proteins would be transferred to was washed in 
transfer buffer along with two 3M papers, cut slightly larger than the gel, and four
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foam pads. The nitrocellulose was laid on top of the gel and sandwiched between the 
two 3M papers, ensuring exclusion of any air bubbles. This sandwich was placed in 
the X-blot module (Invitrogen) between the four foam pads. The module was then 
clamped onto the gel tank and topped up with transfer buffer. The proteins in the gel 
were electro blotted on to the nitrocellulose at 30V for 90 minutes. The nitrocellulose 
was then blocked overnight in 5% milk protein (Marvel) in TEST (blocking solution) 
at 4°C to reduce non-specific antibody binding. The primary antibody was added at 
an appropriate dilution in blocking solution and incubated at room temperature, with 
gentle agitation, for 90 minutes. Antiserum was usually used at a 1:500 dilution 
whereas with commercial antibodies a dilution of 1:2000 was used. The 
nitrocellulose was subsequently washed 3 times in 50ml TEST to remove any 
un/loosely bound antibody. The blot was then incubated for 60 minutes with a 
1:2000 dilution of anti-IgG-peroxidase (specificity dependent on primary antibody) 
(DAKO, Denmark) diluted 1:2,000 in blocking solution. The blots were then washed 
3 times in 50ml TEST. The immune complexes were then visualised by enhanced 
chemiluminescence (ECL) (Amersham, Buckinghamshire, UK). This kit operates 
using an acridan-based substrate which when in close proximity to peroxidase 
releases light. The position of the immune complexes were visualised by exposure of 
the membrane to ECL film (Amersham), which was subsequently developed in a 
Kodak automatic developer. Alternatively, in place of ECL, the immune complexes 
were visualised by incubation in a solution containing 25 mM Tris-HCl, pH 7.2, 75 
mM NaCl, 0.25 mg/ml diaminobenzidine (DAB), 0.1 mg/ml CoCl2, 0.15 mg/ml urea 
hydrogen peroxide, which can be visualised directly.
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To assess equal loading the proteins on the blot were stained with India ink
after alkali pre-treatment, as described by Sutherland and Skerrit (1986). Briefly the 
membranes were washed in TBST before incubation with 0.2M NaOH for 5 minutes. 
The membrane was then submerged in 10% India ink solution for 120 minutes and 
finally washed repeatedly in TBST until only the protein bands were visible.
2.5.5 Expression of Recombinant Proteins 
2.5.5.1 Fermentation Method
For large scale protein production (50mg) a 100ml starter culture of E. coli
containing the expression vector was grown to an OD of 1 in LB at 37°C thus 
ensuring the cells were still in the protein producing, log phase of growth. This 
starter culture was spiked into 10 L LB (containing 100 |J,g/ml ampicillin) within the 
fermentation vessel and grown at 37°C till an OD of 0.8 was reached. Recombinant 
protein expression was induced by treatment with 0.1% (w/v) L-arabinose for 4 h. 
The culture was continuously aerated throughout fermentation. Bacteria were 
harvested by centrifugation at 6500g and were resuspended in Ni-NTA lysis buffer 
containing 1.6 mg/ml of Complete® protease inhibitor cocktail (Roche), and 
mechanically lysed using a French press (16,000 psi, 16°C). A clarified lysate was 
prepared by centrifugation at 20,000 g for 1 h. The clarified lysate, which contained 
the recombinant protein, was stored at -20°C until required.
2.5.5.2 Shake-Flask Method
For small scale protein production (Img) a 10ml starter culture of E. coli 
containing the expression vector was grown overnight at 37°C in LB. The 10 ml 
starter culture was spiked into 1L LB containing 100 ug/ml ampicillin and grown to
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an OD of 0.8 at 37°C. Recombinant protein expression was induced by treatment
with 0.1% (w/v) L-arabinose for 4 hrs. Bacteria were harvested by centrifugation at 
6500g for 15 minutes and were lysed in CellLytic  B-II lysis reagent containing 1.6 
mg/ml of Complete® protease inhibitor cocktail (Roche), 50 mg/ml lysozyme, 5 
jig/ml DNase I, 500 mM NaCl and 10 mM imidazole. Clarified lysates were prepared 
by centrifugation at 20,000 g for 1 h. The clarified lysate was stored at -20°C until 
required.
2.5.6 Immobilised Metal Affinity Chromatography (IMAC)
Affinity chromatography was used to allow purification of recombinant 
protein via a 6 His-tag at the C-terminus of the protein. The method of choice utilised 
Ni-NTA agarose (Qiagen) which uses a captured Ni ion to bind the 6 His tag of the 
recombinant protein. A 5 ml Ni-NTA-agarose column was equilibrated with 10 ml of 
Ni-NTA lysis buffer. Following equilibration, a 20 ml aliquot of the clarified lysate 
was applied to the column. The column was then washed with 50 ml of Ni-NTA 
wash buffer and eluted in 5 ml fractions each by addition of a single column volume 
Ni-NTA elution buffer. The fraction containing the pure recombinant protein was 
then dialysed three times in TBS, pH 7.2 (5 L, 4°C, 24 h) and stored at 4°C prior to 
use.
2.5.7 Circular Dichroism
The secondary structure of the mutant recombinant proteins were compared 
to that of wild type using circular dichroism (CD) to confirm that in each case, the 
mutation(s) had not affected the overall fold of the enzyme. CD spectra were
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recorded on a JASCO J-600 spectropolarimeter by using 0.5 mg/ml solutions of
protein in 20 mM potassium phosphate, pH 7.2, 130 mM sodium sulphate. Far-UV 
CD spectra (260 to 200 nm) were obtained using a cylindrical quartz cell with a path 
length of 0.02 cm. Spectra of the mutant proteins were directly compared with that of 
the wild type to identify structural differences.
2.5.8 Antibody Production and Purification 
2.5.8.1 Antibody Production
Antibodies were raised against the recombinant human PHOSPHO1 protein 
and to a peptide corresponding to the C terminal region of human PHOSPHO1 [Cys 
+ 225-239] with the sequence H-C-G-Y-P-M-H-R-L-I-Q-E-A-Q-K-A-E-OH, which 
is identical in both human and mouse proteins. The peptide was produced and 
conjugated to KLH commercially by AFFINITI Research Products Ltd, Exeter, UK 
by a maleimido based coupling procedure via the N-terminal cysteine sulphydryl 
moiety to afford N-terminally conjugated peptides. The recombinant protein was 
prepared and purified as outlined in 2.5.5.1 and 2.5.6, which was subsequently 
dialysed three times into PBS (5 L, 4°C, 24 h).
The immunisation for the recombinant protein antibody was carried out by 
the Scottish National Blood Transfusion Service, Midlothian, UK, and involved four 
sequential immunisations of 100 fig recombinant protein into a New Zealand white 
rabbit at monthly intervals. The first was in Freund's complete adjuvant and the final 
three in Freund's incomplete adjuvant. Serum was obtained 1 week after the final 
immunisation and stored at -20°C until required.
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The production of the peptide antibody was carried out by AFFINITI
Research Products Ltd. The peptide conjugates were emulsified in Freund's 
incomplete and complete adjuvant and injected at multiple sites on the 
hindquarters/flanks of a New Zealand white rabbit at 100 ng/mL at two week 
intervals for fourteen weeks. Pre-immune serum was collected from each animal 
prior to the commencement of immunisation. Serum was collected 1 week after the 
final immunisation and stored at -20°C until required.
2.5.8.2 Antibody Purification
Affinity purified anti-PHOSPHOl antibodies were prepared using 
recPHOSPHOl immobilised on nitrocellulose as an affinity matrix. The matrix was 
prepared by electrophoresing 100 jig recPHOSPHOl on a 10% preparative NuPAGE 
minigel (1 mm x 2D) and transferring the protein onto a nitrocellulose membrane (as 
described in 2.5.1 and 2.5.4). The PHOSPHOl band was visualised by in situ 
derivatisation with fluorescein isothiocyanate (FITC) (Houston et al, 1989). Briefly 
the nitrocellulose membrane was immersed in a 1 00{j,g/ml solution of FITC in 100 
mM sodium carbonate buffer (pH 9.5) for 5 minutes. A single orange band relating 
to the recombinant protein was visible which fluoresces under UV light. The 
membrane was then blocked with 5% milk protein (Marvel) in PBS overnight at 4°C.
The PHOSPHOl band was excised under UV light, cut into approximately 2 
mm x 2 mm squares, washed several times in PBS and stored in PBS at 4°C until 
required. Purified anti-PHOSPHOl antibody was prepared by incubating the 
PHOSPHOl affinity matrix with 2 ml of antiserum diluted 4-fold in PBS, for 2 h at 
RT. The matrix was washed extensively with PBS and the antibody eluted by
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incubation in 0.5 ml 0.2 M glycine-HCl, pH 2.5 for 20 min at RT. The purified
antibody was immediately neutralised using 1.5 M Tris-HCl pH 8.8 and stored at 4°C 
until use.
2.5.9 Protein Concentration Determination - Bradford Assay
The Bio-Rad protein assay kit used is based on the method described by
Bradford (Bradford, 1976). The Bradford protein assay is a simple procedure for 
determination of protein concentrations in solutions and utilises the change in 
absorbance of Coomassie Blue upon binding to protein. The Bradford protein assay 
is not sensitive to interference by chemicals in the lysis buffer, however high 
concentrations of detergent do cause anomalies in results. The method employed 
uses gamma-globulin as a standard. Nine standards of gamma globulin were 
prepared ranging from 10 jig/ml to 90 ng/ml. 160 jal of each standard was pipetted in 
duplicate into a 96 well plate along with a buffer blank. The protein that was to be 
measured was diluted in the same buffer as gamma-globulin and also added to the 
individual wells in duplicate. 40 \a\ of dye reagent concentrate (Bio-Rad, Herts, UK) 
was added to each well and mixed. The plate was incubated at room temperature for 
5 minutes and absorbance's read at 595 nm. The absorbencies of the samples were 
compared to a standard curve generated from the absorbencies from the standards.
2.6 Biochemical Methods
2.6.1 Malachite Green Phosphatase Assay
The standard discontinuous colorimetric assay used was based on that of
Baykov et al, (1988). The reactions were measured in 96-well plates containing 200 
of 25% (w/v) glycerol, 20 mM TBS, pH 7.2, 25 jig/ml BSA, 2.5 mM substrate, 2
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mM of the corresponding divalent metal chloride salt and appropriate mass of
purified recombinant PHOSPHO1. For investigation of the effect of pH on 
PHOSPHO1 activity, 20 mM MES (2-(N-Morpholino)ethanesulfonic acid) was used 
to obtain pH values between 5.0 and 6.7 and 20 mM CAPS (3-(Cyclohexylamino)-l- 
propanesulfonic acid) for pH 9.0, in place of TBS. The ionic strength of each buffer 
was adjusted to that of 20 mM TBS by addition of NaCl. Standard solutions 
containing known concentrations of Kt^PCU were included in each plate. Reactions 
were allowed to proceed for 15 min at 37°C then stopped by the addition of 50 ul of 
3.75 M sulphuric acid containing 3% ammonium molybdate, 0.2% Tween 20 and 
0.12 % malachite green. The absorbance of each well at 630 nm was measured and 
the specific activity was calculated in units of activity per mg of enzyme, where 1 
unit of activity represents the hydrolysis of 1 nmol of phosphate per min.
2.6.2 Purine Nucleoside Phosphorylase (PNPase)-Coupled Phosphatase Assay
The continuous spectrophotometric assay was performed using the 
EnzChek® Phosphatase Assay Kit (Molecular Probes, Paisley, UK), which is based 
upon the purine nucleoside phosphorylase (PNPase)-coupled assay reported by Webb 
(1992). The reactions were measured in 96-well plates containing 25% (v/v) 
glycerol, 20 mM MES, pH 6.7, 500 mM NaCl, 2 mM MgCl2, 0.2 units PNPase, 200 
uM MESG (2-amino-6-mercapto-7-methylpurine ribonucleoside) and 144 ng of 
purified recombinant PHOSPHO1 at 37°C. PNPase and MESG concentrations were 
optimised to ensure that the phosphatase activity was rate-limiting. PHOSPHO1 
substrate concentrations were varied accordingly. Absorbence values were measured 
continuously at 355 nm using a VICTOR HTS plate-reader.
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2.6.3 Matrix Vesicle Alkaline Phosphatase (ALP) assay
To confirm that a preparation was enriched in MVs (from cartilage and cell
culture) an assessment of ALP activity was carried out. The preparation was 
resuspended in HBSS containing 0.05% Triton-x-100 and 1.6 mg/ml of Complete® 
protease inhibitor cocktail (Roche), and subsequently lysed by freeze thawing 3 
times. ALP was assayed for using the Thermo-line ALP reagent (Melbourne, 
Australia). The enzyme activity of the MV and chondrocyte lysate was determined 
by measuring the cleavage of 16.3 mM p-nitrophenyl phosphate (pNPP) at 405 nm at 
pH 10.7. Total ALP activity was expressed as nmoles pNPP hydrolysed/ min/mg 
protein.
2.6.4 Matrix Vesicle Calcium Uptake Assay -Calcium-O-Cresolpthalein 
Complexone (O-CPC) Method.
This assay involves the reaction of calcium with O-CPC at an alkaline pH 
(10-12) to produce a purple complex which can be measured at 575 ± 5 nm. The 
intensity of the colour is directly proportional to the concentration of calcium in the 
sample. The protocol to measure calcium uptake by matrix vesicles was carried out 
as described by Garimella et al, (2004). Briefly samples of MV protein were 
incubated in calcification buffer in the presence of 0 to 3 mM phosphoester substrate 
for 5.5 h at 37°C. The reaction was terminated by centrifugation at 8800g for 30 
minutes to pellet both matrix vesicles and any calcium phosphate mineral formed 
during incubation. The pellet was then solubilised with 0.6N HC1 for 24 h and used 
directly in for calcium quantification using the O-cresolpthalein complexone method 
(CPC Kit, Thermotrace). Briefly, 2 ul of acidified supernatant was incubated with 
200 ul of detection reagent for 1 minute and the absorbance read at 570 nm. A
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standard curve with calibrators of CaCh in 0.6N HC1 was also included on the
microtitre plate.
2.6.5 Inhibitor Screening
The semi-automated screening utilized a Beckman Coulter dual bridge 
Biomek FX liquid handler, consisting of a 96 tip head bridge for mil plate pipetting. 
The reactions were measured in 96-well plates containing 25 ul 20 mM MES-NaOH, 
pH 6.7, 0.01% (w/v) BSA, 0.0125% (v/v) Tween 20, 2 mM MgCl2, 62.5 uM PEA, 
10 uM test compound and 500 ng (0.6 uM) of purified recombinant PHOSPHO1. 
Substrate addition was used to initiate the reaction thus allowing for an 
enzyme/compound preincubation. Reactions were allowed to proceed for 60 min at 
room temperature then stopped by the addition of 50 ul BIOMOL green reagent. The 
absorbance of each well was measured at 620 run and the inhibitory effect of each 
compound calculated as a percentage of 100 in relation to controls containing 1% 
(v/v) DMSO. Each hit was repeated manually in duplicate, a hit from the primary 
screen was considered if inhibition was above 40%.
2.6.6 Kinetic Characterisation of Inhibitors
The continuous phosphatase assay to determine kinetic parameters of the 
reactions involved monitoring the dephosphorylation of pNPP which causes an 
absorbance change at 405 nm. The reactions were measured in 96-well plates 
containing 20 mM MES-NaOH, pH 6.7, 0.01% (w/v) BSA, 0.0125% (v/v) Tween 
20, 2 mM MgCl2, and 1.5 uM purified recombinant PHOSPHO1 at room 
temperature. pNPP and inhibitor concentrations were varied accordingly.
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10-day old mice were killed by cervical dislocation and tibiae were fixed in 
4% paraformaldeyde in PBS for 24 h before decalcification in 0.5M EDTA (pH 8.0) 
for a further 24 h at 4°C.
2.7.2 Wax Embedding
The fixed tissues were dehydrated by passaging through different 
concentrations of alcohol starting with 70% ethanol for 30 minutes followed by 80% 
and 95% ethanol for a period of two hrs each (changing alcohol after a period of 1 
hr) with constant rotation. The tissues were then placed in 100% ethanol and rolled 
for 2 hrs, changing the alcohol after 1 hr. The tissue specimens were transferred into 
a wax embedding cassette lined with filter paper and placed in xylene and rolled for 
2 hrs. The cassettes were then transferred to wax at 60°C for 2 hrs allowing wax 
infiltration of the tissues. The tissue was then embedded into plastic moulds using an 
embedding machine.
2.7.3 Tissue Sectioning
Paraffin embedded tissues were sectioned, using a microtome, into 6 uM 
thick sections and floated out in a 50°C water bath. The sections were then floated
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onto poly-lysine coated slides and allowed to dry in a 37°C oven. Slides were stored
at room temperature until required.
2.7.4 Probing Using Protein Specific Antibodies
Paraffin sections were dewaxed in xylene and rehydrated through a graded 
series of alcohol solutions, antigen retrieval was achieved by heating in sodium 
citrate for 90 minutes at 70 °C followed by extensive washing in PBS. Endogenous 
peroxidases were blocked by incubating the sections with 3% hydrogen peroxide (in 
methanol), followed by 3 washes in PBS. Unspecific protein binding was blocked by 
normal goat serum (1:5) diluted in PBS for 30 min at RT. Rabbit antisera to mouse 
PHOSPHO1 (a generous gift from Professor Ikramuddin Aukhil, University of 
Florida, USA) was diluted 1:200 in PBS and incubated with the tissue section at 4°C 
overnight. Control sections received a similar dilution of normal rabbit serum. 
Following this the sections were washed in PBS, and incubated with a 1:100 dilution 
of goat anti rabbit IgG - peroxidase (DAKO, Cambridgeshire, UK) for 60 min at RT. 
DAB substrate reagent (0.06% DAB, 0.1% H2O2 in PBS) was incubated for 8 
minutes at RT, rinsed in PBS and counterstained with Harris hematoxylin (Sigma) 
for 5 min. The sections were dehydrated and mounted in DePeX.
2.8 Bioinformatic Methods
2.8.1 Sequence Alignments
DNA or protein sequences were aligned using ClustalW programme available
at http://www.ch.embnet.org/software/ClustalW.html. DNA sequencing results (ABI 
files) were assembled using STADEN at the HGMP bioinformatics centre
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(http://www.hgmp.mrc.ac.uk). Protein and DNA similarity searches were done
through BLAST on the NCBI site.
2.8.2 Structural Modelling and Ligand Docking of PHOSPHO1 and 
PHOSPHO2
The protein sequence of PHOSPHO2 was subjected to homology modelling
as described previously for PHOSPHO1 (Stewart et al, 2003). Submitting the protein 
sequence of human PHOSPHO2 to the 3D-PSSM fold recognition server (Kelley et 
at, 2000) revealed the high resolution (1.8 A) X-ray structure of phosphoserine 
phosphatase (A//PSP) from Methanococcus jannaschii (PDB code: 1F5S) (Wang et 
al, 2001) as the most suitable template for homology modelling. A pairwise 
alignment between the target and template sequence was manually adjusted, taking 
into consideration multiple sequence alignments, structural alignments and the 
continuity of secondary structure elements. Twenty models were built using 
MODELLER v6.2 (Sali and Blundell, 1993), keeping the active site Mg2+ and its 
bound phosphate and water molecules in the positions found in the template. A 
disulfide bridge was introduced between Cysl52 and Cysl85, both of which are 
conserved within the PHOSPHO1/PHOSPHO2 multiple sequence alignment, since 
these residues were found in close proximity to each other in the structural model. 
Non-identical side-chains between template and target were optimised using SCWRL 
(Bower ef a/, 1997).
O-U
Hydrogen atoms and bonds between Mg and its coordinating amino acids 
were introduced in SYBYL v.6.9 (Tripos Associates, St. Louis). The resulting pdb 
files were used as input files for FlexX (Rarey et al, 1996). Based on previous 
findings (Stewart et al, 2003), the active sites were defined manually, and included
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the Mg2+ ion, the two water molecules, the residues 32, 34, 43, 60, 64, 71 and 123 for
PHOSPHO1, or 8, 10, 19, 36, 40, 47 and 99 for PHOSPHO2, plus a 2.9 A margin 
around these residues. Substrate starting structures (PEA, PCho, and pyridoxal-5- 
phosphate) were built and energy-minimised in SYBYL v6.9. As our initial 
homology models were necessarily generated without a substrate in the active site, it 
appears as if the sidechain of Arg60 (or Arg36) is trying to fill the "empty space" of 
the active site. Therefore, for subsequent FlexX runs, the side-chain of this residue 
was manually adjusted. Thirty docked structures were generated for each protein, and 
the best was selected based on the overall FlexX score. The resulting protein- 
substrate complexes were energy-minimised in SYBYL v6.9 applying 50 steps of 
minimisation, restricted to the substrate, the Mg2+ ion, and Arg60 for PHOSPHO1 or 
Arg36 for PHOSPHO2 and their immediate surroundings, followed by 100 steps of 
energy minimisation applied to the entire protein. The minimisation protocol used 
the Powell algorithm and an improved version of the Tripos force-field. The validity 
of the resulting model was assessed using PROCHECK v3.5 (Laskowsky et al, 1993) 
and WHAT IF v4.99 (Vriend, 1990), which are available on-line at the "Biotech 
validation suite" at http://biotech.embl-ebi.ac.uk. The validity of the approach was 
tested by docking phospho-L-serine into A//PSP (PDB code: 1F5S). The resulting 
docked model corresponded well with the structure of the DUN mutant of A//PSP 
with bound substrate (PDB code: 1L7P).
The structural modelling and ligand docking experiments were kindly carried out by 
Dr. Ralf Schmid (Institute of Evolutionary Biology) and Dr. Claudia A. Blindauer, 
(School of Chemistry), University of Edinburgh.
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2.8.3 Statistical Analysis
Analysis of variance (ANOVA) was performed to determine the significance 
of a given result. General Linear Model analysis incorporating pair-wise comparisons 
using Turkeys test was used to compare groups within the ANOVA models. All data 
are expressed as the mean ± SD of three observations within each experiment. 
Statistical analysis was performed using Minitab 14. Statistical significance was 
accepted atp<0.05.
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3.1 Introduction
MV-mediated mineralisation is a process central to the formation of bone, 
cartilage and teeth. Inside the MV, calcium phosphate accumulates until sufficient 
amounts are present for precipitation to occur. This is then converted to an 
intermediate, octa-calcium phosphate, crystals of which are transformed into the less 
soluble hydroxyapatite (Sauer and Wuthier, 1988). The MV membranes then 
breakdown and release preformed hydroxyapatite into the extracellular fluid. 
Calcium accumulation is controlled by Ca2+-binding molecules such as annexin I and 
phosphatidylserine (Wu et al, 1995; Anderson, 2003). Pi accumulation is associated 
with the action of alkaline and acid phosphatases (Roach, 1999; Nakano et al, 2003). 
The most abundant of these being TNAP, an isoenzyme of alkaline phosphatase 
expressed in bone, liver and kidney (Anderson, 1995). In addition to its structural 
role, PI has also been shown to regulate multiple genes during osteoblast 
differentiation, including the immediate response gene, Nrf2 (Beck et al, 2003).
Deficiency of Pi in skeletal tissue (termed hypophosphatasia) is highly 
variable in its clinical expression, ranging from death in utero with an unmineralised 
skeleton to premature loss of teeth (Whyte, 1994). Hypophosphatasia is usually 
attributed to a reduction in TNAP activity. In newborn TNAP knockout mice, bone 
development and mineralisation appear to be normal, although hypomineralisation 
and other abnormalities of the skeleton and dentition have subsequently been 
observed (Waymire et al, 1995; Narisawa et al, 1997; Hessle et al, 2002). Where 
failure occurs is in the propagation of the mineral from the MV to the surrounding 
extracellular matrix (Anderson et al, 1997 and 2004). Support for this concept comes 
from earlier work (Genge et al, 1988), which shows that the catalytic activity of
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TNAP decreases in direct proportion to the extent that MVs induce mineral
formation. TNAP is known to hydrolyse PPj (Moss et al, 1967), which is a potent 
inhibitor of hydroxyapatite crystal formation (Meyer, 1984). Abnormalities found in 
TNAP knockout mice are, however, not present in TNAP/NPP1 double-knockout 
mice (Hessle et al, 2002). NPP1 encodes the enzyme, phosphodiesterase I in 
mineralising cells and generates PPj from nucleotide triphosphates (Narita et al, 
1994). Studies have also shown that TNAP can be removed from some preparations 
of MVs without reducing their potential to mineralise (Register et al, 1986), whilst 
specific inhibitory studies on TNAP provide additional evidence that other 
phosphatases are present within mineralising chondrocytes (Hsu and Anderson, 
1996). These observations suggest that the primary role of TNAP in skeletal 
development is to hydrolyse PPj, preventing its inhibition of mineral crystal growth. 
It therefore appears that TNAP is not essential, at least for the initial events leading 
to MV-induced mineralisation and implies that other phosphatases are involved.
PHOSPHOl was identified which is expressed at levels approximately 100- 
fold higher in mineralising chondrocytes than in non-skeletal tissues (Houston et al, 
1999). Immunolocalisation studies have since shown that PHOSPHOl is specifically 
localised to mineralising regions of skeletal tissue (Houston et al, 2004). The amino 
acid sequence of PHOSPHOl contains three peptide motifs that are conserved within 
the HAD superfamily of Mg2+-dependent hydrolases. Human PHOSPHOl shares 
approximately 30% homology at the amino acid level with the LePS2 family of 
phosphatases (Baldwin et al, 2001; Stenzel et al, 2003). Molecular modeling of 
human PHOSPHOl based upon the crystal structure of phosphoserine phosphatase 
from Methanococcus jannaschii shows that all the characteristic features of the
84
Chapter 3 _____Molecular and Biochemical Characterisation of Human PHOSPHOl
catalytic site, with regard to the HAD superfamily, are preserved (Stewart et al,
2003). Despite these structural data, little is known about the activity and substrate 
specificity of PHOSPHO1.
3.2 Hypothesis
That PHOSPHOl is able to sequester Pi from a source close to its localisation thus 
elevating Pi concentrations allowing for hydroxyapatite formation via calcium 
phosphate precipitation.
3.3 Aims
I. Characterise the human PHOSPHOl gene and determine sequence of all 
predicted isoforms as identified by EST analysis.
II. To produce a recombinant human PHOSPHOl protein. This will utilise a 
prokaryotic system to express a truncated form of the protein containing 
only the region that would be common to all predicted forms.
III. To develop an assay system by which phospho-esters can be screened to 
determine compounds which are permissive to phospho-hydrolysis.
IV. To study the kinetic parameters of the best compounds to allow an 
assessment of whether the reaction is favourable or not and hence 
whether it is likely to occur in vivo.
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3.4 Materials and Methods
3.4.1 Analysis of PHOSPHO1 Splice Variants
RNA was isolated from SaOS-2 osteoblast-like cells by ultraspec extraction, 
as described in 2.4.1 and reverse transcribed as described in 2.4.3. PCR primers 
(shown in appendix 2) were designed to allow amplification of exons created through 
alternative splice patterns (defined by EST analysis) as shown in figure 3.1. Each 
transcript was amplified as described in 2.4.4 utilising a 55°C annealing temperature 
and 200ng cDNA. The PCR products were then electrophoresed on a 2% agarose gel 
as described in 2.3.5 and purified using the Qiagen QiaQuick gel extraction kit as 
outlined in 2.3.6. The PCR products were cloned directly into the pGEM-T-Easy 
vector (Promega, as shown in appendix 1) as outlined in 2.3.9.2. This plasmid is pre- 
linerarised and can ligate to the deoxyadenosine (A) at the 3' ends of PCR products 
(as described in 2.3.9.1). The PCR product and plasmid were ligated in a 3:1 ratio 
using lOOng of PCR product. This mixture was used to transform JM109 competent 
cells as outlined in 2.3.1. Liquid cultures and plasmid minipreparations of individual 
clones were subsequently carried out (section 2.3.2 and 2.3.3 respectively). DNA 
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3.4.2 Production of Recombinant Human PHOSPHO1
RNA was isolated from SaOS-2 osteoblast-like cells by ultraspec extraction, 
as described in 2.4.1 and reverse transcribed as described in 2.4.3. cDNA 
corresponding to Metl9-Cys267 of human PHOSPHO1 was amplified by PCR with 
the specific primers (as described in 2.4.4), hs_phosl-fl primer (5'- 
ATGGCCGCGCAGGGC-3') and hs_phosl-rl primer (5'- 
GCACGACTTCAGCACCTGTTGC-3'). This strategy was adopted in view of the 
splice variants arising from the PHOSPHO1 gene and therefore expressing a protein 
which contained only the region that would be common to all predicted forms. The 
expression plasmid of choice was the pBAD TOPO TA vector (Invitrogen, appendix 
1) which is designed to express the recombinant protein fused to a V5 epitope and a 
6 His-tag at the C-terminal (nucleotide and protein sequences shown in appendix 3). 
The cDNA fragment was ligated into the pBAD TOPO TA vector (2.3.9.1) and this 
used to transform TOP 10 cells as described in 2.3.1. Liquid cultures and plasmid 
minipreparations of individual clones were subsequently carried out (section 2.3.2 
and 2.3.3 respectively). A clone containing the PHOSPHO1 fragment in the correct 
orientation was identified by restriction digestion of plasmid minipreps as described 
in 2.3.8. Briefly the plasmid DNA was digested with the restriction enzymes Sphl, 
Pmel and Ascl, the latter is found only within the PHOSPHO1 coding sequence 
(CDS). The E. coli containing the PHOSPHO1 expression vector were grown a 10L 
fermentation vessel and recombinant protein expressed by the addition of arabinose 
outlined in section 2.5.5.1. The recombinant protein was purified by Immobilised 
Metal Affinity Chromatography (IMAC) as described in 2.5.6. Briefly the NiNTA 
agarose utilises NTA which is a tetradentate chelating adsorbent. NTA occupies four
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of the six ligand binding sites in the coordination sphere of the nickel ion, leaving
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Figure 3.2 Mechanism of nitrilotriacetic acid mediated affinity 
chromatography. Note the ability of NT A to occupy 4 of the six binding sites in the 
coordination sphere thus allowing 6 His binding through the remaining two sites.
3.4.3 Western Blotting
To confirm that the purified protein was indeed PHOSPHO1 1 jig of purified 
protein was subjected to SDS-PAGE as described in 2.5.1, which was subsequently 
blotted onto nitrocellulose and used for Western blotting analysis as outlined in 2.5.4. 
This utilised a 1:3000 dilution of mouse monoclonal horseradish peroxidase-labeled 
anti-V5 antibody (Invitrogen). The immune complexes were then visualised using 
the DAB technique as described in 2.5.4.
3.4.4 Phosphatase Assays
The standard discontinuous colorimetric assay used was based on that of 
Baykov et al, (1988) as described in section 2.6.2 utilising 600ng of purified 
recombinant PHOSPHO1 per reaction. Twelve compounds were analysed for
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phosphatase activity (Table 3.1); specific activities were calculated in units of 
activity per mg of enzyme, where 1 unit of activity represents the hydrolysis of 1 
nmpl of phosphate per min. A standard curve using 5 to 50 nmoles phosphate 
(KH2PO4) under the conditions described in section 2.6.2 is shown in figure 3.3, a 
typical assay plate is shown in figure 3.4.
To analyse kinetic constants for these reactions the continuous 
spectrophotometric assay was performed using the EnzChek® Phosphatase Assay 
Kit (Molecular Probes) as described in 2.6.2 utilising 144ng of recombinant 
PHOSPHO1 per reaction.
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Figure 3.3 Standard curve showing linear absorbance. The reaction utilises the 
modified malachite green assay as described in section 2.6.2 and known 
concentrations
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Figure 3.4 Malachite green assay plate containing blank reactions and 
standards. The reaction utilises the modified malachite green assay as described in 
section 2.6.2 and known concentrations of Kt^PCU as standards. The phosphate 
containing substrates are set up in triplicate reactions, note the presence of two 'hits' 
when comparing the substrates (indicted by the red boxes) to the blanks (indicted by 
the blue box).
3.5 Results
3.5.1 Splice Variant Analysis
Analysis of the PCR products from section 3.4.1 as shown in figure 3.5 
revealed several bands which correspond directly to the expected size of certain 
PHOSPHO1 splice variants. Primer pair 1 should amplify both splice variant 1 and 2, 
however only a band of 230bp (bandl, 230bp) corresponding to splice variant 2 is 
observed. Primer pair 2 should amplify splice variants 1 to 3 however only bands 
corresponding to splice variant 2 (band 2, 638bp) and splice variants 3 (band 3, 
51 Ibp) are present. To identify spice variant 4 primer pair 3 was used, the expected 
product sizes were 31 Ibp (band 4) for large Exon 1 (la and Ib) transcript and 202bp 
(band5) for a transcript containing exon la only, corresponding to splice variant 4. 
The sequence of each of these transcripts was determined and compared directly to
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the ESTs which suggested the existence of each of these varients. This confirmed the
existence of splice variants 2, 3 and 4. Interestingly analysis of the reading frames 
from the sequences of the EST clones reveal that only three proteins can arise from 
these splice variants due to the start codon arising on exon 2. The introduction of 
exon 3 a causes this to be lost and due to a frame shift giving rise to a new start codon 
within exon 3 a, however the introduction of exon Z causes the frame shift to be 
corrected thus creating a protein containing information from exon 2, Z, 3a and 3b. 
However as it was not possible to amplify splice varient 1, it either does not exist, or 
is not expressed within bone cells, thus only two potential proteins are present within 
bone cells (29 and 32 KDa forms).
200bp
Figure 3.5 Agarose gel electrophoresis of PCR products corresponding to splice 
variants of human PHOSPHO1. 1 & 2 correspond to splice variant 2, 3 
corresponds to splice variant 3, band 4 corresponds to variant 2 and 3, band 5 
corresponds to variant 4.
3.5.2 Production of a pBAD-PHOSPHOl Clone
pBAD-PHOSPHOl clones were analysed for orientation in respect to the 
bacterial arabinose inducible promoter. As seen in figure 3.6 the clones display two 
different digestion patterns when digested with Sphl, Pmel and Ascl. When in the 
correct orientation the clones should display DNA fragments equal to 2656bp,
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1384bp and 833bp and when inverted, sizes 2656bp, 2103bp and 144bp would be 
present. From this is can be deduced that clone A and clone C have the PHOSPHOl 
CDS in the correct orientation while clone B is inverted. All clones with PHOSPHOl 
in the correct orientation were DNA sequenced and one displaying the correct 






Figure 3.6 Analysis of three pBAD-PHOSPHOl clones by restriction digestion 
with enzymes Sphl, Pmel and Ascl. Clones A and C represent plasmids that have 
PHOSPHOl CDS in the correct orientation.
3.5.3 Purification of Recombinant Human PHOSPHOl
Recombinant His-tagged PHOSPHOl protein in fractions eluted from a Ni- 
NTA-agarose column were assayed by SDS-PAGE. Typically, fraction 2 yielded a 
single band of the expected mass (32 kDa) consistent with >99% purity (figure 
3.7A). The final yield of protein was approximately 35 mg per 10 litres of culture. 
Western blotting of the purified protein yielded a band of expected size which 
showed the presence of the V5-epitope tag (figure 3.7B).
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Figure 3.7 SDS-PAGE and Western analysis of purified recombinant human
PHOSPHOl. (A), the cell lysate (L) and the flow-through (FT), wash (W) and 
eluted fractions 1 and 2 (Fl and F2) from each stage of Ni-NTA purification were 
subjected to SDS-PAGE under reducing conditions and visualised by Coomassie 
Blue staining. Molecular weight standards are also shown (M). (B), Western blot 
(WB) of the purified protein (1.2 jig) with anti-V5 antibody, which recognises the V5 
epitope tag fused to the recombinant protein near its C-terminus.
MALDI-TOF mass spectrometry (commercial analysis at Moredun Research 
Institute, Functional Genomics Unit) was carried out on a purified recombinant 
PHOSPHOl as a secondary method for protein identification and verification that it 
was indeed PHOSPHOl. The peptide masses were searched against the mascot 
database which returned a top score of 97 for the protein and was therefore identified 
as PHOSPHOl (figure 3.8). This score is the probability mowse score for the 
peptides where the score is equal to -10*Log(P), where P is the probability that the 
observed match is a random event. Protein scores greater than 58 are significant 
(p<0.05). 13 of the identified peptides matched tryptic fragments of PHOSPHOl 
spanning from the N to the C terminus of the protein.
94





Figure 3.8 MALDI-TOF mass spectra of recombinant PHOSPHO1. All labelled 
peaks represent major fragments relating to tryptic peptides from the recombinant 
PHOSPHO1 protein (Expected peptide masses shown in appendix 5).
3.5.4 Catalytic Properties of Recombinant Human PHOSPHO1 
3.5.4.1 Substrate Specificity
Twelve phosphate compounds were investigated as potential substrates for 
human PHOSPHO1. The resultant specific activities are shown in Table 3.1. 
PHOSPHO1 was found to have the highest specific activities toward 
phosphoethanolamine (PEA) and phosphocholine (PCho), with PEA being 
hydrolysed approximately 1.5 times faster than PCho. Six of the potential substrates 
tested (pyrophosphate, phospho-L-serine, glycerone phosphate, fructose-6- 
phosphate, phospho-L-tyrosine and ATP) yielded no detectable phosphatase activity.
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_ . Specific activity Compound r J 
________________________(units/mg)
">" Phosphoethanolamine 4,600 ±5 82
y





Ribose-5-phosphate 74.8 ± 6.2
.o o





" o- \o f ° (3-Gtycerol phosphate 39.6 ± 6.2
Pyridoxal-5-phosphate 17.6 ± 12.4
Pyrophosphate <0.1
Phospho-L-serine < 0.1









0 0H ° "c Fructose-6-phosphate < 0.1
,\__/ ^ ,o Phospho-L-tyrosine < 0.1
« 
'o- •*>•*- ATP <0.1
o 'a o
Table 3.1 Substrate specificity of recombinant human PHOSPHOl.
Recombinant human PHOSPHOl (3 j^g/ml) was incubated with each substrate and 
assayed for phosphatase activity by the discontinuous assay at 37°C. The 200 jil 
reaction mixture contained 25% (v/v) glycerol, 20 mM TBS, pH 7.2, 25 jig/ml BSA, 
2.5 mM substrate and 2 mM MgCli. The results are the averages of triplicate assays.
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3.5.4.2 Magnesium and pH Optimum
The concentration of MgC^ was varied between 2 jjM and 200 mM and
activity was found to be maximum at 2 mM MgC^. In the presence of 2 mM Mg + at 
37°C, the recombinant enzyme exhibited a pH optimum around 6.7 for both PEA and 
PCho (figure 3.9). High catalytic activity (greater than 70% of maximum) was 
observed between pH 6.0 and 7.2. This high level of activity extends up to at least 




















Figure 3.9 Determination of the optimum conditions for activity of recombinant
PHOSPHOl. Enzymatic activity was measured in the presence of 3 |J,g/ml enzyme
^ i _concentration (A) dependence of apoenzyme activation by Mg for PEA (solid line) 
and PCho (dashed line); (B) the optimum pH was measured utilising buffers 
spanning pH 5 to 9, enzyme activity was measured using the discontinuous assay in 
the presence of 2 mM Mg2+, for PEA (solid line) and PCho (dashed line).
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3.5.4.3 Kinetic Constant Determination
The kinetic constants of recombinant PHOSPHO1 were determined for PEA 
and PCho using the continuous coupled assay in the presence of 2 mM Mg2+ at 37°C 
(pH6.7). The enzyme exhibited Michaelis-Menten kinetics for both substrates (Hill 
coefficients = 1.00). A plot of reaction rate versus substrate concentration for PEA 
and PCho and also Lineweaver-Burke plots, allowing the calculation of Km and Vmax 
values, are shown in figure 3.10 for PEA and 3.11 for PCho. PHOSPHO1 displayed 
an apparent Km of 3.0 uM and a kcat of 2.27 s" 1 for PEA, and a Km of 11.4 uM and a 
kcat of 1.98s' 1 for PCho.
3.5.4.4 Requirement for Metals
To investigate the requirement of metal ions for the recombinant enzyme, the 
purified enzyme solution was extensively dialysed against metal-free buffer to 
remove any weakly bound metal ions. The effect of different metal ions on the 
hydrolysis of PEA and PCho was assessed by addition of 2 mM concentrations of 
various metal salts. As controls, reactions were also carried out in buffers without 
added metal ions. The results are shown in figure 3.12.
The phosphatase activity was approximately 80-fold higher for both 
substrates in the presence of Mg2+ compared to the metal-free control. Co2+, Mn2+
_ /~n i
and Ni also stimulated activity but to a lesser extent than Mg , whereas the 
presence of Ca2+ and Zn2+ had no apparent effect on activity compared to the control 
(Mg2+ > Co2+ > Mn2+ > Ni2+ > Ca2+ = Zn2+ = no metal). Interestingly, PHOSPHO1 has
_ -^ i -^ i
a higher activity toward PCho than to PEA in the presence of Co and Mn . This is
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most likely to be due to an allosteric effect caused by a difference in the metal- 
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Figure 3.11 Kinetic analysis of substrate hydrolysis catalysed by recombinant
PHOSPHO1. Kinetic activity towards (A) phosphoethanolamine and (B) 
phosphocholine, measured using the continuous assay as described in 2.6.2. Shown 
are the reaction velocities (V) as a function of substrate concentration. Insets, 
Lineweaver-Burke plots from which Km and Vmax values were calculated, kcat =
99
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Figure 3.12 Metal requirement for activity of recombinant PHOSPHO1.
Enzyme activity toward PEA (shaded boxes) and PCho (white boxes) was measured 
in the presence of the indicated metal ions (final concentration 2 mM). No metal, the 
activity of the apoenzyme was measured in the absence of added metals.
3.5 Discussion
The characterisation of the human PHOSPHO1 gene reveals five splice 
variants from which 3 proteins with alternative N terminal regions can be produced. 
This is not uncommon within the haloacid dehalogenase superfamily, in fact H+-K+- 
ATPases show a somewhat similar splicing pattern with alternative transcriptional 
initiation and mRNA splicing giving rise to distinct N-terminal variants of the 
HKalpha2 subunit (Kone and Higham, 1998). The splice variants of PHOSPHO1 
only differ in the N terminal region thus these variants are perhaps encoding 
PHOSPHO1 proteins with slightly different functions within or outside the cell. In
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fact when the variant with the 3a Exon is analysed with the SignalP package it has a
relatively strong secretory domain hinting that this form is either being secreted or in 
some way signalled to somewhere in the cell. All three domains within the 
PHOSPHO1 gene are conserved within the exon 3b thus indicating that these splice 
variants are all functioning against a common substrate or substrate structure, as with 
the example of H+-K+-ATPases, the N terminal alteration causes the differences in 
pharmacological profile but not on substrate specificity. Although ESTs are present 
for all 5 splice variants, hence indicting the potential for all three proteins to be 
expressed, only two are present in bone cells as no splice variant containing the Z 
exon could be amplified from SaOS-2 cell RNA. The lack of quantitative data for 
these two transcripts, however, mean that no hypothesis to which isoform is more 
predominant can be formed.
The results of the biochemical characterisation show that PHOSPHO1 has an 
activity which is typical of most enzymes within the HAD superfamily, with a strong 
Mg2+-dependence and a pH optimum within the acid-to-neutral pH range (Morais et 
al, 2000; Klutts et at, 2003; Wu and Woodard, 2003). A high level of activity 
extends up to at least pH 7.5 for PEA but begins to decline significantly for PCho 
after pH 7.2. The pH of the extracellular fluid of growth plate cartilage is close to pH 
7.6 (Howell et al, 1968) and so the activity of PHOSPHO1 may be restricted mainly 
to PEA at this region. Overall, PHOSPHO1 has a high specific activity toward PEA 
and PCho compared with the other phosphomonoesters investigated, which is not 
surprising due to the high degree of structural similarity between these two 
compounds. The results are highly significant for the mineralisation process in cells. 
Both PCho and PEA are present in mineralising cells and are the two most abundant
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phosphomonoesters in cartilage (Kvam et al, 1992). The very low Km values for both
PEA and PCho (uM range) suggest that they would be half-saturated at levels of 3 
and 11.4 uM, respectively. This indicates that under the reported conditions both 
substrates would be rapidly hydrolysed. These compounds are therefore likely to be 
natural substrates of PHOSPHO1.
The hydrolysis of PEA and PCho is known to occur in vivo, although the 
enzyme responsible has not been identified previously. It has been hypothesised that 
PEA is a natural substrate for TNAP (Whyte, 1994, 1995) due to an increase in its 
urinary excretion in patients diagnosed with hypophosphatasia (Rasmussen, 1968). 
However, this appears unlikely following examination of kinetic data for the TNAP- 
catalysed hydrolysis reaction at physiological pH, with reported high Km values at 
mM concentrations (Tenenbaum and Palangio, 1987; Fedde et al, 1988; Muller et al, 
1989). It is therefore possible that the genetic defect assumed to be caused by a loss 
of TNAP in hypophosphatasia is actually due to a loss or defect of PHOSPHO1. 
Although the mutation which causes this disease is mapped directly to the TNAP 
gene an indirect effect on PHOSPHO1 activity can not be ruled out. It is known that 
when TNAP is absent the components of the extracellular fluid are altered (Anderson 
et al, 2004). Brain alkaline phosphatase (BAP), an isoenzyme of TNAP, is reported 
to have PCho phosphatase activity (Sok, 1999). However, the specific activity of 
BAP toward PCho in the reported study was measured under alkaline conditions (pH 
8.5) and is likely to be much lower at physiological pH. PCho hydrolysis has been 
studied in hamster heart and is not catalysed by alkaline phosphatase but by a 
separate unidentified enzyme (Hatch and Choy, 1987). It has also been shown that 
the hydrolysis of PEA and PCho is due to the action of an acid phosphatase in a
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variety of tissues including bone and teeth (McDonald et al, 1980), a study which
agrees well with our present finding that PHOSPHO1 displays high activity toward 
both substrates between pH 6.0 and 7.2.
PEA and PCho are metabolites in the cytidine 5'diphosphoethanolamine 
(CDP-EA) and cytidine 5'-diphosphocholine (CDP-Cho) pathways, respectively 
(Scheme 3.1). These are the main pathways involved in the formation of 
phosphatidylcholine and phosphatidylethanolamine (Walkey et al, 1997), which are 
involved in the metabolism of complex glycerolipids, GPI-anchors, prostaglandins, 
leukotrienes and the amino acids glycine, serine and threonine (Kanehisa, 2002). 
These pathways are also implicated in the pathogenesis of Alzheimer's and 
Huntingdon's disease (Ellison et al, 1987; Farber et al, 2000). Therefore the 
identification of a phosphatase with specificity toward PEA and PCho is highly 
significant. Conversely, phosphatidylethanolamine and phosphatidylcholine may be 
hydrolysed by phospholipase C to form PEA and PCho, respectively (van Dijk et al, 
1997). The synthesis of phosphatidylcholine from choline by the CDP-Cho pathway 
in mineralising cells has previously been investigated. PCho accumulation is greatly 
decreased in neo-natal rat calvaria compared with the liver of the same animal (Stern 
and Vance, 1987). PCho concentration is usually determined by the relatively higher 
activity of choline kinase compared with that of phosphate cytidylyltransferase 1. 
However, the low PCho accumulation in mineralising compared with non- 
mineralising cells may be due to the upregulation of PHOSPHO1. PHOSPHO1 is 
highly expressed at sites of mineralisation (Houston et al, 2004) and as a 
consequence will reduce the levels of PCho and PEA in chondrocytes and 
osteoblasts. Pi may be scavenged from PEA and PCho during the mineralisation
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Scheme 3.1 Human PEA and PCho metabolism. Proposed metabolic pathways for 
the generation of PEA and PCho. The basis of the diagram is information from the 
Kyoto Encyclopedia of Genes and Genomes (KEGG) (Kanehisa et al, 2002).
The MV-membrane is a rich source of both phosphatidylethanolamine and 
phosphatidylcholine and may act as a pool for PEA and PCho in MVs. Wu et al, 
(2002) have found that the phosphatidylethanolamine and phosphatidylcholine 
composition of the MV membrane decreases during mineralisation and that 1,2-
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diacyl glycerol accumulates in MVs, indicative of phospholipase C activity.
However in the absence of any kinetic data relating to phosphatidylethanolamine or 
phosphatidylcholine degradation in MVs it is impossible to say at this time whether 
such a mechanism exists as a viable means of generating PEA or PCho. Ca2+ and PI 
are present at high levels in MVs even before induction of mineral formation and are 
derived from cellular activity prior to MV formation (Wu et al, 1997). Since the 
ambient concentration of Pi in the extracellular fluid is close to 2 mM (Wuthier, 
1977), it is doubtful that the amount of P, released from MV lipids would be 
sufficient to increase the overall level of extracellular Pi. However, the local effect of 
this limited release may be sufficient to alter the Pi/PPi ratio thus facilitating mineral 
formation.
In conclusion, these results show for the first time that human PHOSPHO1 is 
a PEA and PCho phosphatase. PHOSPHO1 is known to be upregulated in 
mineralising cells, these findings therefore provide a novel means of generating PI in 
mineralising cells and may have implications for the diagnosis hypophosphatasia and 
treatment of bone mineralisation abnormalities such as osteomalacia and pathological 
soft-tissue ossification, a process clinically significant in atherosclerosis and heart 
failure.
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4.1 Introduction
The discovery of PHOSPHO1 provides a close link between PEA and PCho 
accumulation and the generation of Pi in mineralising cells. PHOSPHO1 is therefore 
a potential target in the design of new therapeutics toward diseases such as 
osteopetrosis and craniosynostosis, which lead to skeletal abnormalities characterised 
by excess or premature mineral formation (Kaplan et at, 1991). Inhibition of 
PHOSPHO1 may also be of benefit in the treatment of vascular calcification, a 
process that shares many similarities with the mineralisation of bone and is clinically 
significant in atherosclerosis and heart failure (Bostrom, 2001).
Enzymes of the HAD superfamily catalyse the hydrolysis of C-C1, C-OP and 
C-P bonds from a wide range of substrates and demonstrate great functional diversity 
from a single protein fold. The amino acid sequence of PHOSPHO1 contains three 
motifs that are conserved within the HAD superfamily. These motifs form the active 
site of this group of enzymes, which includes a variety of magnesium-dependent 
phosphatases (Ridder and Dijkstra, 1999). In motif 1, DXDX(T/V), both Asp
O_i_
residues coordinate to the catalytic Mg ion, and the first Asp also forms a phospho- 
protein intermediate during hydrolysis (Wang et al, 2002). In motif 2, (S/T), the 
conserved serine or threonine is involved in hydrogen bonding to a phosphoryl 
oxygen. Motif 3, K(X)i 8.30(G/S)(D/S)XXX(D/N), is also involved in phosphoryl 
oxygen hydrogen bonding and coordination to the Mg2+ ion (Wang et al, 2002; 
Collet etal, 1999).
A search for homologous proteins to PHOSPHO1 revealed the sequence of 
PHOSPHO2, a putative human phosphatase that shares 42% sequence identity with 
human PHOSPHO1. Analysis of ESTs in dbEST indicate that PHOSPHO2 is
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expressed in a wide range of tissues. In addition, analysis of transcript levels in chick
has revealed that the transcript is present in both mineralising and soft tissues and 
expression is comparable in all tissues analysed as shown in figure 4.IB (Houston, 
unpublished data). The transcript levels do not alter depending on degree of 
chondrocyte differentiation and transcript is present in both SaOS-2 and MG-63 
cells, which is the converse of PHOSPHO1 expression, as shown in figure 4.1. 
Orthologous proteins to PHOSPHO2 were also found and figure 4.2 shows a 
sequence alignment of PHOSPHO1 and PHOSPHO2 proteins from a number of 
species. Analysis of sequences with the program SignalP v3.0 (Bendtsen et al, 2004) 
suggests the absence of any signal sequences in the PHOSPHO1 or PHOSPHO2 
proteins suggesting both enzymes are cytosolic. Closer inspection of the amino acid 
sequence of PHOSPHO2 protein revealed that all three catalytic motifs are 
conserved. Also conserved are Asp 19 and Asp99, which correspond to two residues 
(Asp43 and Asp 123) previously postulated to be involved in substrate-specific 
interactions in PHOSPHO1 (Stewart et al, 2003). These two residues were found to 
line the substrate-binding pocket in a structural model of PHOSPHO1 (as shown in 
figure 4.3), and are the only residues in this region that are conserved between 
orthologous proteins from other species, but not in PSPs, which are a closely related 
group of enzymes within the HAD superfamily. In contrast, in PSP with bound 
substrate (PDB: 1L7P; AspllAsn mutant), Glu20, Met43, Phe49 and Arg56 have 
been shown to be involved in phospho-L-serine binding, and these residues are fully 
conserved in PSPs, but not present in PHOSPHO1 or PHOSPHO2 (Wang et al, 
2002). These observations have led to the suggestion that PHOSPHO1 and
108
Chapter 4 ___ Probing the Substrate Specificities of Human PHOSPHOl and PHOSPHO2 
PHOSPHO2 might utilise the same, or highly similar substrates. If true, this would
intimate functional redundancy between PHOSPHOl and PHOSPHO2 in vivo.
B
18SRNA 













Figure 4.1 Analysis of PHOSPHO2 expression in tissues and cells. (A)
Expression of PHOSPHOl, PHOSPHO2 and marker genes in growth plate 
chondrocytes at varying stages of differentiation (B) Expression of PHOSPHOl and 
PHOSPHO2 in chick tissues (C) Expression of PHOSPHOl, PHOSPHO2 and TNAP 
(ALP) in the human osteoblast cell lines SaOs-2 and MG-63 (Houston et al, 1998 
and unpublished data).
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Figure 4.2 Alignment of the amino acid sequences of PHOSPHO1 with
PHOSPHO2 and its homologues. The three catalytic motifs are highlighted in grey. 
The white on black letters denote residues which are proposed to be involved in 
substrate specific interactions. The following sequences are used (accession numbers 
are shown in parentheses): HsPUOSl, human PHOSPHO1 (Q8TCT1); MmPHOSl, 
mouse PHOSPHO1 (Q8R2H9); tf«PHOSl, rat PHOSPHO1; GgPHOSl, chicken 
PHOSPHO1 (O73884); TrPHOSl, puffer fish PHOSPHO1; //sPHOS2, human 
PHOSPHO2 (Q8TCD6); MmPHOS2, mouse PHOSPHO2 (Q9D9M5); /toPHOS2, 
rat PHOSPHO2 (XP_230005); GgPHOS2, chicken PHOSPHO2 (XP_422006); 
Z)rPHOS2, zebrafish PHOSPHO2 (ENSDARP00000004689); 7>PHOS2, puffer fish 
PHOSPHO2 (SINFRUP00000138420). "*" = identical or conserved residues in all 
sequences in the alignment, ":" = indicates conserved substitutions and "." = 
indicates semi-conserved substitutions.
In this study site directed mutagenesis has been used to confirm PHOSPHO1 
as a member of the HAD superfamily and also to ascertain the importance of Asp43 
and Asp 123 residues for the catalysed hydrolysis of PEA and PCho. The activity of 
PHOSPHO2 protein toward PEA and PCho as well as a range of other potential 
substrates is investigated. In addition, structural models of PHOSPHO1 and
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PHOSPHO2 based upon the X-ray crystal structure of PSP from Methanococcus
jannaschii are presented and potential enzyme-substrate interactions using in silico 
ligand docking experiments examined.
Figure 4.3 PHOSPHOl binding site showing 4 residues targeted for mutation.
Asp32 and Asp203 are critical for bond hydrolysis in the HAD superfamily, whereas 
Asp43 and Asp 123 have been hypothesised to be involved in substrate specific
_ O-|-interactions. The Mg ion is coloured green and the Phosphate moiety coloured 
orange.
4.2 Hypothesis
That PHOSPHO2 displays a similar substrate specificity profile to PHOSPHOl due 
to the conservation of the three catalytic motifs found in PHOSPHOl and residues 
that have previously been implicated in substrate specific interactions. Also that D32 
and D203 are essential for PHOSPHOl mediated catalysis of PEA.
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4.3 Aims
I. To produce a recombinant human PHOSPHO2 protein in an identical manner 
to the PHOSPHO1 protein described in chapter 3 and compare substrate 
specificity profile of the two enzymes
II. To create mutants of the PHOSPHO1 protein to confirm its identity as a HAD 
enzyme and to investigate substrate binding residues of the active site.
III. To study the kinetic parameters of the mutant PHOSPHO1 protein to allow 
an assessment of mutational effect.
IV. To model the PHOSPHO2 protein and compare this to the existing 
PHOSPHO1 model allowing an assessment of active site differences and 
further investigate residues essential for catalysis.
4.4 Materials and methods
4.4.1 Site-Directed Mutagenesis of Human PHOSPHO1
DNA corresponding to Metl9-Cys267 of human PHOSPHO1 was amplified 
and cloned into the pBAD TOPO TA vector (Invitrogen) as described in chapter 3. 
Oligonucleotide-directed mutagenesis was used to prepare cDNAs encoding the 
PHOSPHO1 mutants. Mutagenesis was performed using the QuikChange Site- 
Directed Mutagenesis kit (Stratagene). This kit utilises PCR-based methodology 
using overlapping sense and antisense primers containing the desired mutation. As 
the primers intrinsically become part of the PCR product the mutation will be
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incorporated into the product produced by PCR as described in 2.4.4. Briefly the
reaction mixture used for mutagenesis contained 500ng PHOSPHO1 clone, 125 ng 
each primer (sequences shown in appendix 6), 1 |il dNTP mix, 2.5units Pfu Turbo 
DNA Polymerase. The reaction was cycled at 60 seconds at 95°C for 1 cycle, 50 
seconds at 95 °C; 50 seconds at 60 °C; 300 seconds at 68 °C, for 18 cycles, followed 
by 420 seconds at 68 °C for one cycle. Treatment of DNA after PCR with the 
restriction enzyme, Dpnl, selectively destroys the parental DNA while leaving the 
newly mutated DNA intact. This is due to the parental DNA being methylated when 
cloned in bacteria. The restriction enzyme Dpnl will only digest methylated DNA 
and since PCR-amplified DNA is unmethylated it will survive the digestion process. 
The digest was conducted as described in 2.3.8 utilising the entire PCR reaction and 
10U Dpnl enzyme. Five mutants were prepared in this manner (D32N, D43N, 
D123N, D203S and a double mutant D43N/D123N). The digestion mixture (1 ul) 
was then used to transform TOP 10 cells as described in 2.3.1. Liquid cultures and 
plasmid mini-preparations of individual clones were subsequently carried out 
(section 2.3.2 and 2.3.3 respectively). Clones containing the desired mutation(s) were 
identified commercially (The UK Centre for Functional Genomics in Farm Animals 
(ARK-Genomics), Roslin, UK) by nucleotide sequence analysis across the mutation 
site. The mutant proteins were expressed utilising the shake flask method as 
described in 2.5.5.2 and purified by Immobilised Metal Affinity Chromatography 
(IMAC) as described in 2.5.6. The secondary structures of the mutants were 
compared to that of wild type recombinant PHOSPHO1 using circular dichroism 
(CD) to confirm that in each case, the mutation(s) had not affected the overall fold of 
the enzyme. CD spectra were recorded on a JASCO J-600 spectropolarimeter by
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using 0.5 mg/ml solutions of the recombinant PHOSPHO1 proteins in 20 mM
potassium phosphate, pH 7.2, 130 mM sodium sulphate. CD analysis was performed 
by Dr Sharon Kelly, University of Glasgow.
4.4.2 Production of Recombinant PHOSPHO2 Protein
DNA corresponding to PHOSPHO2 was amplified from human genomic 
DNA, as the whole coding sequence was found to be on the same exon, by PCR as 
described in 2.4.4. The expression plasmid of choice was the pBAD TOPO TA 
vector (Invitrogen) as used for PHOSPHO1 and PHOSPHO1 mutant expression. The 
cDNA fragment was ligated into the pBAD TOPO TA vector (2.3.9.1) and this used 
to transform TOP 10 cells as described in 2.3.1 (nucleotide and protein sequences 
shown in appendix 3). Liquid cultures and plasmid mini-preparations of individual 
clones were subsequently carried out (section 2.3.2 and 2.3.3 respectively). A clone 
containing the PHOSPHO2 fragment in the correct orientation was identified by 
restriction digestion of plasmid minipreps as described in 2.3.8. Briefly the plasmid 
DNA was digested with the restriction enzymes Ncol and Hindinthe latter is found 
only within the PHOSPHO2 CDS. The E. coli expressing the recombinant protein 
were grown in a 10L fermentation vessel as outlined in section 2.5.5.1. The 
recombinant protein was purified by Immobilised Metal Affinity Chromatography 
(IMAC) as described in 2.5.6.
4.4.3 Phosphatase Assays
The standard discontinuous colorimetric assay used was based on that of 
Baykov et al, (1988) as described in section 2.6.2 utilising 600ng of purified
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recombinant enzyme per reaction. Buffers used were 20 mM MES, pH 6.7 for the
PHOSPHO1 and mutants assays and 20 mM Tris-HCl pH 7.2 for the PHOSPHO2 
experiments to allow the direct comparison with previous results. Twelve compounds 
were analysed for phosphatase activity by PHOSPHO2 (figure 4.8); whereas PEA 
and PCho were analysed for hydrolysis by PHOSPHO1 mutants. Specific activities 
were calculated in units of activity per mg enzyme, where 1 unit of activity equals 
the hydrolysis of 1 nmol phosphate/min.
To analyse kinetic constants for these reactions the continuous 
spectrophotometric assay was performed using the EnzChek® Phosphatase Assay 
Kit (Molecular Probes) as described in 2.6.2 utilising 0.65 ug of PHOSPHO1 or 9.98 
ug PHOSPHO2 at 37°C. The concentration of substrate was varied from 2 uM to 100 
uM for PHOSPHO1 and from 2 uM to 150 uM for PHOSPHO2.
4.4.4 Structural Modelling and Ligand Docking
The protein sequence of PHOSPHO2 was subjected to homology modelling 
as described previously for PHOSPHO1 (Stewart et at, 2003) and outlined in section
2.7.2.
4.5 Results
4.5.1 Production of pBAD-PHOSPHO2 Clone
pBAD-PHOSPHO2 clones were analysed for orientation in respect to the 
bacterial arabinose inducible promoter. As seen in figure 4.4 the clones display two 
different digestion patterns when digested with Ncol and Hindlll. When in the 
correct orientation the clones should display bands equal to 4728 and 124bp, and
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when inverted bands of 4166bp and 686bp would be present. From this is can be
deduced that clone A and clone B have the PHOSPHO2 CDS in the inverted 
orientation while clone C and D are correct. All clones with PHOSPHO2 in the 
correct orientation were DNA sequenced and one displaying the correct sequence 







Figure 4.4 Amplification and cloning of PHOPSHO2 into pBAD-TOPO 
plasmid. Analysis by restriction digestion with enzymes Hindlll and Ncol. (A)
Amplification of human PHOSPHO2 CDS from genomic DNA by PCR (B) 
Identification of CDS orientation by restriction digestion, clones A and B are in the 
inverted orientation while clones C and D are in the correct orientation.
4.5.2 Analysis of DNA Sequence from PHOSPHO1 Mutant Clones
The pBAD-PHOSPHOl mutant plasmids were sequenced in both directions 
and assembled using STADEN (HGMP). The sequences were compared at the 
specific point of mutation with the wild type sequence (NM_178500). As seen in 
figure 4.5 each of the chosen PHOSPHO1 clones contained the desired mutation.
116




CC'G.-CCTTCGACTT C G .A C G .- <











C G GCG ft C G A T T CGAT
A/V v
C G - :\ A .- C ,-, G C -. C G - 1' t C G ". T
Wild Type
Clone 6
C T C « T CTC CG'GCCAACAC
T C ~ C A T C T C C A A T G C C A * C A C
Figure 4.5 Analysis of DNA sequencing results from site directed mutagenesis of
pBAD-PHOSPHOl clones. The upper panel of each figure relates to the wildtype 
control sequence. As seen on each of the lower panels the mutations have been 
successful in the cloned plasmids.
4.5.3 Purification of Recombinant Human PHOSPHO2 and PHOSPHO1.
Recombinant His-tagged PHOSPHO proteins were eluted in fractions from a 
Ni-NTA-agarose column and assayed by SDS-PAGE. Typically, fraction 2 yielded a 
single band of the expected mass (32 kDa) consistent with >99% purity. The final 
yield of protein was ca. 25 mg per 10 litres of culture for the PHOSPHO2 expressed 
by fermentation and approximately 2mg per 1 litre for the PHOSPHO 1 mutants. The 
mutant proteins were compared to the wild type protein by CD analysis. The spectra 
of the mutants were similar to the native protein showing that the mutations did not 
cause any significant changes in secondary structure as shown in figure 4.6.
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D43N ——D43N/D123N —— D123N ——D203S
Figure 4.6 Analysis of human recombinant PHOSPHO1 mutant proteins by 
circular dichroism. CD spectra, in the far UV range, of human Recombinant 
PHOSPHO1 mutant proteins D123N (purple), D43N (pink), D123N/D43N (blue), 
D32N (red), D203N (green) and human recombinant wild type PHOSPHO1 (navy).
4.5.4 PEA and PCho Phosphatase Activity from PHOSPHO1 Mutants
Phosphatase activities toward PEA and PCho were assayed using the standard 
discontinuous assay for the five PHOSPHO1 mutants. The resultant specific 
activities are shown in Table 4.1. No detectable phosphatase activity was observed 
with either of the two active site mutations (D32N and D203S). Mutations of Asp43 
(D43N) and Asp 123 (D123N) dramatically decreased the reactivity toward both 
substrates when compared with the wild-type enzyme, the D123N mutation reduced 
activity -20-fold for PEA and -60-fold for PCho. The D43N mutation reduced 
activity ~60-fold for PEA, whilst no activity was observed with PCho. No activity 
was detected with the double mutant, D43N/D123N-PHOSPHO1, with either 
substrate.
The reaction with PEA catalysed by the D43N mutant was too slow to allow 
accurate determination of the kinetic parameters. However, the kinetic constants 
were determined for recombinant D123N-PHOSPHO1-catalysed hydrolysis of PEA 
in the presence of 2 mM Mg2+ at 37°C. The reaction exhibited Michaelis-Menten
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kinetics. A plot of reaction rate versus PEA concentration and also a Lineweaver-
Burke plot for the D123N-PHOSPHO1-catalysed reaction are shown in figure 4.7. 
The enzyme displayed apparent Km, Vmax and kcat values of 9.5 uM, 175 nmol min" 1 
mg" 1 and 0.094 s" 1 , respectively.
Specific activity (units/mg) 
Protein
PEA PCho
Wild-type 4959 ± 327 2203 ± 147
D32N <0.1 <0.1
D203S <0.1 <0.1
D43N 92 ±42 <0.1
D123N 277 ±12 40 ±18
D43N/D123N <0.1 <0.1
Table 4.1 Specific activities of recombinant human PHOSPHOl mutants. Wild- 
type recombinant human PHOSPHOl and the five mutants (3 jag/ml) were incubated 
with 2.5 mM PEA or PCho and assayed for phosphatase activity by the 
discontinuous assay at 37°C. The 200 ul reaction mixture contained 25% (w/v) 
glycerol, 20 mM TBS, pH 7.2, 25 ng/ml BSA, 2.5 mM substrate and 2 mM MgCl2 . 
The results are the averages of triplicate assays.
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Figure 4.7 Kinetic analysis of the hydrolysis reactions catalysed by recombinant 
PHOSPHO1 D123N mutant. Plot of the reaction velocity (V) as a function of 
substrate concentration. Inset, Lineweaver-Burke plot from which Km and Vmax values 
were calculated. Kinetic activity toward PEA was measured using a method based 
upon the PNPase-coupled continuous phosphatase assay.
4.5.5 Substrate Specificity of Recombinant PHOSPHO2 Protein
Eleven phosphate compounds were investigated as potential substrates for 
human PHOSPHO2. A comparison of the resultant specific activities with those 
previously reported for human PHOSPHO1 in chapter 3 is shown in figure 4.8. Of 
the phosphate compounds tested, pyridoxal-5-phosphate (P5P) was hydrolysed by 
PHOSPHO2 with the highest specific activity (464.1 ± 19.5 units/mg), which was 
approximately 3 times higher than that towards ATP and phospho-L-serine. 
PHOSPHO2 also hydrolysed pyrophosphate, PEA, phospho-L-tyrosine, fructose-6- 
phosphate, p-nitrophenyl phosphate, p-glycerophosphate and PCho. No hydrolysis of
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ribose-5-phosphate was observed in the presence of PHOSPHO2. PHOSPHOl has
previously been shown to have high specific activities toward PEA and PCho (4600 
±582 and 2980 ±335 units/mg, respectively). Five of the potential substrates that 
previously yielded no detectable phosphatase activity with PHOSPHOl showed 
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Figure 4.8 Specific activities of PHOSPHO2 and PHOSPHOl in the presence of 
a range of substrates. PHOSPHOl and PHOSPHO2 activities were determined 
using a discontinuous assay at 37°C. The 200 ul reaction mixture contained 25% 
(v/v) glycerol, 20 mM IBS, pH 7.2, 25 jag/ml BSA, 2.5 mM substrate and 2 mM 
MgCl2. The results are the averages of triplicate assays (± SD).
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Kinetic constants were determined for recombinant PHOSPHO2-catalysed
hydrolysis of P5P in the presence of 2 mM Mg2+ at 37°C. The reaction exhibited 
Michaelis-Menten kinetics. A plot of reaction rate versus PEA concentration and also 
a Lineweaver-Burke plot for the PHOSPHO2-catalysed reaction are shown in figure 
4.9. The enzyme displayed apparent Km, Fwa*and kcat values of 45.5 uM, 633.3 nmol 
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Figure 4.9 Kinetic analysis of the hydrolysis reactions catalysed by recombinant
PHOSPHO2. Plot of the reaction velocity (V) as a function of substrate 
concentration. Inset, Lineweaver-Burke plot from which Km and Vmax values were 
calculated. Kinetic activity toward P5P was measured using a method based upon the 
PNPase-coupled continuous phosphatase assay.
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4.5.6 Molecular Modelling of PHOSPHO2
4.5.6.1 Construction of a PHOSPHO2 Model
In the absence of structural data for PHOSPHO2, a three-dimensional model 
was built based on the X-ray crystal structure coordinates of MjPSP (PDB: 1F5S). 
Sequence identity between MjPSP and PHOSPHOl is 19.4% whilst identity between 
MjPSP and PHOSPHO2 is 18.0%. Despite the low sequence identity, fold 
recognition strongly suggests that PHOSPHO2 (and PHOSPHOl) and PSPs belong 
to the same fold (alignment shown in figure 4.10), therefore allowing us to build a 
meaningful structural model (figure 4.11). The protein model consists of two 
domains: the catalytic a/(3 domain and a four-helix-bundle. The a/|3 domain forms a 
Rossman fold structure consisting of a six-stranded parallel |3-sheet, surrounded by 
six a-helices.
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Figure 4.10 Alignment of /ftPHOSPHOl, ^sPHOSPHO2 and the scaffold 
protein A//PSP, showing the secondary structure for PSP and secondary 
structure prediction for PHOSPHO2. The following sequences are used (accession 
numbers are shown in parentheses): HsPHOSl, human PHOSPHO1 (Q8TCT1); 
/M>HOS2, human PHOSPHO2 (Q8TCD6); MjPSP, phosphoserine phosphatase 
from Methanococcus jannaschii (Q58989). Secondary structure elements for 
PHOSPHO2 (secPHOS2) and MjPSP (secPSP) are denoted as h = a-helix, e = 0- 
strand. Black shading indicates identical, and grey shading highly similar amino acid 
residues.
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Figure 4.11 Ribbon diagram of the human PHOSPHO2 model showing the 
overall fold. The model is based on the crystal structure of phosphoserine 
phosphatase from Methanococcus jannaschii (A//PSP; PDB code: 1L7P). P5P was 
modelled into the catalytic site as this was found to be the best substrate for 
PHOSPHO2 of those tested.
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4.5.6.2 Ligand Docking
The homology models of PHOSPHO2 and PHOSPHOl were subjected to in
silico docking calculations, a model of PHOSPHO2 incorporating P5P as substrate is 
presented in figure 4.11. In this model, a hexadentate Mg2+ ion is bound in an 
octahedral geometry via three Asp residues (Asp8, Asp 10 (backbone oxygen) and 
Asp 179), O-ligands are also provided by the phosphate group of P5P and two water 
molecules.
Previous modelling studies of PHOSPHOl suggested that as well as Asp43 
and Asp 123, two additional residues, Arg60 and TyrTl, also line the substrate- 
binding pocket (Stewart et at, 2003). A comparison of this region in both the 
PHOSPHOl and PHOSPHO2 models is shown in figure 4.12. The active sites of 
PHOSPHOl and PHOSPHO2 in our models are very similar. Apart from the
f\ •
conserved Mg -binding site (side-chains of Asp8 and Asp 179, backbone-CO of 
Asp 10 in PHOSPHO2), and phosphate-binding site (backbone-NH of Phe9, side- 
chains of Ser98, Lysl53 and Asnl82; PHOSPHO2), residues in or close to the 
predicted substrate pocket are: Asnll, Asnl7, Asp 19, Thr20, Arg36, Tyr39, Arg40, 
Phe47, Tyr54, Asp99, and SerlOO in PHOSPHO2 (corresponding to Glu35, Asn41, 
Asp43, Asp44, Arg60, Tyr63, Arg64, Tyr71, Tyr78, Aspl23 and Alal24 in 
PHOSPHOl respectively).
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Figure 4.12 Models of the active sites of PHOSPHO1 without and with 
phosphoethanolamine (A and C) and PHOSPHO2 with pyridoxal-5-phosphate
(B and D). Key residues around the sites likely to be involved in substrate binding 
and catalysis are shown. Amino acid residues are coloured according to type: 
negatively charged (red), positively charged (blue), hydrophilic uncharged (green), 
aromatic (violet), and hydrophobic (grey). Atoms of the ligands are coloured as 
follows: hydrogen (cyan), carbon (grey), nitrogen (blue), oxygen (red), phosphorus 
(orange); the magnesium ion is shown in purple.
127








Figure 4.13 Electrostatic potential surfaces for PHOSPHO1 (left) and 
PHOSPHO2 (right). Negative and positive potentials on the surface of each protein 
are shown in red and blue, respectively. The models suggest that a large difference in 
potential exists between the two proteins around the entrance to their catalytic sites. 
The large negative charge at this region of PHOSPHO1 is partly due to Glu65, which 
corresponds to a positively charged Lys41 in PHOSPHO2.
4.6 Discussion
The results of chapter 3 have indicted that the natural substrates of
PHOSPHO1 are likely to be PEA and PCho, both of which are positively charged. 
Previous molecular modelling studies implicated two negatively charged residues 
(Asp43 and Asp 123), which line the substrate-binding pocket of PHOSPHO1, in 
substrate-specific interactions (Stewart et al, 2003). Mutation of active-site residues 
Asp32 (D32N) and Asp203 (D203S) of PHOSPHO1 resulted in a complete loss of 
activity toward PEA and PCho. This characteristic is a hallmark of the HAD 
superfamily of proteins (Maruyama et at, 1989; Clarke et al, 1990; Aravind et al, 
1998; Selengut, 2001; Tootle et al, 2003), and confirms PHOSPHO1 as a member of
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this family. PHOSPHOl mediated hydrolysis of PEA and PCho is therefore likely to
follow by the same Mg +~dependent mechanism as other HAD-like phosphatases. 
Scheme 4.1 illustrates how PHOSPHOl is likely to interact with the phosphate 
moiety of the substrate during the reaction cycle based upon previous 
crystallographic studies investigating PSP-catalysed hydrolysis of phosphoserine 
























Scheme 4.1 Proposed reaction pathway of PHOSPHOl-catalysed hydrolysis based 
upon the molecular model of PHOSPHOl (Stewart et al, 2003) and the known 
pathway for PSP from Methanococcus jannaschii (Wang et al, 2002) (Figure created 
by Stephen J. Paisey, University of Edinburgh).
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Upon analysis of this scheme, it is likely that the substitutions D32N and D203S
have dramatically reduced the affinity of Mg2+ towards the site, whilst the D32N 
mutation would also prevent the formation of a phospho-protein intermediate during 
the reaction.
The mutations D43N and D123N also greatly affected PHOSPHO1 activity 
towards PEA and PCho. Both mutations reduced the specific activity, by varied 
degrees toward PEA and PCho, with D43N having the more pronounced effect. The 
double mutant, D43N/D123N, exhibited no activity toward either PEA or PCho. 
Kinetic analysis revealed that PEA hydrolysis by the D123N mutant is reduced by a 
factor of 24 compared to wild type PHOSPHO1 under the same conditions. This 
suggests that Asp 123 is important for hydrolysis of PEA. Asp 123 mutation has only 
a moderate effect on substrate binding (reduction of Km by a factor of ca. 3). The Km 
value is, under true Michaelis-Menten conditions, an estimate of the dissociation 
constant of enzyme from substrate. A probable explanation for these kinetic data is 
that Asp 123 of PHOSPHO1 does not interact directly with the substrate but plays a 
similar role to that of Glu20 in A//PSP, which stabilises an attacking nucleophilic 
water molecule during phosphoserine hydrolysis and is conserved in all known PSPs 
(Wang et al, 2002). Such a role for Asp 123 during the reaction would account for the 
relatively larger difference in Vmax and kcat values and small difference in Km value 
observed between the D123N mutant and wild type enzyme. However a role for this 
residue stabilising the positive charge of the NH3+ group both in the initial complex 
and during catalysis cannot be eliminated. The D43N mutation has a much more 
dramatic effect than D123N. No activity toward PCho was observed with the D43N 
mutant and activity toward PEA was reduced -60-fold compared to wild type. This
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suggests that Asp43 is a more likely candidate than Asp 123 to directly interact with
the substrate. Such an interaction would presumably be more important for the 
binding of the bulkier choline moiety of PCho than the smaller ethanolamine moiety 
of PEA as our results suggest.
Recombinant PHOSPHO2 protein was assayed for phosphatase activity in the 
presence of a number of phosphomonoesters. Surprisingly, activities toward PEA 
and PCho were -100 times lower for PHOSPHO2 compared to PHOSPHO1 under 
the same conditions. The highest activity corresponded to the hydrolysis of P5P (ca. 
464.1 ± 19.5 nmol min" 1 mg' 1 ). This activity is -10-fold less than that measured for 
PHOSPHO1 catalysed hydrolysis of PEA under the same conditions. The relatively 
low Km (ca. 45.5 uM) suggests that this molecule may be hydrolysed by PHOSPHO2 
in vivo, however the existence of a more specific ligand is conceivable. It would 
however be likely if P5P is not the physiological substrate of PHOSPHO2, such a 
substrate would retain some defining features of P5P, such as a positively-charged 
aromatic ring.
These results show that despite the overall high level of identity (ca. 42%), 
PHOSPHO1 and PHOSPHO2 are distinct enzymes with different substrate 
specificities. Indeed sequence similarity in proteins with distinct functions is well 
documented (Orengo et al, 1993). Specific examples of this include spinach 
glycolate oxidase (EC 1.1.3.15) and yeast flavocytochrome b2 (EC 1.1.2.3). These 
enzymes share 37% identity but catalyse oxidoreductase reactions with distinct 
substrates and acceptor molecules (Lindqvist et al, 1991). It is however surprising 
that these two enzymes, which share such close similarity outwith the catalytic 
motifs have such different specificities.
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Human PHOSPHO2 protein was modelled based on the crystal structure of 
A//PSP to allow a better understanding of why these two proteins are functionally 
distinct. The model shows that the characteristic features of the catalytic site found in 
the HAD superfamily are all preserved. This includes all residues involved in the 
recognition of the phosphate group in A//PSP, with the exception of GlylOO (in PSP), 
which is replaced by Asp99 (in PHOSPHO2). Considering that only the backbone 
oxygen of this residue is involved in substrate binding in PSP, the modelled catalytic 
site in PHOSPHO2 closely resembles the catalytic site in A//PSP (Wang et al, 2001). 
The models including bound substrate molecules have been generated by in silico 
docking. The conformation shown for each substrate is just one of many possible, but 
is probably a reasonable representation of the general orientations of the molecules. 
Although no restraints were used during the docking procedure, the interactions 
between the phosphate group and the amino acid side-chains (Serl22, Lysl77, 
Asn206 for PHOSPHO1 or Ser98, Lysl53, and Asnl82 for PHOSPHO2) agree very 
well with those observed in the X-ray structures of related phosphatases (Wang et al, 
2001 and 2002; Kim et al, 2002). The situation is slightly more complicated for the 
remainder of the binding pocket, as the residues defining the "non-phosphate" moiety 
of the substrate-binding site are not conserved between our template and the two 
target proteins. Although it is therefore not possible to predict reliably the orientation 
of the side-chains of these residues, the models allow us to define the residues lining 
the binding pocket and to predict some of the interactions which may contribute to 
substrate specificities. In the theoretical PHOSPHO1/PEA model, the negatively 
charged side-chains of Asp34, Asp43, and Asp 123 are all in the vicinity of the 
positively charged ammonium group of PEA, potentially providing both a highly
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negatively charged pocket as well as H-bond acceptor atoms. These interactions are
consistent with the decrease in activity for the D43N, the D123N, and the 
D43N/D123N mutants. Residues in or near the substrate pocket that are not highly 
conserved between PHOSPHO2 and PHOSPHOl are Asnll/Glu35, Thr20/Asp44, 
SerlOO/Alal24 and Phe47/Tyr71. Of these, only Thr20/Asp44 and SerlOO/Alal24 
are fully conserved within the two subfamilies. With the exception of chicken 
PHOSPHOl, Glu35 is also conserved within the PHOSPHOl sub-family; 
PHOSPHO2 proteins carry either an Asn or a His residue at this position. In the case 
of Tyr71, there does not appear to be any specific conservation within sub-families. 
Clearly, the binding site of PHOSPHOl is more negatively charged than that of 
PHOSPHO2, and there are subtle changes in the location of potential H-bond donors. 
In addition, the surface charges of the putative entry sites are also different (figure 
4.13): whilst Glu65 in PHOSPHOl renders the surface rather negative, the respective 
Lys41 residue in PHOSPHO2 has the opposite effect. Again, these amino acids are 
fully conserved within their respective sub-families. Changes in surface charges are 
likely to contribute to the rate of both ligand binding and product release.
These results clearly demonstrate that the two enzymes, PHOSPHOl and 
PHOSPHO2, both belong to the HAD superfamily but have different substrate 
specificities. Asp43 and Asp 123 in PHOSPHOl (and, by inference, presumably also 
Asp 19 and Asp99 in PHOSPHO2) contribute to catalysis but other residues are also 
involved. The structural models help to identify potential candidates for these 
residues through the discovery of subtle differences inside the substrate-binding 
pockets and on the surfaces of the active sites. Given the overall high similarity 
between PHOSPHOl and PHOSPHO2, it was important to elucidate whether or not
133
Chapter 4_______Probing the Substrate Specificities of Human PHOSPHOl and PHOSPHO2
the enzymes had similar activities. PHOSPHOl is associated with high levels of
expression at mineralising regions of bone and cartilage. The discovery of another 
phosphatase with comparable PEA and PCho phosphatase activity would have given 
rise to serious questions regarding a role in mineralisation for PHOSPHOl as gene 
expression studies carried out in chicken and EST analysis in mammals have shown 
that PHOSPHO2 expression is not specific to bone and is indeed expressed in a wide 
range of soft tissues. In addition, functional redundancy would likely complicate 
future gene knockout and inhibitory experiments. Furthermore, this is the first 
investigation of human PHOSPHO2 structure and activity, providing a platform for 
the further study of this enzyme.
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5.1 Introduction
As previously revealed by Houston et al, (2004) and in section 1.7.1 
PHOSPHO1 protein is localised to the mineralising centres of both avian bone and 
cartilage. This localisation mirrors that of the other major bone phosphatase, TNAP. 
To allow a link between PHOSPHO1 and bone/cartilage mineralisation in the 
mammalian system a localisation pattern similar to that found in the chick is 
required. The process of matrix mineralisation occurs in the extra-cellular matrix 
which surrounds terminally differentiating chondrocytes, osteoblasts and 
odontoblasts and is the mechanism by which growth plate cartilage, bone and tooth 
formation occurs by each of these cell types, respectively. Mineralisation in growth 
plate cartilage increases as chondrocytes progress through differentiation till they 
obtain a hypertrophic phenotype resulting in cell death thus leaving a calcified 
cartilage template for bone growth. The sites of bone mineralisation are characterised 
by osteoblast activity which is found at various bone forming surfaces such as 
primary spongiosa, osteons and areas of bone remodelling. Each of these sites are 
characterised by the presence of TNAP on the surface of mineralising cells as well as 
among the collagen fibrils within the bone osteoid matrix (Bonucci et al, 1994). It is 
widely regarded that MVs are the initial sites for apatite formation by providing an 
environment permissive for calcium phosphate precipitation (Ali and Evans, 1973).
The localisation of TNAP to all sites of mineralisation serves to strengthen 
the potential role it has in this process and it is now thought that this role is to 
hydrolyse the potent mineralisation inhibitor PPi (Harmey et al, 2004). The action of 
TNAP, however does not seem to be critical for the initial stages of mineralisation as 
in newborn Tnap knockout mice, bone development and mineralisation appear
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normal and MVs contain crystals of hydroxyapatite. Skeletal hypomineralisation
does subsequently appear in these mice (Narisawa et al, 1997; Hessle et al, 2002) 
however this is likely to be due to an increased concentration of PPi at mineralising 
sites (Meyer 1984). This hypomineralisation can be reversed by NPP1 knockout as 
this reduces the PPi pool and subsequently allows physiological mineralisation to 
occur as discussed in 1.6.4.2.
TNAP activity displays a regulatory pattern which is directly related to the 
stage of cellular differentiation. If differentiation is induced in vitro through the 
addition of AA, chondrocytes display a hypertrophic phenotype which is 
accompanied by an increased expression of collagen type X and TNAP activity. It 
has been known for many years that AA is required for the production of a normal 
extracellular matrix as it is important in stabilising the triple helical structure of 
collagen (Kivirikko and Myllyla, 1987). It is, however, unclear how exactly AA 
influences chondrocyte gene expression and the activity of TNAP. It has been 
hypothesised that it is due to the vitamin inducing an increased matrix production 
and deposition which subsequently triggers expression of genes required for the 
development of this matrix (Leboy et al, 1989). A similar effect of AA is seen on 
osteoblast differentiation with an increase in TNAP activity coupled with an increase 
in collagen expression evident (Sugimoto et al, 1986; Franceschi et al, 1994). It is 
unknown whether PHOSPHO1 is regulated in this manner, however if it did show a 
regulatory pattern similar to TNAP it would further the hypothesis that PHOSPHO1 
plays a central role in the formation of a mature cartilage/bone matrix.
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5.2 Hypothesis
That PHOSPHOl is localised in a similar fashion in mammals to that of the already 
characterised avian model. Also that gene expression mirrors that of the avian model 
with increased transcript levels observed in mineralising tissues.
5.3 Aims
I. Further analyse the localisation on PHOSPHOl in the chick model by 
analysing protein content of MVs.
II. To analyse gene expression quantitatively through the use of real time PCR in 
a mouse model.
III. To produce a mouse/human specific PHOSPHOl antibody and use this for 
immunohistochemical analysis of tissue sections.
IV. To analyse PHOSPHOls relationship to differentiation factors in both cells 
and MVs and investigate if PHOSPHOl is active at these sites.
138
Chapter 5 PHOSPHO1 Expression and Localisation
5.4 Materials and Methods
5.4.1 MV and Chondrocyte Isolation
MVs and chondrocytes were isolated from dissected chick tibial growth plate 
cartilage as described in section 2.2.7 and shown in figure 5.1. Chondrocytes were 
cultured as outlined in this section. Briefly the cells were seeded at Ixl06/cm2 in T25 
flasks and cultured in DMEM containing 10% FBS and 4units/ml hyaluronidase until 
confluence had been achieved (day 5). At this point 50 |^g/ml ascorbic acid 2- 
phosphate (AA) was added to the culture medium to induce cellular differentiation. 
This was classed as day 0. Differentiation was assessed by TNAP histochemistry as 
outlined in 2.2.9.3. MVs were isolated from the chondrocyte monolayer periodically 
following this point at 2, 5, 8 and 12 days according to the method outlined in 2.2.7. 
Protein concentration of the MV preparations were determined as outlined in section 
2.5.9.
Figure 5.1 Location of the tibial growth plate. The highlighted section represents 
the growth plate cartilage which was dissected to allow the isolation of chondrocytes 
and MVs as outline in section 2.2.7.
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5.4.2 Purification of anti-PHOSPHOl Antibodies from Sheep Antisera
Ami chick-PHOSPHOl antibodies were purified from sheep antisera 
according to the protocol detailed in 2.5.8. The resultant purified antibody was 
electrophoresed on a Novex 10% Bis-Tris as outlined in 2.5.1. The antibody protein 
was either in a reduced or non-reduced state. As IgG is held together by disulphide 
bonds the reduced antibody should appear on the gel as two bands (heavy and light 
chains) and the non-reduced should appear as one band (assembled antibody). 
Following electrophoresis the gel was stained with coomassie blue as outlined in 













Figure 5.2 Purification of anti-PHOSPHOl antibodies from sheep sera.
Immobilised recombinant PHOSPHOl used as a matrix to pull specific antibodies 
from anti-sera. (R) Represents antibody reduced with DTT showing bands 
corresponding to both heavy and light chains (NR) corresponds to a non-reduced 
sample.
5.4.3 Western Blotting
To allow detection of PHOSPHOl in chick MVs lOug MV protein was run 
on a Novex 10% Bis-Tris as outlined in 2.5.1. This was then used for Western
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blotting as detailed in 2.5.4. The nitrocellulose was probed with a solution of 2 (ig/ml
purified antibody in 5% milk protein/TBST solution. The secondary antibody used 
for this detection was mouse anti sheep IgG-peroxidase (Sigma) diluted 1:2,000. To 
assess equal loading of the protein lysates an Indian ink stain was carried out on the 
membrane as outlined in 2.5.4
To test the antisera raised against the recombinant human PHOSPHO1 
protein and the synthetic peptide antibody, 50 j^g samples of cell line and tissue 
proteins were subjected to electrophoresis as outlined in 2.5.1. Both antisera were 
used at a dilution of 1:500 in 5% milk protein/TBST solution to probe Western blots 
(produced as outlined in 2.5.4). The secondary antibody used for this detection was 
goat anti rabbit IgG-peroxidase (Dako) diluted 1:2,000.
To detect PHOSPHO1 in differentiating cell lines and murine MVs, 50 jig 
and 25 jig protein was utilised respectively and run on a Novex 10% Bis-Tris as 
outlined in 2.5.1. This was then used for Western blotting as detailed in 2.5.4. The 
nitrocellulose was probed with a 1:750 dilution of anti-mouse PHOSPHO1 antisera 
in 5% milk protein/TBST solution. The secondary antibody used for this detection 
was goat anti rabbit IgG-peroxidase (Dako) diluted 1:2,000.
5.4.4 MV TNAP Assay
This was carried out as detailed in section 2.6.3 using approximately 10 jig of 
MV protein. The final activity was expressed as nmoles pNPP hydrolysed/ min/mg 
protein (thus normalising the protein content).
141
Chapter 5_______________________ PHOSPHO1 Expression and Localisation 
5.4.5 Quantitative PCR of Mouse RNA
The quantitative PCR was carried out directly on mouse RNA in a one step 
reaction using the Brilliant® SYBR® Green QRT-PCR Master Mix Kit (Stratagene), 
as detailed in section 2.4.5.
5.4.6 Immunohistochemistry
10-day old mice were killed by cervical dislocation and tissues processed as 
described in section 2.7.1. The protocols for sectioning, wax embedding and probing 
of these tissues are outlined in section 2.7.
5.4.7 Isolation of MVs from Cultured Osteoblasts
To isolate MVs from cultured osteoblasts a protocol was employed which is 
similar to that used for chondrocytes, as outlined in section 2.2.8. Firstly the primary 
murine osteoblasts were cultured for 13 days in alpha MEM (Gibco) containing 10% 
FBS and 50 uM AA. The cell monolayer was then washed with 50 mM Tris-HCl pH 
7.6, 120 mM NaCl and 10 mM KC1, and then incubated with 0.45% collagenase 
(Worthington, type II) in 50 mM Tris-HCl pH 7.6, 120 mM NaCl and 10 mM KC1 at 
37°C for 120 minutes at 37°C, with constant agitation. This cell suspension was 
subjected to differential centrifugation as described in section 2.2.7. Cell phenotype 
(Tnap+/~ and wild-type cells) was confirmed using TNAP histochemistry as detailed 
in 2.2.9.3 and mineralisation capability by von Kossa staining as outlined in 2.2.9.2.
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5.4.8 Identification of Active PHOSPHO1 in MVs
The phosphatase assay used for this analysis was identical to that detailed 
under section 2.6.1 using 12 ug of MV protein in place of recombinant PHOSPHO1. 
The MV protein was either intact or sonicated thus causing the vesicles to rupture.
5.5 Results
5.5.1 PHOSPHO1 in Isolated MVs
The presence of PHOSPHO1 was examined in MVs isolated from chick 
growth plate cartilage. Two forms of PHOSPHO1 (30.4 and 28.6 kD) were detected 
in MVs isolated directly from the tibial growth plates of 3 week-old chicks (figure 
5.3A) and from primary cultured chondrocyte cells (figure 5.3B). PHOSPHO1 
expression in the MVs isolated from the primary cells was found to increase with 
time in culture and appeared to be much greater in the presence AA after 12 days in 
culture. Equal loading of the samples was confirmed by India ink staining of the 
membrane (figure 5.3C). No overt signs of matrix mineralisation were noted in these 
cultures. TNAP activity in the presence of AA was found to double after 5 days in 
culture and was 4-times that of the control after 12 days but was not found to alter 
with time in the control cultures (figure 5.3D). This was confirmed using TNAP 
histochemistry where enzyme activity was concentrated in cartilaginous nodules with 
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Figure 5.3 Localisation of PHOSPHO1 in chick growth plate MVs (A)
Immunoblot showing PHOSPHO1 expression in MVs isolated from the tibial growth 
plates of 3 week old chicks. (B) Immunoblots examining PHOSPHO1 expression in 
MVs isolated from primary chondrocytes cultured in the presence or absence of 50 
ug/ml AA. (C) India Ink Staining of MV Immunoblot demonstrating equal loading in 
each lane. (D) TNAP activity of MVs isolated from primary chondrocyte cultures.
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Figure 5.4 TNAP histochemistry on day 12 avian chondrocyte cultures (A)
Localisation of TNAP activity to cartilaginous nodules in cells treated with 50 ug/ml 
AA. (B) Localisation of TNAP activity in control cultures, arrows indicate randomly 
distributed regions. (Scale Bar = 200um)
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5.5.2 Analysis of PHOSPHOl Expression
To investigate how PHOSPHOl gene expression varies between mammalian 
tissues, qPCR was utilised to obtain relative expression values. From this analysis, 
bone had the highest expression levels with the least amount of PHOSPHOl 
transcript found in the liver (figure 5.5). The difference in expression between these 
two tissue types was 119.4 fold. Low transcript levels were detectable in all tissues 
examined; heart (5.67), bone marrow (3.57), adipose tissue (3.38), brain (1.96) and 
gut (1.20) (numbers in brackets represent the fold difference when compared to 
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Figure 5.5 Q-PCR of PHOSPHOl in murine tissues. Data shows relative 
expression of PHOSPHOl with liver denoted 1 due to it having the lowest 
expression profile. RNA was isolated from mouse tissues by phenol chloroform 
extraction and used directly in a quantitative PCR reaction utilising the DNA 
intercalating dye, SYBR green. Results are mean ±SD(n = 3).
5.5.3 Antibody Production
Two strategies were utilised to raise an antibody capable of recognising 
human/mouse PHOSPHOl, firstly immunising rabbits directly with recombinant 
human PHOSPHOl protein and secondly producing a synthetic peptide to the c
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terminal region of the protein (identical in human and mouse), linking this to KLH
(keyhole limpet haemocyanin) and using this as an antigen for immunisation.
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Figure 5.6 Testing antibodies raised against PHOSPHOl for immunoreactivity 
towards cell and tissue lysates. (A) Immunoblot using an antibody raised against 
recombinant human PHOSPHOl (B) Immunoblot using an antibody raised against 
the synthetic peptide CGYPMHRLIQEAQKAE. Both of these antibodies were 
produced in New Zealand white rabbits.
As seen in figure 5.6 both antibodies recognise the recombinant protein, 
however no bands are present on the western blot at a size corresponding to 
PHOSPHOl in either cell line or bone tissue lysates. As discussed in chapter three, 
the predicted size for the two splice variants are approximately 29 and 32 KDa. 
These antibodies also failed to stain bone sections positively by 
immunohistochemistry. Therefore in order to advance my studies a rabbit antiserum 
to mouse PHOSPHOl was sourced from Professor Ikramuddin Aukhil, University of 
Florida, USA. This antiserum was raised against the 32KDa form of mouse 
recombinant PHOSPHOl.
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5.5.4 PHOSPHOl Protein Levels in Differentiating Cells
To analyse the effect of differentiating factors on the presence of PHOSPHOl 
within murine MLOA5 (osteoblast) cells and ATDC5 (chondrocyte), cells were 
cultured in the presence of 10 mM pGP and 50 ug/ml AA. Two forms of 
PHOSPHOl (32 and 29KDa) were detected in each cell type corresponding to two 
splice variants from the Phosphol gene, as seen in figure 5.7. However, PHOSPHOl 
appeared to be constitutively expressed and protein levels did not alter during cell 
differentiation and mineralisation (point where mineralisation is evident depicted by 
red lettering in figure).
MLOA5 ATDC5
| 3 7 14 18 | 21 22 24 28
32KDaPHOSPHOl ^-29KDa 
p-Actin
Figure 5.7 Immunoblot showing the effect of mineralising conditions on 
PHOSPHOl expression by the murine osteoblast cell line, MLOA5 and the 
chondrocyte cell line, ATDC5. Each cell line was cultured in the presence of 10 
mM PGP and 50 ^ig/ml AA. The day in red indicates the time point at which 
mineralisation of the monolayer was evident.
5.5.6 Immunolocalisation of PHOSPHOl to Skeletal Cells and Identification of 
PHOSPHOl in Mouse MVs
Confirmation that, as with the avian model, PHOSPHOl is present in MVs 
from a mammalian source was obtained by localisation to MVs isolated from mouse 
calvarial osteoblasts (figure 5.8). A single band of 29 KDa was detected which 
agrees with the expel 6ted protein size for one of the PHOSPHOl splice variants.
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The high expression levels of PHOSPHO1 in bone noted by qPCR (figure
5.5) was confirmed and extended by the localisation of PHOSPHO1 to primary 
regions of ossification in growth plate cartilage, trabecular bone and calvarial bone. 
Positive staining was restricted to the hypertrophic zone of the growth plate with 
strongest staining observed in the early hypertrophic region, observed both in tibia 
and fibula (figure 5.9 and 5.10A). No staining was observed in the proliferating 
chondrocytes and in comparison to the pre-hypertrophic chondrocytes, the terminally 
differentiated hypertrophic chondrocytes displayed little staining. PHOSPHO1 
immunoreactivity was also observed within the chondrocytes of the developing 
secondary ossification centre of the fibula (figure 5.9).
Positive staining was present on the surface of the trabecular bone of the 
secondary spongiosa as well as within the osteoblasts lining the bone forming 
surfaces of the primary osteons within the periosteal area of the cortical bone. Bone 
forming regions of the calvaria also stained positive for PHOSPHO1 (figure 5.1 OB).






Figure 5.8 Immunoblot showing the localisation of PHOSPHO1 to murine MVs 
isolated from murine calvarial osteoblasts. MVs were isolated as indicted in 5.4.7 
and 20 ug used for western blot analysis, immunoreactivity is compared to that of 
recombinant PHOSPHO1. The recombinant protein is of greater mass due to the 
presence of a C-terminal tagged region.
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Figure 5.9 Immunohistochemistry showing the localisation of PHOSPHO1 in 
mouse fibula. (A) Section was probed using a PHOSPHO1 specific antisera, 
localisation was restricted to the mineralising regions of the bone, including (from 
top to bottom) the developing secondary ossification centre, pre-hypertrophic 
chondrocytes and trabecular bone (B) Control section probed with pre-immune sera. 
(Scale Bar = lOOjim).
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Figure 5.10 Immunohistochemistry showing the localisation of PHOSPHOl in 
mouse tibial sections. (A) Tibial growth plate probed with PHOSPHOl specific 
antisera, Control section to the left (Scale bar = 1 OOjam) (B) Higher magnification of 
mineralising centres including the calvaria, osteon and trabecular bone (control 
sections displayed in the lower panel). (Scale Bar = 50jim)
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5.5.7 Identification of Active PHOSPHO1 in MVs
To determine if the PHOSPHO1 present in murine MVs was active I tested 
for hydrolase activity within intact and sonicated MVs isolated from cultures of 
Tnap'', Tnap +/~ and wild-type osteoblasts. This strategy was adopted to eliminate 
the possibility that TNAP hydrolysis of PEA may mask PHOSPHO1 activity. Cell 
phenotype (Tnap'7', Tnap+/' and wild-type cells) was confirmed using TNAP 
histochemistry, and mineralisation capability by von Kossa staining (figure 5.11). 
TNAP activity of MVs purified from these cultures mirrored that of TNAP 
histochemistry (figure 5.12A). MV preparations were used directly in the standard 
discontinuous colorimetric assay. It was found that the wild-type and Tnap'1' intact
MVs had a hydrolase activity of 3.3 + 0.4 and 0.07 + 0.4 nmol.min" mg" MV 
protein, respectively. Tnap heterozygous MVs had an activity of 1.68 + 0.5 
nmol.min^mg" 1 MV protein (figure 5.12B). Sonication of the MV preparation 
caused an increase of approximately 1 nmol.min^mg" in all cases (P<0.05), 
suggesting that the enzyme responsible for this increased hydrolysis is cytosolic.
Figure 5.11 Phenotypic confirmation of osteoblasts. (A) TNAP histochemistry on 
osteoblast monolayers (B) von Kossa staining of osteoblast monolayers. Both 
techniques were carried out on day 13 - the same time as MV harvest. (Scale Bar = 
500um)
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Figure 5.12 Hydrolase activity of MVs from Tnap+/+, +/", ~7~ osteoblasts. (A) pNPP 
and (B) PEA phosphatase activity of MV preparations. Data is presented as the mean 
+ SEM of nine replicates from each genotype (units = nmol/min). PEA hydrolase 
activity was significantly higher (p<0.05) in sonicated vs. intact MVs. Two way 
analysis of variance used for generation of p value.
5.6 Discussion
It has previously been shown that PHOSPHO1 expression is upregulated 
approximately 100 times in mineralising chondrocytes compared to non skeletal 
tissues in the avian system (Houston et al, 1999). As shown in figure 5.5 
PHOSPHO1 expression is approximately 120 times higher in murine bone tissue 
than in liver, which was deemed the lowest expresser by quantitative PCR. When 
compared to the chick expression profile the pattern exhibited in the mammalian 
system would indicate that PHOSPHO1 is involved in a specific pathway that is 
closely associated with bone development. The data already presented in chapter 3 
speculates that due to the high activity PHOSPHO1 exhibits when incubated with 
PEA this pathway is likely to be that of glycerolipid metabolism, which may be
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harnessed during bone mineralisation as a means of generating Pi. Interestingly the
expression of PHOSPHO1 in bone is only 20 times higher than that of heart, 
however under normal development heart muscle should not mineralise as this is 
associated with pathological disease. Interestingly, PHOSPHO1 has also been shown 
to be able to cleave PCho, the hydrolysis of which has been studied in hamster heart 
and has been shown to be catalysed by an unidentified enzyme (Hatch and Choy, 
1987). PCho is an important regulatory compound for the metabolism of 
phosphatidylcholine, the major phospholipid in mammalian tissues (Zelinski and 
Choy, 1982), thus the action of a phosphocholine phosphatase would provide a 
means for regulating this system in the heart. It has been documented that the 
phosphocholine pool in the heart is much lower than that in the liver or HeLa cells 
(Pelech and Vance, 1984) thus a novel regulatory mechanism may be present in this 
tissue which is absent in others. This may be controlled by the PCho activity of 
PHOSPHO1 hence explaining the increased expression in this tissue when compared 
with others, and implicating PHOSPHO1 in a possible novel pathway which may be 
mediated by one of the alternate transcript from the PHOSPHO1 gene. The low 
transcript level in bone marrow (figure 5.5) would indicate that mesenchymal stem 
cells and osteo-progenitor cells do not express PHOSPHO1 thus indicting that it is 
perhaps a protein which is found only in mature cells thus implying an involvement 
in a pathway that is unique to the terminally differentiated cells of the bone.
To allow a link for PHOSPHOls involvement in tissue mineralisation to be 
formed, the protein would not only have to be localised to mineralising surfaces of 
both bone and cartilage, it would also have to be closely associated with MVs, the 
site of initial crystal formation (Anderson, 1969). Previous studies have shown that
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in the avian system PHOSPHOl protein is localised to the mineralising sites of both
bone and cartilage, however no data is present regarding the potential involvement of 
PHOSPHOl in MV mediated mineralisation (Houston et al, 2004). The 
immunolocalisation of PHOSPHOl in the murine system analysed in the present 
study mirrors that found by Houston and colleagues, namely that PHOSPHOl is 
found at every site of mineral production in both bone and cartilage, thus further 
implicating this protein in matrix mineralisation. As shown in figures 5.9 and 5.10 
the PHOSPHOl protein is localised to mineralising growth plate chondrocytes of the 
early hypertrophic region and also to bone forming surfaces situated on trabecular, 
cortical and calvarial bones. This localisation mirrors that of TNAP (Miao and Scutt, 
2002), which has been long associated with matrix mineralisation and perhaps 
indicates synergy between the two enzymes to achieve hydroxyapatite crystal growth 
through the depletion of the mineralisation inhibitor PPi and the elevation of Pi from 
PEA hydrolysis. The lower expression of PHOSPHOl in the terminally 
differentiated chondrocytes of the mammalian growth plate would indicate that 
PHOSPHOl is required for the initial events of mineralisation (Phase 1, as discussed 
in 1.6.3.1) and not the growth of hydroxyapatite crystal (Phase 2), which is readily 
seen in this zone. Phase 2 is generally attributed to TNAP action, which is consistent 
with the localisation of TNAP activity throughout the whole of the hypertrophic zone 
(Farquharson et al, 1999). Interestingly the hypertrophic region of the growth plate is 
characterised by concentration of MVs in the longitudinal septa (Anderson, 1969), it 
is within these MVs that hydroxyapatite nucleation occurs hence if PHOSPHOl is 
present within these vesicles the distribution would be concordant with a role in the 
initial events of mineralisation.
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It has previously been shown that chick growth plate chondrocytes contain
the 30.4 and 28.6 kD forms of PHOSPHO1, corresponding to transcripts derived 
from alternative start sites in the PHOSPHO1 gene (Houston et al, 2004). The amino 
acid sequences of both putative transcripts contain all three of the catalytic motifs 
found within the HAD enzyme superfamily (Ridder and Dijkstra, 1999) and so both 
forms are likely to be catalytically active. It is unknown whether each form has a 
distinct physiological significance. Both forms of PHOSPHO1 were found to be 
present in chick MVs providing strong evidence that PHOSPHO1 is involved in the 
first phase of the mineralisation. Interestingly only the smaller of the two forms was 
found to be present in MVs from cultured murine calvarial osteoblasts. This may be 
due to the smaller transcript possessing the higher capacity for Pi generation within 
MVs. Upon analysis of the immunoblot in figure 5.3A it is evident that the smaller 
transcript forms higher proportion of PHOSPHO1 content within the chick MV thus 
also implicating this protein as more important of the two in regard to MV mediated 
calcification. Primary chick chondrocytes were cultured in the presence and absence 
of AA. The addition of AA was found to increase both PHOSPHO1 levels and 
TNAP activity in isolated MVs. AA is a known stimulant for osteogenesis and 
mineralisation in vitro (Peck et al, 1967; Spindler et al, 1989). This suggests that 
PHOSPHO1 expression and TNAP activity are both influenced by the state of 
differentiation and may be controlled by similar mechanisms within growth plate 
chondrocytes. Interestingly, as seen in figure 5.7, mineralising agents do not increase 
the cellular content of PHOSPHO1 in either chondrocytes or osteoblasts when 
cultured over a time period spanning the mineralisation of the cell monolayer. This is 
in contrast to the protein content observed within MVs and indicates that the protein
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is perhaps being targeted to the vesicle in response to mineralising conditions, hence
explaining the increase of PHOSPHOl levels within MVs. When compared with 
PHOSPHOl, AA does not increase the transcript levels of TNAP found in 
chondrocytes, but an increased activity is observed and is thought to be due to an 
interaction of TNAP with collagen during matrix synthesis (Franceschi and Young, 
1990;Hitomi^a/, 1992)
To analyse the ability of MV derived PHOSPHOl to catalyse the hydrolysis 
of PEA (the phosphomonoester found to show the most favourable kinetics when 
incubated with recombinant human PHOSPHOl), MVs were isolated from murine 
calvarial osteoblasts which had been differentiated with AA, as this has been shown 
to increase their PHOSPHOl content in chick matrix vesicles. The cells from which 
these were isolated were genetically different in relation to the presence of TNAP 
(Tnap'7', Tnap+/~ and wild-type cells) hence allowing the quantification of PEA 
hydrolysis with varying degrees of TNAP present. PEA hydrolase activity was 
observed with wildtype and Tnap+/~ but not in Tnap 1' MVs. However upon 
sonication of the MV preparations PEA hyrolase activity was observed with all 
phenotypes. Sonication would cause the MV to rupture thus when these MVs were 
analysed for PEA hydrolase activity intravesicular proteins would be exposed to the 
substrate. This would indicate that the enzyme responsible for this degradation is 
cytosolic and as according the KEGG database only PHOSPHOl has the ability to 
cleave PEA at a neutral pH, it is likely that this enzyme is in fact PHOSPHOl, as 
seen in figure 5.13. It is worth noting that previously documented hydrolysis of PEA 
by TNAP was under alkaline pH (Muller et al, 1989), thus this reaction would not be 
favourable under assay conditions or in vivo. The only other reported mammalian
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enzyme capable of hydrolysing PEA is acid phosphatase, however its action against 
PEA has not been reported in bone (McDonald et at, 1980). The rationale behind 
why hyrolase activity is observed with intact MVs is due to TNAP being anchored to 
the outer leaflet of the plasma membrane thus TNAP would be exposed to the 
substrate if the vesicles were intact or ruptured. This is confirmed through the 
analysis of TNAP activity of intact MVs as this pattern mirrors that of PEA 





• | 3 1.1.4 | II _____
«« 2.3.1.23) J Ij 3.1.1.5 















— — — —t>f Pyruvatt metabolism j 




stt-Glycero-3-phaspho311 A [ 11 3t o3 c
JJTIsl^UlTTsn 6^111^ [jij






Figure 5.13 Extract of the phosphoglycerolipid metabolism pathway from the 
KEGG database. This pathway indicates enzymes known to catalyse specific 
reactions within different metabolic pathways. Note the only enzyme documented to 
catalyse the hydrolysis of PEA and PCho to ethanolamine and choline respectively is 
enzyme 3.1.3.75 (PHOSPHO1) as indicated by red boxes.
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In conclusion PHOSPHO1 expression is up regulated in bone tissue and
protein localisation is restricted to sites of mineralisation in the mammalian model. 
Further to this, PHOSPHO1 protein is found within chondrocyte and osteoblast 
derived MVs. This protein is cytosolic and in an active state, retaining the ability to 
hydrolyse the PEA, as already demonstrated with the recombinant enzyme. In 
addition to this it is regulated by AA thus exhibiting similar characteristics as TNAP. 
These data further strengthens the hypothesis that PHOSPHO1 has a role in bone 
mineralisation, likely to be linked to the glycerolipid metabolism pathways involving 
the degradation of phosphatidylethanolamine and phosphatidylcholine hence 
producing Pi for MV mediated mineralisation.
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Chapter 6_______________________Functional Analysis of Mammalian PHOSPHO1 
6.1 Introduction
Although PHOSPHO1 has now been implicated in the glycerolipid 
metabolism pathway due to its high catalytic activity towards both PCho and PEA its 
exact function with respect to bone mineralisation is yet to be discovered. The in vivo 
function of PHOSPHO1 appears to be closely associated with the bone 
mineralisation process due to its location to mineralising sites in both bone and 
cartilage in both mammals and birds; the identification of PHOSPHO1 in MVs also 
strengthens the evidence for a role in this process.
To assign function to this protein cells can be modified to have a reduced 
content of PHOSPHO1 thus creating a line that can be examined for phenotypic 
alterations and discrepancies in cellular function. The method now commonly used 
for this type of investigation is short interfering (si) RNAs which function to 
modulate mRNA levels of the cell. This process known as RNA interference (RNAi) 
is a natural phenomenon triggered by double stranded RNA, from which a template 
is formed for the sequence-specific targeting and degradation of endogenous RNAs. 
This process is observed as a natural anti-viral mechanism in plant immune systems, 
however pioneering work using C. elegans has further characterised the use of 
antisense and in particular antisense/sense duplexes for modulation of mRNA (Fire et 
al, 1998; Baulcombe, 2004). Upon detection of dsRNA within a cell the RNA is 
processed by the dicer enzyme which is a cytoplasmic RNAse like enzyme, to 
produce siRNAs of approximately 21 nucleotides in length. The siRNAs combine 
with an RNAi inducing silencing complex (RISC), which triggers the destruction of 
the complimentary mRNA, upon binding. In addition to this system if the siRNA 
pairs with the target RNA in the absence of RISC a RNA directed RNA polymerase
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can use this as a primer to amplify the mRNA, this can be subsequently cleaved by 
DICER to produce new siRNAs (Sijen et al, 2001). In addition to this, short hairpin 
(sh)RNAs which can be produced from vector systems are also processed by the 
DICER thus allowing exploitation of this system for stable transcript knockdown, 
something that cannot be achieved by conventional 21 nucleotide dsRNA 
oligonucleotides. This process of stable gene knockdown is desirable when studying 
proteins thought to be involved in the mineralisation process as matrix mineralisation 
in vitro occurs after 20 days post confluence with the SaOS-2 osteosarcoma cell line 
(McQuillan et al, 1995). The knockdown effect when using synthetic siRNA 
oligonucleotides is typically around 96 hrs thus to achieve knockdown over a 
prolonged period multiple transfections would need to be carried out. However cell 
transfection is only effective pre-confluence (usually 50-70%) thus due to the 
kinetics of the mineralisation process synthetic dsRNA oligonucleotides are of no 
value when using these cell lines.
An additional method for attributing functionality to phosphatases is to over 
express the protein within cells while observing any alterations in phenotype or cell 
behaviour, this process has successfully aided in attributing function to several 
phosphatases including the protein phosphatases PTPMEG, PTP-alpha and PTP36 
(Gu, et al, 1996; Cong et al, 1999; Ogata et al, 1999). As it has been hypothesised 
that PHOSPHOl is involved in the initial stages of the mineralisation process this 
may be adequate to trigger monolayer calcification. In converse the 'knockdown' of 
gene transcript may modulate the deposition of hydroxyapatite. If this is the case it 
would show for the first time that PHOSPHOl is involved directly in producing Pi, 
hence aiding calcium phosphate precipitation and matrix mineralisation.
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6.2 Hypothesis
That the reduction of PHOSPHOl within bone cells will reduce their capacity to 
mineralise and conversely overexpression of PHOSPHOl within non-skeletal cells 
will increase their potential to form calcium phosphate.
6.3 Aims
I. To map human PHOSPHOl RNA to indicate which sites are suitable for 
siRNA targeting.
II. To produce a construct to stably express shRNA in both osteoblast and 
chondrocyte cells.
III. To investigate the use of preformed siRNAs with the rapidly mineralising 
MLO-A5 cells.
IV. To tag the PHOSPHOl CDS with a Hemagglutinin (HAg) tag and engineer 
this into a construct suitable for mammalian expression. The tagging of 
PHOSPHOl will allow the identification of expressed protein with 
commercially available antibodies
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6.4 Materials and Methods
6.4.1 Secondary Structure Mapping
The secondary structure mapping of PHOSPHO1 mRNA was carried out in 
conjunction with Expresson Biosystems Ltd. This process utilises a 4069 element 
degenerate six-base oligonucleotide array, which allows the mapping of in vitro 
transcribed RNA within a 4 hr time frame and at physiological conditions.
To produce gene specific RNA the purified PHOSPHO1 CDS produced in 
3.4.2 was cloned into the pGEM-T-Easy vector as described in 2.3.9.2. The ligation 
reaction was used to transform JM109 competent cells as outlined in 2.3.1. Liquid 
cultures and plasmid minipreparations of individual clones were subsequently carried 
out (section 2.3.2 and 2.3.3 respectively). Orientation of the PHOSPHO1 CDS was 
analysed by digestion with Ncol. A clone in the correct orientation was used for the 
production of in vitro transcribed RNA from the T7 and Sp6 RNA promoters.
The RNA production and array analysis was undertaken at Expression 
Biosystems Ltd.
6.4.2 Production of a shRNA Expressing Construct
The pSUPER vector (Oligoengine, appendix 1) was supplied linearised with 
Bglll Hindlll 'sticky' ligation sites. This vector was first described in Science by 
Brummelkamp et al (2002), in a study that detailed stable suppression of p53 in 
MCF-7 cells. From this study several variants of the original pSuper vector have 
been developed. The preferred vector for this work would be the pSUPER.gfp/neo, 
this vector utilises the HI RNA polymerase III promoter to drive shRNA synthesis, 
this has many advantages including the ability to function without additional
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transcriptional elements unlike other pol III promoters, this promoter also drives 
endogenous siRNA production. The phosphoglycerate kinase (PGK) promoter drives 
the production of the gfp/neomycin resistance fusion protein. This is a housekeeping 
gene promoter thus not tissue specific allowing expression of this protein in all cell 
types.
The region that was identified in the secondary structure mapping of 
PHOSPHO1 was designed as a shorthairpin RNA. To produce the shRNA two 60mer 
complimentary oligonucleotides were synthesised (Sigma-Genosys) containing a 19- 
mer target region specific to the target region of PHOSPHO1, a loop region and a 
stem region, as shown in figure 6.1. The oligonucleotides (3 ug of each) were 
annealed in a 50 ul reaction containing 25 mM Tris-Acetate pH 7.5, 100 mM K- 
Acetate, 10 mM Mg-Acetate, 1 mM DTT. The reaction was cycled at 90°C for 4 
minutes, 70°C for 10 minutes, the reaction was then step cooled to 10°C (2°C 
/minute). The annealed oligonucleotides were ligated downstream of the HI 
promoter via Hindlll/Bglll restriction sites which are engineered to the end regions 
of the oligonucleotide pair. This was done as outlined in section 2.3.9.1 using a 10:1 
ratio. When RNA is transcribed from this region, a gene specific shRNA is produced 
which is cleaved into a conventional 21mer siRNA by the cells dicer enzyme. The 
ligated plasmid/oligonucleotide was used to transform SURE-2 cells as described in 
2.3.1. Liquid cultures and plasmid minipreparations of individual clones were 
subsequently carried out (section 2.3.2 and 2.3.3 respectively). Clones containing the 
oligonucleotide pair were identified by restriction digestion of plasmid 
minipreparations as described in 2.3.8. Briefly the plasmid DNA was digested with 
the restriction enzymes EcoRl and Sail, a fragment of 302bp would be present if the
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oligonucleotides had ligated to the vector successfully. DNA sequencing of plasmids 
was carried out by the DNA sequencing facility at Dundee University.
Leader Stem_______ Loop ______Stem_______ Tail
GGGGCTCCCGAAGATGTTGCTCAAGTTCTCTGAGCAACATCTTCGGGAGCAAAAATTCGA-5'
Figure 6.1 Design of the oligonucleotides required for shRNA production. Each 
individual oligonucleotide was synthesised by Sigma-Genosys and annealed to form 
an insert for the pSUPER vector. When transcribed the two complimentary stem 
regions come together producing a hairpin like structure.
6.4.3 Transfection of SW1353 and SaOS-2 Cells
These two cell types were transfected with the pSUPER vector, described 
above, as outlined in 2.2.6. The drug used for selection of stably transfected cells was 
G418 (neomycin), this was used at concentrations of 700 ug/ml and 500 ug/ml for 
SW1353 and SaOS-2 cells respectively. These concentrations were deemed the 
lowest needed for 100% cellular death through kill curve analysis of concentrations 
between 200 and 800 jj,g/ml. Selective pressure was kept on until no sign of cellular 
death was evident and 100% of cells were fluorescing green when viewed over UV 
light.
6.4.4 Analysis of Transfected Cells
RNA was isolated from cells by Ultraspec extraction, as described in 2.4.1 
and reverse transcribed as described in 2.4.3. PHOSPHO1 transcript was amplified 
as described in 2.4.4 utilising the gene specific primers 
TACAGGTGGTGCTCACGGTA (forward) and CAAAGGGATGGCTTCGTAGA
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(reverse), a 57°C annealing temperature with 200ng cDNA. The PCR products were 
then electrophoresed on a 2% agarose gel as described in 2.3.5. The band densities 
were compared using multi-analyst after normalisation to the density of the |3-actin 
band.
The transfected SW1353 cells were cultured, as outlined in section 2.2.3, in 
DMEM supplemented with 10% FBS and 0.5% genomycin, the cells were initially
A Oseeded at a density of 5x10 cells/cm in a 6 well plate (day 0). The cells were either 
supplemented with 50 ug/ml AA and 10 mM 0GP on day 3 or with AA alone. The 
cells supplemented with AA alone were changed to DMEM containing 5% FBS, 8 
amino acids (Ala 7 mM, Asn 0.4 mM, Asp 4 mM, Glu 10 mM, Gly 7 mM, Pro 3 
mM, Ser 2 mM, and taurine 2 mM), and insulin (5 jig/ml), transferrin (5 jig/ml), 
sodium selenite (5 ng/ml), and 1 mM Na2HPC>4 to bring total inorganic phosphate 
(Pi) to 1.9 mM and Ca2+ to 1.8 mM (DATP5 media) on day 6, along with 50nM 
retinoic acid. The addition of phosphate to this media means no addition of a 
phosphoester is required. The cells were cultured to day 12 and then stained with 
alizarin red as outlined in section 2.2.9.1 and a digital image taken.
6.4.5 Tansfection of MLO-A5 Cells with siRNA
Cells were maintained as outlined in section 2.2, with the following 
modifications. The cells were cultured in alpha MEM (Gibco) containing 5% FBS, 
5% FCS. The cells were seeded into 12 well plates at a density of 10,000 cells/cm2 , 
and cultured overnight to allow cellular attachment. The transfection protocol was 
similar to that described in 2.2.6 with the following adjustments. Lipofectamine was 
utilised as the transfection reagent, 100 pmols of pre-annealed oligonucleotides
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(Dharmacon Smart-pool or GFP control) were combined with 250 ul Opti-MEM and 
the same was carried out for 5 ul Lipofectamine-2000, these were combined after 5 
minute incubation at room temperature and incubated for a further 20 minutes. The 
complexed RNA/Lipofectamine was added to the 1.5ml cell culture media on the cell 
monolayer and incubated for 6 hrs at 37°C (5% CO2). The media was then replaced 
with alpha MEM containing 5% FBS, 5% PCS, 50 ug/ml AA and 10 mM pGP. The 
cells were culture for 6 days changing the media daily.
6.4.6 Analysis of siRNA Transfected MLO-A5 cells
This analysis was similar to that in 6.4.4 with the following adjustments. The 
PCR that was carried out utilised the mouse specific PHOSPHO1 primers 
GACAATGAGCGGGTGTTTTC (forward) GGGGATGGTCTCGTAGACAG 
(reverse). The external control used for this PCR was 18s RNA in place of p-actin. 
The cells were cultured to day 6 during differentiation with 50 jig/ml AA and 10 mM 
pGP, they were then stained with alizarin red and a digital image taken.
6.4.7 Production of a HAg-Tagged PHOSPHO1 Expression Construct
To tag PHOSPHO1 a PCR method was employed. This utilised a protocol as 
outlined in section 2.4.4, however the reverse primer used was modified to engineer 
a HAg tag into the amplified product, as shown in figure 4.2. The primer would 
initially only partly anneal to the template DNA, however subsequent cycles of PCR 
would ensure all product contained the tagged sequence. The template used for the 
generation of this tagged PHOSPHO1 was the pBAD-PHOSPHOl clone detailed in 
3.4.2. The reaction conditions were as detailed in section 2.4.4, using lOOng plasmid
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DNA and an annealing temperature of 69.2°C. The PCR products were then 
electrophoresed on a 1.5% agarose gel as described in 2.3.5 and purified using the 
Qiagen QiaQuick gel extraction kit as outlined in 2.3.6. The PCR products were 
cloned directly into the pGEM-T-Easy vector (Promega, as shown in appendix 1). 
The PCR product and plasmid were ligated in a 3:1 ratio using lOOng of PCR 
product as described in 2.3.9.1. This mixture was used to transform JM109 
competent cells as outlined in 2.3.1. Liquid cultures and plasmid minipreparations of 
individual clones were subsequently carried out (section 2.3.2 and 2.3.3 
respectively). DNA sequencing of plasmids was carried out by the DNA sequencing 


















PHOSPHO1 C Terminal HA Tag STOP
Figure 6.2 Technique used to introduce a C terminal HAg tag to the
PHOSPHO1 CDS using PCR. (A) The reverse primer contains a non 
complimentary region coding for the HAg tag which upon PCR would be integrated 
into the amplified product. (B) Primer sequences used for the amplification which 
allows the introduction of the peptide sequence indicated.
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The pWGBlO mammalian expression vector (as shown in appendix 1) was a 
kind gift from Dr Cui, Roslin Institute. pWGBlO contains a phosphoglycerate kinase 
(PGK) promoter to drive recombinant protein expression, simian virus 40 (SV40) 
small t intron/polyA and a SV40/Puromycin to allow cell selection. The plasmid 
backbone is composed of pBluescript. Both pWGBlO and a pGEM clone containing 
the correct sequence of tagged PHOSPHO1 were digested with EcoRl as outlined in 
2.3.8. The linerised pWGBlO plasmid was dephosphorylated with shrimp alkaline 
phosphatase in a reaction containing lOOng vector DNA, 2 units SAP (Roche) and Ix 
reaction buffer, this was incubated at 37°C for 10 minutes and heat killed at 70°C for 
15 minutes, this process stops the re-circularisation of the empty vector. The digested 
pGEM clone was run on a 1.5% agarose gel as described in 2.3.5 and the 
PHOSPHO1 fragment purified using the Qiagen QiaQuick gel extraction kit as 
outlined in 2.3.6. The tagged PHOSPHO1 CDS was ligated to the linerarised 
pWGBlO vector in a 3:1 ratio as outlined in 2.3.9.1. This ligation reaction was used 
to transform JM109 competent cells as outlined in 2.3.1. Liquid cultures and plasmid 
minipreparations of individual clones were subsequently carried out (section 2.3.2 
and 2.3.3 respectively). The clones were analysed by multiple restriction digestions 
with enzymes Apal, BamHl, Hindlll, Ncol, EcoRl and Smal to assess insert 
orientation. A clone containing the insert in the correct orientation with respect to the 
PGK promoter was used for (Endofree) plasmid production (2.3.4).
6.4.8 Transfection of HeLa Cells
This cell type was transfected with the pWGBlO-PHOSPHOl (HAg) vector 
(or empty vector as a control) as outlined in 2.2.6. The drug used for the selection of
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stably transfected cells was puromycin, this was used at a concentration of lug/ml. 
Selective pressure was kept on until no sign of cellular death was evident.
6.4.9 Analysis of PHOSPHO1 Expressing HeLa Cells
RNA was isolated from the control and overexpressing cells as described in 
2.4.1 and reverse transcribed as described in 2.4.3. Transcripts were amplified as 
described in 2.4.4 utilising gene specific primers for PHOSPHO1 exon3 
GACGAAAACAGCGACGATTC (forward) and CGGAGATGAGAATCACCTCG 
(reverse) (annealing temperature 55.3°C), PHOSPHO1 spanning intron 2 
TACAGGTGGTGCTCACGGTA (forward) and CAAAGGGATGGCTTCGTAGA 
(reverse) (annealing temperature 56.9°C), puromycin resistance gene 
(puromycin^ATGACCGAGTACAAGCCCAC (forward) and 
TCAGGCACCGGGCTTGCGGG (reverse) (annealing temperature 60.5°C), 18s 
primers (ambion) were used as an external control. Each reaction utilised 200ng 
cDNA, however only the puromycin PCR incorporated 20% betaine (PCR enhancer). 
The PCR products were then electrophoresed on a 2% agarose gel as described in 
2.3.5.
Protein extracts from both cell lines were seperated on a 10% Bis-Tris no vex 
gel as outlined in 2.5.1 and Western blotted (2.5.4). The primary antibodies that were 
used include and anti mammalian PHOSPHO1 antiserum, an anti HAg antibody 
(Sigma) an anti p-Actin (Sigma). The anti HAg antibody was also blocked by 
incubation with 10 (J,g/ml HAg peptide (Sigma) in blocking buffer for IHr and 
subsequently used to probe the nitrocellulose membrane.
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HeLa cells were plated down at 6000/cm2 and cultured in the presence of 10 
mM POP or PEA and 50 ng/ml AA for 12 days as outlined in 2.2.3. The cell 
monolayer's were then stained using the von Kossa method as outlined in 2.2.9.2.
6.5 Results
6.5.1 Secondary Structure Mapping of PHOSPHO1
ACCESSarray analysis was used to allow the determination of accessible 
sites on the human PHOSPHO1 structure. From the mapping of human PHOSPHO1 
4 specific regions were identified as potential targets for siRNA, as shown in figure 
6.3, between regions 40 - 59, 138-157, 195-214 and 545-564. However the best 
target from these regions is the one between 138 and 157 due to its increased 
accessibility compared to the others and also due to its falling 5' to 3' free energy 
signature, which is a characteristic of effective siRNAs. From this region the siRNA 
CTCGTTGTAGAAGCCCTCG (and scrambled control, 
TAGGTACACGCTCTCGCGC) was designed which was further adapted to be 
produced from a shRNA producing vector by insertion into a 64 mer oligonucleotide 
consisting of the tail, target and loop regions required for this type of knockdown.
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B.
110 110 13* M*
TCOCCCACACCCTCCCAGCCACCTACCCCCAeOCCTTCTACAACCACTACATCCACCCCCTCTTCAACTACCTCCCCCACC
C.





Figure 6.3 Secondary structure mapping of human PHOSPHO1 RNA. (A)
ACCESSmap of 727 nucleotide region relating to exon 3 of human PHOSPHO1, the 
horseshoe represents the sequence of RNA from 5' to 3' in a clockwise direction, the 
red bars indicate accessible regions of the RNA with the red trace indicating the free 
energy profile. (B) Zoomed section of the area indicted by blue shading in (A), this 
area was selected for siRNA design due to its superior properties. (C) This sequence 
is that from the accessible area of the RNA detailed in (B) this display details the 
sequence from 5 f to 3'. The green strand (sense) and the red strand (antisense) are 
shown in their annealed state. This diagram represents how close these stands are 
thought to be under ideal conditions.
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6.5.2 PHOSPHO1 Knockdown in SW1353 and SaOs-2 Cells
To knockdown PHOSPHO1 gene expression in the human chondrocyte 
(SW1353) and osteoblast (SaOS-2) lines the cells were transfected with the pSUPER 
shRNA vector, which produces hairpin RNAs which are processed by the cellular 
machinery to produce an active siRNA. The region targeted was that identified by 
the secondary structure mapping of PHOSPHO1. A scrambled control was also used 
which bore no resemblance to any mammalian gene. PHOSPHO1 expression was 
verified in both cell lines, along with TNAP as a marker of mineralisation capacity. 









Figure 6.4 Analysis of TNAP and PHOSPHO1 expression in SW1353 and SaOS- 
2 cells. RNA was extracted from each cell type and reverse transcribed before being 
amplified by PCR using gene specific primers.
The pSUPER vector contained a GFP marker gene which allowed analysis of 
tranfection efficiency, this was estimated at 10% for both cell lines. Following 14
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days with G418 selective pressure greater than 70% fluorescence was seen for both 
cell types as shown in figure 6.5. Interestingly the SW1353 cells fluoresced brighter 
than the SaOS-2 cells, indicated by the obvious fluorescence at 4x magnification to 
the very low fluorescence at lOx in the SW1353 and SaOS-2 cells respectively. The 
SaOS-2 cells also contained a greater variation of fluorescent signal with some cells 
only weakly visible over UV light to the eye.
A.
B.
Figure 6.5 Cells stably transfected with the pSUPER shRNA expressing vector 
construct. (A) SW1353 cells viewed on 4x magnification. Left panel represents cells 
viewed under phase contrast, centre panel represents cells viewed under UV light, 
right panel represents the two images merged (scale bar = SOOfim). (B) SaOS-2 cells 
viewed on lOx magnification. Left panel represents cells viewed under phase 
contrast, centre panel represents cells viewed under UV light, righ panel represents 
the two images merged (scale bar = 200um).
The PHOSPHO1 status of the stably transfected cell lines was analysed by 
RT-PCR and quantified by band densitometry. No apparent knockdown was seen in
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the SaOS-2 cells, however the SW1353 cell line exhibited a knockdown of 59.6 ± 
2.92% (SD of 3 replicates), as shown in figure 6.6.
A. SaOS-2 SW1353


















aOS-2 &OS2SC SW1353 SW1353 3C 
siRNA siRNA
Figure 6.6 Analysis of PHOSPHOl expression in stably transfected SW1353 
and SaOS-2 cells. (A) RNA was extracted from each cell type and reverse 
transcribed before being amplified by PCR using PHOSPHOl specific primers. The 
external control p-Actin was used to detect any inconsistencies in initial RNA 
concentrations. (B) Quantification of PHOSPHOl knockdown by band desitometric 
analysis. Each band was normalised to the intensity of the P-Actin band. Error bars 
represent the SD of three replicates.
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6.5.3 Mineralisation Potential of the SW1353 Knockdown Cell Line
To analyse the effect of PHOSPHO1 knockdown on chondrocyte 
mineralisation the SW1353 cells were cultured in two types of mineralisation media 
previously documented to induce calcification in chondrocyte cells. The well 
documented method of Tacchetti et al (1989) utilising AA and pGP and the method 
detailed by Ishikawa and Wuthier (1992) which is 0GP free and was originally 
developed for the in vitro mineralisation of avian growth plate chondrocytes. After 
culture for 12 days the cells were stained with alizarin red for detection of calcium 
phosphate; however no evidence of mineralisation was present in either control or 
knockdown cells. Upon analysis of cell morphology and monolayer appearance 
distinct differences were apparent. The knockdown cells produced large lesions in 
the cell monolayer when differentiation was induced by both culture conditions, 
which was in contrast to the control cells which had a normal appearance, as seen in 
figure 6.7.
6.5.4 PHOSPHO1 Knockdown in the Murine MLO-A5 (Osteoblast) Cell Line
The cells were transiently transfected with Dharmacons smart pool of RNA 
oligonucleotides which contains a pool of four SMARTselection™ designed siRNA 
duplexes. Following transfection transcript levels were 62.8 ± 8.8 %, 75.9 ± 5.3% 
and 96.9 ± 12.9% at 44 hrs 96 hrs and 144 hrs respectively, post transfection when 
compared to control cells (transfected with a GFP siRNA).
Upon alizarin red staining of the cultures a reduced quantity of mineral was 
observed in the knockdown cultures when compared to the control cultures. As seen 
in figure 6.8 the quantity of dye incorporated in the knockdown cells has an OD of
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Figure 6.7 Analysis of SW1353 cells which are genetically modified to have a 
reduced expression of PHOSPHO1 (A) Alizarin red staining of knockdown and 
control cells following 12 days in mineralising media, two protocols were used to 
induce mineralisation, these utilised either POP and AA or AA and RA in the culture 
media (B) Analysis of cell morphology, at 4x magnification, following 12 days in 
mineralising media (scale bar = 500um).
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Figure 6.8 Analysis of PHOSPHOl expression in MLO-A5 cells, transiently 
transfected with smartpool siRNA mixture. (A) RNA was extracted from cells 
transfected with the PHOSPHOl siRNAs (P) and a GFP control oligo (G) at three 
time points. This was reverse transcribed before being amplified by PCR using 
PHOSPHOl specific primers. The external control 18s RNA was used to detect any 
inconsistencies in initial RNA concentrations. (B) Quantification of PHOSPHOl 
knockdown by band desitometric analysis. Each band was normalised to the intensity 
of the 18s RNA band and that of the control (G) band. Error bars represent the SD of 
three replicates. (C) Alizarin red staining of cells 144 hrs following transfection, the 
dye incorporation was quantified; error bars represent the SD of three replicates.
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6.5.5 Over-Expression of PHOSPHO1
6.5.5.1 Production of a pWGBlO-PHOSPHOl-HAg Clone
A PHOSPHO1 CDS was designed to contain a C-terminal HAg Tag which 
was subsequently cloned into the pWGBlO mammalian expression vector (appendix 
1). pWGBlO-PHOSPHOl-HAg clones were analysed for orientation in respect to the 
mammalian phosphoglycerate kinase promoter. The digested clone shown in figure 
6.9 is in the correct orientation as when digested with Apal and Ncol, which are 
both contained within the coding sequence, DNA fragments of 1071 and 1319bp are 
present, respectively. If this clone was inverted the band sizes when digested with 
























Figure 6.9 Analysis of a pWGBlO-PHOSPHOl-HAg clone by restriction 
digestion with enzymes Apal, BamHl, Hindlll, Ncol, EcoRl and Smal.
Enzymes Apal and Ncol both cut the clone within the PHOSPHO1 CDS, close to 
the 3' region, hence allowing the assessment of orientation. The clone the CDS is 
aligned in the correct orientation with respect to the PGK promoter, if it was inverted 
the band sizes of 2 and 8 would be 830 and 1560 respectively. EcoRl cuts out the 
CDS which was originally cloned into the vector.
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6.5.5.2 Analysis of HeLa cells Expressing PHOSPHO1
To assess if the HeLa cells stably transfected with the PHOSHO1 construct 
described in 6.5.5.1 were expressing the recombinant protein, extracted RNA and 
protein was analysed for the presence of transcript and HAg peptide respectively. In 
addition the protein was also probed with the anti mouse PHOSPHO1 antibody 
described in chapter 5. As seen in figure 6.10A RNA corresponding to exon 3 of 
PHOSPHO1 transcript is present within the cells transfected with the over- 
expression construct, with only a faint band present in the control cells. To assess 
endogenous expression of PHOSPHO1 in HeLa cells a PCR was carried out to 
amplify between exon 2 and 3 (spanning intron 2), however no amplification was 
seen from this PCR indicating no endogenous expression of PHOSPHO1 in HeLa 
cells. As seen in figure 6.10A both control and over-expression cell lines are also 
positive for puromycin1 , with an apparent equal expression in both, indicating that 
the both are stably transfected with the control and over-expression vector.
Upon analysis of the Western blot detailed in 6.1 OB it can be seen that a band 
corresponding to the expected size of the recombinant PHOSPHO1 protein (29KDa) 
is present, in the overexpression cells, when probed with the anti mouse PHOSPHO1 
antisera and the anti HAg antibody. This protein is not present in the control cells. In 
addition the identification of the protein using the anti-HAg antibody can be blocked 
by incubating the primary antibody with HAg peptide, showing the interaction is 
specific. The membrane was stripped and probed for p-actin to ensure equal loading.
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Figure 6.10 Analysis of PHOSPHOl expression and protein content in stably 
transfected HeLa cells. (A) RT PCR of RNA from HeLa cells modified to express 
PHOSPHOl. RNA was extracted from both the control and the over-expression cells 
and reverse transcribed before being amplified by PCR using gene specific primers. 
The external control 18s RNA was used to detect any inconsistencies in initial RNA 
concentrations. (B) Western blot of proteins from HeLa cells modified to express 
PHOSPHOl. Antibodies used include and anti mammalian PHOSPHOl antiserum 
(top) an anti HAg antibody, as the recombinant protein was designed to contain a C 
terminal HAg tag, this band can be blocked by the incubation of 10 (J,g/ml HAg 
peptide with the primary antibody. The loading control (3-Actin was used to detect 
any inconsistencies in initial protein concentrations.
6.5.5.3 Analysis of Mineralising Potential of PHOSPHOl Expressing HeLa Cells
To investigate whether HeLa cells expressing the HAg tagged PHOSPHOl 
protein had the ability to mineralise they were cultured in the presence of AA and 
pGP. In a second experiment the cells were cultured in the presence of AA and PEA 
as from chapter 3 this is now deemed as PHOSPHOls natural substrate. As seen in 
figure 6.11 upon von Kossa staining of 12 day old cultures, although sporadic 
staining of calcium phosphate is present with both treatments, no difference is seen 
when PHOSPHOl expressing cultures are compared to control cultures.
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0/EBGP O/E PEA
Figure 6.11 Von Kossa staining of HeLa cells which are genetically modified to 
have an increased expression of PHOSPHO1. Analysis of calcium phosphate 
staining, at 4x magnification, following 12 days in mineralising conditions. The 
mineralising media contained either pGP or PEA as a phosphate source for mineral 
precipitation (scale bar = 500um).
6.6 Discussion
The analysis of the secondary structure of human PHOSPHO1 allowed the 
assessment of accessible sites of the mRNA. Target accessibility has been shown to 
be of the utmost importance for the effective silencing of gene expression as any 
sites which lie within tightly folded RNA structures may resist RISC mediated 
targeting (Schubert et al, 2005). Identification of effective siRNA targets within 
mRNA sequences give rise to the potential for a new class of therapeutics. This type
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of RNAi therapy is broad spanning and includes any disease which requires a 
reduction in gene expression. Indeed if PHOSPHO1 is involved in the generation of 
Pi for mineralisation, diseases characterised by excess mineral production such as 
osteopetrosis or pathological soft tissue calcification could be combated through 
novel RNAi therapeutic approaches. Indeed the sequence generated from the 
accessibility map shown in figure 6.3 allowed the knockdown of PHOSPHO1 in the 
SW1353 chondrosarcoma cell line of approximately 60%. However no knockdown 
was observed in the SaOS2 cells, interestingly this was accompanied by a lower 
degree of fluorescence from the GFP marker. This phenomenon has previously been 
reported when using retroviral vectors and is thought to be due to DNA methylation 
(Gram et al, 1998). Although this has not been directly reported in non-retroviral 
vectors it is known that DNA methylation can have a major effect on eukaryotic gene 
expression. Indeed it has been demonstrate that methylated cytosines present in 
vector DNA can inhibit a flanking promoter (Curradi et at, 2002). It is therefore 
conceivable that this is occurring in the SaOS2 transfected cells thus causing a 
decrease in GFP transcription and siRNA transcription. It is however unclear why 
this does not occur with the SW1353 cells. As these two cell lines were originally 
isolated from different cancers, and that sarcoma cell lines have been shown to 
contain differing methylation patterns (Paz et al, 2003) and different levels of DNA 
methyl transferase, the cause of DNA methylation (Vilain et al, 1999), this may go 
some way to explaining why this vector behaves differently in the two lines. 
Although due to lack of experimental data to reinforce this hypothesis the theory is 
only speculation.
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Upon analysis of the mineralisation capacity of both the control and 
knockdown SW1353 lines it is evident that this cell type does not have the capacity 
to mineralise. Interestingly it does express both TNAP and PHOSPHO1 which are a 
hallmark of SaOS-2 cells, these cells do mineralise and when absent, as with MG63 
cells mineralisation cannot be achieved. This obviously raises questions about the 
potential role of PHOSPHO1 in the mineralisation process, however it cannot be 
ruled out that the presence of PHOSPHO1 and TNAP transcript is a result of an 
altered gene expression profile by a transformed line or an in vitro artefact. 
Interestingly the knockdown cells do posses a phenotype that is different to that of 
the control cells. Upon culture large lesions appear in the cell monolayer resulting in 
the regression of the cartilaginous matrix. The cells below this appear to be sparse 
thus perhaps indicating a possible cytotoxic effect of the siRNA, interestingly this 
has been documented and has been attributed to off-target effects of the siRNA 
(Fedorov et al, 2006). This study (Fedorov et al, 2006) revealed that almost 30% of 
siRNAs in their randomly generated library were able to reduce overall cellular 
viability. Alternative explanations for this phenotype, in my study, could be that 
PHOSPHO1 is also involved in matrix maintenance, that gene knockdown causes 
cellular de differentiation or that this particular phenotype is an in vitro artefact. All 
of these explanations would require extensive experimental evidence to conclude the 
cause, which is unfortunately out with the scope of this project.
The MLO-A5 pre-osteocyte (post-osteoblast) cell line mineralises in culture 
in sheets, without nodule formation within 3 days of culture in the presence of (3GP 
and AA (Kato et al, 2001). This cell line has previously been shown to express 
PHOSPHO1 (Stewart et al, unpublished data). Thus due to the kinetics of this cell
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line it allows the possibility of gene knockdown using 21mer dsRNA 
oligonucleotides. Upon transfection of the Dharmacon Smartpool (4 gene specific 
oligonucleotides) transcript levels were calculated at 62.8 ± 8.8 % at 44 hrs rising to 
96.9 ± 12.9% after 144 hrs. This strategy gave the potential to monitor mineralisation 
of this cell line in a PHOSPHO1 reduced environment. As seen in figure 6.8 the 
incorporated mineral was reduced approximately 3.5 fold when PHOSPHO1 levels 
were reduced. A greater effect may have been observed if the knockdown had been 
stable as the transcript, thus protein, content of the cells had returned to normal after 
a 144 hr period thus allowing a 'normal' environment to be re-established. It would 
be expected if PHOSPHO1 is critical to the mineralisation process a more severe 
phenotype would be observed from this knockdown, as seen with Tnap 1' osteoblasts 
where they have a complete inability to form a mineralised matrix (Wennberg et al, 
2000). However the alternative roles that TNAP exhibits such as depletion of the 
mineralisation inhibitor PPi and the hydrolysis of the mineralisation promoter pGP to 
form Pi for HA deposition need to be taken into account. In addition to this as TNAP 
is still active in the MLO-A5 cells the activity of this enzyme may be partly masking 
the knockdown of PHOSPHO1. However as a slight reduction in the initial signs of 
mineralisation were noted this data provides preliminary functional evidence for a 
role of PHOSPHO1 in the mineralisation process.
To investigate whether PHOSPHO1 was able to initiate deposits of seed 
crystals, as observed within MVs, the human protein was overexpressed in the HeLa 
cell line. As seen in figure 6.10 the PHOSPHO1 protein was overexpressed at both 
the transcript and protein level in cell extracts. This indicates that my overexpression 
strategy was successful. However upon analysis of cell phenotype and cell
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mineralisation capacity no differences were observed between control cells and those 
overexpressing PHOSPHOl (figure 6.11). This is most likely due to PHOSPHOl not 
having the capacity to induce a mineralised phenotype by itself, rather than an 
indication that it has no involvement in the mineralisation process. It is known that 
mineralisation is a multi step, multi component pathway that requires the 
synchronisation of many factors as previously discussed 1.6.4. As many of these 
factors will be specific to mineralising skeletal cells and not the fibroblast-like HeLa 
cells it is likely that such osteoblast/chondrocyte specific genes would need to be 
expressed along with PHOSPHOl to induce a mineralised phenotype. However as 
stated in section 6.1 the function of many phosphatases have been clarified using 
similar techniques to this, thus the rationale for this investigation is justified.
In conclusion this study demonstrates effective areas of the PHOSPHOl 
mRNA which can be targeted for siRNA mediated gene knockdown thus giving rise 
to potential future study on PHOSPHOl modulation using siRNA both in vitro and 
in vivo. MLO-A5 cells cultured in mineralising conditions, with a reduced cellular 
content of PHOSPHOl, display a reduction of mineralisation capacity. This data 
further strengthens the hypothesis that PHOSPHOl is involved in matrix 
mineralisation, however further work relating to gene knockdown in primary skeletal 
cells would need to be undertaken to allow an exact role of PHOSPHOl in this 
process to be established.
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7.1 Introduction
As outlined in chapter 3 the hydrolysis of PEA by PHOSPHO1 has 
favourable kinetics thus it is therefore likely that this reaction would occur in vivo. 
This hypothesis is furthered as PEA is one of the most abundant phosphomonoesters 
in cartilage (Kvam et al, 1992), a site that PHOSPHO1 is present at in large 
quantities. In addition, the proportions of membrane phospholipids containing these 
groups decrease in MVs during mineralisation, whilst 1,2-diacyl glycerol 
accumulates, indicative of phospholipase C activity (Wu et al, 2002). This gives rise 
to the possibility of a novel mechanism whereby plasma membrane bound phosphate 
may be released through the action of PHOSPHO1 and phospholipase C to 
contribute to the PI concentration inside the MV.
To further examine this mechanism, the mineralisation potential of cells and 
cell associated factors such as MVs need to be assessed whilst modulating the 
activity ofPHOSPHOl. The most common way of modulating enzyme activity is to 
use small molecule inhibitors which can be utilised in biological systems to inhibit 
the pathway that the enzyme is involved in. However as PHOSPHO1 is a novel 
enzyme belonging to a specific group of the phosphor-monoesterase section of the 
HAD superfamily (Tirrell et al, 2006), no inhibitors are yet known for this enzyme 
thus in such circumstances methods such as high throughput screening of chemical 
libraries are employed in an attempt to find compounds able to modulate enzyme 
catalysis.
Inhibitors are a powerful tool in both the research and pharmacological 
industry. Indeed, small molecule inhibitors are used to investigate cellular pathways 
such as the MEK-ERK signalling pathway (Klein et al, 2006) and the AKT pathway
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(Yang et al, 2004). In addition to this some of the most powerful antiviral agents 
available at present are enzyme inhibitors. Retroviral protease inhibitors are one of 
the most successful groups of anti-HIV therapeutics, including drugs such as 
Ritonavir. This particular drug was launched in 1995 and presented a novel target of 
interception within this disease (Banner et al, 1995). Other powerful pharmaceutical 
inhibitors include the influenza neuraminidase inhibitor Tamiflu (oseltamivir) which 
is active against the H5N1 strain of avian influenza (Leneva et al, 2000). It will be 
the main drug of choice in fighting any avian flu epidemic. Discovery of inhibitors to 
PHOSPHO1 may lead to the generation of reagents that will facilitate future studies 
aimed at understanding the process of matrix mineralisation and how PHOSPHO1 is 
involved in this cellular pathway.
It is known that the first step of mineralisation (initiation step) mediates the 
deposition of seed crystals of HA. It is proposed that this step, which is independent 
of the function of TNAP, involves the function ofPHOSPHOl in increasing the local 
concentration of PI inside the MVs. If correct, it would be envisaged that an 
inhibition ofPHOSPHOl activity would result in decreased mineralisation within the 
MV. Therefore, in this study this hypothesis has been tested by affecting the first 
step of MV-mediated mineralisation and cell mediated matrix mineralisation using a 
pharmacological approach.
7.2 Hypothesis
That the inhibition of PHOSPHO1 will reduce the concentration of Pi at potential 
sites of mineralisation thus causing a decrease in HA formation via calcium 
phosphate precipitation.
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7.3 Aims
I. Screen chemical libraries for compounds with an inhibitory potential for 
recombinant human PHOSPHO1.
II. Characterise these inhibitors through the production of dose response curves 
and analysis of kinetic values during PHOSPHO1 mediated hydrolysis of 
PEA in the presence of inhibitor.
III. To study effects of these inhibitors on cell mediated matrix mineralisation.
IV. Assess the ability of these inhibitors to reduce the Pi producing potential and 
calcification of MVs.
7.4 Materials and Methods 
7.4.1 Inhibitor Screening
Recombinant protein produced in the same manner as detailed in section 
3.4.2 was utilised in a modified reaction system outlined in section 2.6.5. These 
reaction conditions used BSA rather than glycerol to stabilise the PHOSPHO1 
protein. This was due to the liquid handler not being able to pipette a solution 
containing glycerol accurately due to liquid retention in the tip. The screening was 
carried out as outlined in section 2.6.5 in a 96 well plate format. This allowed the 
screening of 80 compounds per plate, as shown in figure 7.1. These compounds were 
drawn from the LOP AC 1280 (Sigma) and Spectrum (Microsource Discovery) 
libraries. The LOP AC library consists of 1280 pharmacologically active compounds
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covering most of the major target classes i.e. G protein coupled receptors and 
kinases. The spectrum library contains 2000 compounds including known bioactives, 
natural products and their derivatives. The use of these two libraries allowed the 
evaluation of hundreds of marketed drugs and biochemical standards. Each 
compound that exhibited an inhibition of 40% or more using the automated system 
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Figure 7.1 Histogram relating to the screen of one plate from the LOPAC 
Library. This assay was conducted as outlined in section 2.6.5. The section labelled 
X relates to the negative controls (i.e. no inhibition, contained both enzyme and 
PEA) and section Y relates to the positive control (i.e. 100% inhibition, contained 
only PEA)
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7.4.2 Characterisation ofPHOSPHOl Inhibitors
The commercially available BIOMOL green assay system (based on the 
classical malachite green assay detailed by Martin et al, (1985)), which measures the 
amount of Pi in a reaction solution was utilised for the calculation of ICso values. 
This protocol employs an identical assay to that described in section 2.6.5 for the 
automated screening, however the reaction was scaled up to 50 jaL. Briefly 500ng of 
purified recombinant PHOSPHO1 protein was incubated with 62.5 uM PEA in the 
presence of serial dilutions (5:6) of inhibitors from 100 uM to 351 nM in triplicate. 
The reaction was incubated at room temperature for 60 min. Phosphate released 
during the reaction was measured by addition of 100 uL BIOMOL Green reagent and 
absorbance read at 620nm. The data of absorbance vs. inhibitor concentration was 
plotted using SigmaPlot and four parameter logistic curve fitted. The ICso was 
calculated using the equation; y = min + (max-min/l+
To analyse kinetic constants for these inhibited reactions a continuous 
phosphatase assay was employed as described in section 2.6.6. This involved the 
monitoring of /?NPP dephosphorylation which causes an absorbance change at 
405 nm due to the release of free p-nitrophenol (yellow in colour) and is directly 
proportional to phosphate bond hydrolysis. Both inhibitor and pNPP concentrations 
were varied between 0-60 uM and 0-10 mM respectively and hydrolysis 
measured in the presence of 1.5 uM recombinant human PHOSPHO1.
7.4.3 Effect of Inhibitors on MLO-A5 Cell Mineralisation
Cells were maintained as outlined in section 2.2, with the following 
modifications. The cells were cultured in alpha MEM (Gibco) containing 5% FBS,
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5% PCS. The cells were seeded into 12 well plates at a density of 40,000 cells/cm2, 
and cultured in the presence of 10 mM POP and 50 ug/ml AA. Inhibitors were 
supplied at 0, 5, 7.5 and 10 uM in triplicate, the no inhibitor control contained an 
equal volume of DMSO. The cells were then stained with alizarin red as outlined in 
section 2.2.9.1.
7.4.4 MV Isolation
MVs were isolated from chick growth plate cartilage as outlined in section 
2.2.7 with the following modifications. The diced growth plate cartilage was 
immersed directly in a solution of 0.45% collagenase (Worthington, type II) in 50 
mM Tris-HCl pH 7.6, 120 mM NaCl and 10 mM KC1 and incubated at 37 °C for 
three hrs with constant agitation. The MVs were purified from this suspension by 
differential ultracentrifugation as outlined in section 2.2.7.
To isolate MVs from cultured osteoblasts a protocol was employed which 
was similar to that used for chondrocytes, as outlined in section 2.2.8. Firstly the 
primary murine osteoblasts were cultured for 21 days in alpha MEM (Gibco) 
containing 10% FBS and 50 jig/ml AA. The cell monolayer was then washed with 50 
mM Tris-HCl pH 7.6, 120 mM NaCl and 10 mM KC1, and then incubated with 
0.45% collagenase (Worthington, type II) in 50 mM Tris-HCl pH 7.6, 120 mM NaCl 
and 10 mM KC1 at 37°C for 120 minutes at 37°C, with constant agitation. This cell 
suspension was subjected to differential centrifugation as described in section 2.2.7.
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7.4.5 MV Phosphatase Assay
The phosphatase assay used for the analysis of inhibitor effects on Pi 
production by MVs was identical to that detailed under section 2.6.5 with the 
following adjustments. The reaction volume was scaled up to 100 jil from 25 ul and 
1.2 jxg MV protein was used in place of recombinant enzyme. The assay was run in 
triplicate in the presence of 1 mM PHOSPHO1 inhibitors and 100 uM PEA with a no 
inhibitor and no substrate control containing equal quantities of DMSO or reaction 
buffer respectively. The reaction was incubated for 60 minutes at room temperature 
and stopped by the addition of 100 ul BIOMOL green reagent, the absorbance of 
each well was measured at 620 nm and converted to standard units (nmol min" 1 mg" 1 ) 
by comparison to phosphate standards of known concentration.
7.4.6 MV Calcification Assay
This was carried out according to the procedure detailed in section 2.6.4. This 
utilised 15 ug samples of chick MVs and 20 ug of TNAP null osteoblast derived 
MVs. Briefly these were incubated with calcification buffer containing 3 mM PEA or 
PGP and 1 mM inhibitor in a 200 ul reaction for a period of 6 hrs. The resultant 
calcium phosphate was harvested, solubilised and calcium content measured as 
outlined in section 2.6.4.
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1.5 Results
7.5.1 Identification and Characterisation of PHOSPHOl Inhibitors
7.5.1.1 Discovery of PHOSPHOl Inhibitors
Seventeen compounds in the LOP AC and SPECTRUM chemical libraries 
were found to inhibit recombinant PHOSPHOl activity with IC50 values of 10 uM or 
less (structures shown in appendix 7). From these seventeen compounds three were 
selected based on certain criteria, i.e. having a reconfirmed inhibitory potential of 
80% or more and also the absence of any reactive groups such as thiols etc. This led 
to the identification of SCH 202676, Lansoprazole and Ebseleln as compounds for 





Figure 7.2 Structures of three compounds found to inhibit recombinant
PHOSPHOl. The compounds were selected on the basis of their chemical properties 
i.e. having a reconfirmed inhibitory potential of 80% or more and also the absence of 
any reactive groups such as thiols etc.
7.5.1.2 Inhibitory Concentration50 (IC50) Calculations
The ICso values for each of these compounds were calculated by varying the 
concentrations of inhibitors, and observing the effect on PHOSPHOl mediated
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hydrolysis of PEA. These values were computed using the; y = min + (max-min/l +
were
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Figure 7.3 ICso determination of each PHOSPHOl inhibitor. Recombinant human 
PHOSPHOl was incubated with various concentrations of SCH 202676, 
Lansoprazole or Ebseleln at room temperature for 60 min. Phosphate released during 
the reaction was measured by addition of 100 pL BIOMOL Green reagent and 
absorbance read at 620nm. Results are mean ± SD (n = 3).
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7.5.1.3 Inhibitor Classification
The inhibition type displayed by each of the compounds was investigated by 
analysis of data relating to the initial velocity of the hydrolysis reaction in the 
presence of varying concentrations of inhibitor and the colorimetric substrate pNPP. 
From analysis of the resultant Line-weaver burke plots (figure 7.4) each inhibitor 
displayed an apparent mixed or non-competitive type inhibitory profile as the lines 
were not parallel as seen with un-competitive inhibition. All three inhibitors display 
lines which intercept after the y axis, close to the x axis. A Michaelis Menten curve 
was constructed under saturating quantities of pNPP as seen in figure 7.5, this also 
shown the inhibitors are of a non competitive or mixed nature. If these inhibitors 
were competitive the lines of the inhibited reaction vs. the uninhibited reaction would 
intercept due to a dilution effect of substrate on inhibitor. Upon analysis of the Km 
values for the inhibited reactions displayed in Tables 7.1, 7.2 and 7.3, both SCH 
202676 and Lansoprazole display apparent non-competitive characteristics due to the 
Km values not altering significantly. However when the data relating to Ebselen is 
examined it is evident that with increasing concentrations of inhibitor the Km of the 
reaction also increases. This is a hallmark of mixed type inhibition. The inhibitor 
constant K» dissociation constant for the inhibitor/enzyme complex, was also 
calculated for each of these reactions with SCH 202676, Lansoprazole and Ebseleln 
displaying Kt values of 1.08 ± 0.83 , 71.28 ± 9.21and 31.00 ± 0.74 uM respectively 
(calculations are shown in tables 7.1 to 7.3).
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Figure 7.4 Kinetic analysis of PHOSPHO1 mediated hydrolysis of pNPP in the 
presence of inhibitors. Recombinant human PHOSPHO1 was incubated with 
various concentrations of SCH 202676, Lansoprazole or Ebselen and various 
concentrations of pNPP and change in absorbance (405nm) measured over 30 
minutes. Initial velocity was calculated from the increment of the graph relating to 
the start of the reaction. Line weaver burke plots indicate the mode of inhibition is of 
the non-competitive type due to the lines interception around the x axis.
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Figure 7.5 Kinetic analysis of PHOSPHO1 mediated hydrolysis of pNPP in the 
presence of inhibitors. Recombinant human PHOSPHO1 was incubated with 
various concentrations of SCH 202676, Lansoprazole or Ebseleln and up to 
saturating concentrations of pNPP. The change in absorbance (405nm) was measured 
over 30 minutes. Initial velocity was calculated from the increment of the graph 
relating to the start of the reaction. This plot indicate the mode of inhibition is of the 
non-competitive type due to the lines not nearing interception with the uninhibited 
reaction under saturating quantities of substrate, (units of initial velocity = 
milliOD/miri).
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Equation of Line 
(y=mx+c)
y = 0.0734x + 00051
y = 0.0858x + 0.0056
y = 0.097x + 0.0061



















Mean JT/ ( uM) 3 1 .00 ± 0.74
Vmax = 1/c, Km = Vmax x m, c Ki=
Table 7.1 Properties of Ebselen on pNPP hydrolysis by PHOSPHO1.
Concentrations of Ebselen varied between 0 and 10 uM, constants calculated from 







Equation of Line 
(y=mx+c)
y = 0.0699x + 0.0057
y = 0.0866x + 0.0071
y = 0.1 191x + 0.009



















Mean K{ ( uM) 7 1.28 ±9.21
Vmax = 1/c, Km = Vmax x m, c Kr
Table 7.2 Properties of Lansoprazole on pNPP hydrolysis by PHOSPHO1.
Concentrations of Lansoprazole varied between 0 and 50 uM, constants calculated 
from equations of Lineweaver-Burke plots.
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Equation of Line 
(y=mx+c)
y = 0.0692x + 0.0052
y = 0.08 16x + 0.0069
y = 0.1384x + 0.0134



















Mean Kt ( jiM) 1.08± 0.83
Vmax = 1/C, b Km = Vmax X m, C Kr
Table 7.3 Properties of SCH 202676 on pNPP hydrolysis by PHOSPHOl. (A)
Concentrations of SCH 202676 varied between 0 and 4 [oM, constants calculated 
from equations of Lineweaver-Burke plots
7.5.2 Effect of PHOSPHOl Inhibitors on Cell Mediated Mineralisation
To analyse whether any of the PHOSPHOl inhibitors had an effect on matrix 
mineralisation the rapidly mineralising osteoblast-like cell, MLO-A5 was used. The 
inhibitors were added directly to the cell suspension on the day of plating and the 
media/inhibitors changed each day up to day nine. Three twelve well plates were set 
up for each inhibitor, utilising three wells for each inhibitor concentration (0, 5, 7.5 
and 10 uM) and one plate for each time point (4, 7, and 9 days). Mineralisation was 
observed in all wells on day 4 which increased till day 9. Lansoprazole showed no 
effect on mineralisation and no apparent cellular toxicity. However SCH 202676 and 
Ebseleln at all concentrations displayed high levels of cellular toxicity depicted by 
large unoccupied plaques in the culture well becoming apparent after 4 days in
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culture. The remaining cells that did continue to grow in the presence of these 
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Figure 7.6 Analysis of mineralisation in the presence of PHOSPHO1 inhibitors.
Murine MLO-A5 osteoblast like cells were grown in the presence of the 
mineralisation promoters (3GP and AA and incubated with various concentrations of 
SCH 202676, Lansoprazole or Ebselen. Mineralisation was assessed using the 
Alizarin red calcium staining technique.
7.5.3 Effect ofPHOSPHOl Inhibitors on MV Phosphatase Activity
MV protein (chick and murine) was used directly as a source of wild type 
PHOSPHO1 in a malachite green assay to assess Pi generation in the presence of 
PHOSPHO1 inhibitors. PEA was supplied as PHOSPHOls preferential substrate and 
each inhibitor used at a concentration of 1 mM. As seen in figure 7.7 the uninhibited
MV protein exhibits a PEA hydrolase activity of 87.1 ±1.8 nmol min" mg" with 
Lansoprazole and SCH202676 exhibiting the most inhibition of this reaction, 62.9 ± 
1.1 nmol min" 1 mg" 1 and 73.0 ± 2.7 nmol min" 1 mg" 1 respectively. These activities 
relate to a reduction in activity of approximately 28% for Lansoprazole and 16% for 
SCH202676.
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Figure 7.7 Phosphoethanolamine hydrolase potential of chick MVs in the 
presence of PHOSPHO1 inhibitors. Chick MVs were isolated from tibial growth 
plate cartilage and used directly to assess PEA hydrolase potential. The reaction was 
allowed to proceed for 60mins and terminated by the addition of 100 uL BIOMOL 
Green reagent and absorbance read at 620nm as described under Materials and 
Methods. Results are mean ± SD (n = 3, *** = p<0.001 when inhibited reaction 
compared to uninhibited).
7.5.4 Effect ofPHOSPHOl Inhibitors on MV Calcification
To investigate the ability of these inhibitors to inhibit the calcification of MV 
preparations a protocol based on that of Garimella et al, (2004) was used. This 
protocol allows the assessment of the ability of MVs to form calcium phosphate in 
vitro. PEA supports the calcification of chick MVs, purified from growth plate 
cartilage, comparable to that shown by the phosphoester POP, 1.0 ± 0.01 and 1.3 ± 
0.04 units of calcium precipitated respectively under these assay conditions (figure 
7.8a). Chick MV preparations were subsequently incubated with 1 mM of
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Lansoprazole or SCH202676 resulting in a slight decrease in calcifying potential in 























































Figure 7.8 Potential for MVs to calcify in vitro in the presence of 
phosphoethanolamine and PHOSPHOl inhibitors. (A) The ability of chick MVs 
to induce calcification in the presence of PEA and pGP. (B) Calcification of chick 
MVs in the presence of 1 mM Lansoprazole or SCH 202676 (C) Calcification of 
murine TNAP null osteoblast derived MVs in the presence of 1 mM Lansoprazole or 
SCH 202676. MVs were incubated in calcification buffer with 3 mM phosphoester 
for 6 hrs, precipitated calcium phosphate was harvested by centrifugation and 
solubilised for 24Hrs in 0.6N HC1, Calcium concentration was measured by the 
Calcium-O-cresolpthalein complexone (O-CPC) method as described in section 
2.6.4. Results are mean ± SD (n = 3, *** = pO.OOl, ** = p<0.01 when inhibited 
reaction compared to uninhibited).
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To increase the sensitivity of this assay MVs were extracted from cultured 
TNAP"7" osteoblasts, as these contain no alkaline phosphatase the possibility of this 
enzyme hydrolysing the phosphoester will be eliminated. When incubated in an 
identical reaction to that of chick MVs (figures 7.7 -7.8B) a more pronounced 
inhibitory effect was seen with Lansoprazole and SCH202676. Lansoprazole 
exhibited a 56.8 % inhibition of calcification by TNAP null MVs whereas 
SCH202676 inhibited calcification by 70.7%, as detailed in figure 7.8C.
7.6 Discussion
High throughput screening of compounds from the two chemical libraries 
LOP AC and SPECTRUM revealed 17 inhibitors of PHOSPHOl mediated hydrolysis 
of PEA. Many of these inhibitors however had undesirable properties. Compounds 
such as cisplatinin which could conceivably intercalate between the disulfide bridge 
in PHOSPHOl. In addition to this, compounds such as the dimeric disulfide 
containing compound THIRAM would be susceptible to nucleophilic attack and 
reduction. Other compounds deemed unsuitable include those which posses thiol 
groups (-SH) due to their propensity to form disulphide bridges with other thiol 
groups. The functional group of the amino acid cysteine is indeed a thiol thus it is 
likely that compounds such as mercaptbenzothiazole, which was identified during 
this screen as a PHOSPHOl inhibitor, would be causing inhibition through chemical 
modification of the PHOSPHOl structure. This compound structure screening led to 
the identification of three inhibitors for further investigation - SCH 202676, 
Lansoprazole and Ebselen.
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As seen in figure 7.4 and 7.5 all of the inhibitors display characteristics which 
suggest they do not belong to either the un-competitive or competitive classes i.e. the 
Km of the inhibited reaction remains apparently unchanged (due to the interception of 
the x axis) but there is a reduction in the Vmax . This is due to the inhibitor binding to a 
site on the enzyme distinct from the active site causing inactivation of the enzyme 
molecule. This effectively reduces the total concentration of enzyme available for 
catalysis. As Vmax is proportional to enzyme concentration, Vmax is reduced and as the 
uninhibited enzyme molecules are unaltered, Km is unchanged. However upon closer 
inspection the Km for Ebselen does seem to rise slightly (table 7.1) with addition of 
inhibitor thus indicating a mixed inhibition type - characterised by the decrease in 
Vmax with a subsequent rise in Km due to inhibitor binding of both enzyme and 
enzyme/substrate complex (Stryer, 1995).
The selective inhibition of TNAP within mineralising cultures and tissues has 
previously been shown to have a negative effect on the mineralisation process. The 
inhibitory potential of levamisole towards TNAP was first documented in 1973 
(Borgers, 1973) and since then has been classified a stereospecific, un-competitive 
inhibitor of bone alkaline phosphatase (TNAP) (Van Belle, 1976). When levamisole 
is incubated with cultures of osteoid forming cells, mineralisation is blocked through 
inhibition of TNAP activity (Tenenbaum, 1987). Although it was originally 
postulated that the inhibition of TNAP reduced the Pi pool thus decreasing 
mineralisation it is more likely that the inhibition seen is due to an increase in 
TNAPs natural substrate and hydroxyapatite inhibitor, PPi (Wang et al, 2005). It was 
investigated, in the present study, whether PHOSPHO1 inhibitors would function in 
a similar manner to alkaline phosphatase inhibitors when incubated with osteoblast
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like cells. The cells of choice were the well characterised MLO-A5 cell type which 
have the capacity to mineralise their matrix in culture (Kato et at, 2001). As seen in 
figure 7.6 none of the inhibitors had an effect on the mineralisation of cell 
monolayers by MLO-A5 cells. This may be due to the inaccessibility of the 
inhibitors to the site where PHOSPHO1 resides, within MVs, however a more likely 
explanation is that the action of TNAP is masking any effect of the PHOSPHO1 
inhibitors. As reported in chapter 3, the mineralisation promoter PGP is a poor 
substrate for PHOSPHO1, displaying a specific activity of 39.6 ± 6.2 nmol phosphate 
released/min/mg, over lOOx less than that observed with PEA as a substrate. 
Although it is widely accepted that the main function of TNAP is to hydrolyse the 
mineralisation inhibitor PPi, a function when studying in vitro mineralisation is to 
cleave (3GP thus producing Pi for mineral formation (Chung et al, 1992). It has also 
been shown that 0GP increases TNAP transcript levels and hence protein content of 
cells during the non-mineralisation phase of osteoblast development (Chak et al, 
1995). Together these data possibly explain why no effect was seen when 
PHOSPHO1 inhibitors were incubated with osteoblast cultures.
It has been hypothesised that PHOSPHO1 functions at the first step of 
mineralisation (initiation step), which mediates the deposition of seed crystals of HA 
within the MV lumen, therefore modulation of PHOSPHO1 activity within these 
compartments would allow the precise function of this enzyme to be deduced. It has 
previously been shown that inhibition of TNAP sequestered on the surface of MVs, 
by levamisole, causes a decrease in both Ca2+ and PC>43 ~ uptake into the vesicle 
lumen, however apatite growth in this compartment was only weakly affected 
indicating that TNAP is not directly involved in vesicle mediated calcification
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(Register et al, 1984). In addition, MVs from TNAP null mice show normal HA 
formation (Anderson et al, 2004). This only strengthens the hypothesis that another 
enzyme is present at these sites and functions to increase the intravesicular 
concentrations of Pi to a level which is conducive for calcium phosphate 
precipitation. To investigate whether PHOSPHO1 could be this enzyme, PEA 
hydrolase activity was monitored in the presence ofPHOSPHOl inhibitors. As seen 
in figure 7.7 both Lansoprazole and SCH 202676 decrease the liberated Pi by 28% 
and 16% respectively. Ebselen had no effect on the PEA hydrolase activity of MVs 
thus it is likely that it is not effective against wild type enzyme. Also as this is a non- 
competitive inhibitor it is known that the inhibitor is binding at a site distinct from 
the active site. As the recombinant protein used for inhibitor screening has a C 
terminal tagged region, which is not present on the wild type enzyme it is 
conceivable that Ebselen is binding PHOSPHO1 around this site thus serving to 
inhibit the recombinant enzyme but not wild type.
SCH 202676 is a thiadiazole compound that acts upon and inhibits signalling 
through G protein-coupled receptors (Fawzi et al, 2001). It is thought that this 
compound is an allosteric modulator of G protein-coupled receptors and may 
recognise an intracellular regulatory domain of the protein, however it remains 
unknown what the exact mode of inhibition is (Lanzafame & Christopoulos, 2004).
Lansoprazole, however, is an extremely well characterised compound. This 
drug belongs to a class of compounds known as the 2-(2-pyridylmethylsulfinyl)-l//- 
benzimidazoles and is an inhibitor of H+ and K+ (H+/K+)-ATPase of stomach 
parietal cells. Because this enzyme system is regarded as the acid (proton) pump, 
Lansoprazole is classified as a gastric acid-pump inhibitor, in that it blocks the final
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step of acid production. Interestingly this drug is widely used in the treatment of 
acid-reflux disorders but no side effects involving bone have been noted, thus the 
finding that this compound displays PHOSPHO1 inhibition in vitro suggests that the 
drug may be absent at sites of mineralisation or if present, in a altered form. This is 
consistent with the site of action for this drug - the stomach. Indeed it has been 
proposed that under acidic conditions, Lansoprazole is converted into an acid 
activated cationic sulphenamide form (AG2000) which acts as the proton pump 
inhibitor (Kihira, 1988), this drug is thought to be stomach restricted as the activated 
sulphenamide form is unable to traverse membranes. At this site it reacts with thiol 
groups within the catalytic subunit of the H,K-ATPase to form disulfide bonds with 
cysteine in the a-subunit, as shown in figure 7.9 (Lorentzon et al, 1987). It is 
unlikely that this is the mode of inhibition displayed during Lansoprazole mediated 
inhibition of PHOSPHO1 as the reaction conditions used during this study are near 
neutral (pH6.7-7.6) thus the formation of the protonated active form would not be 
facilitated. In humans this form only occurs when the pH is below 4 (Riel et al, 
2004) and with the pH of gastric acid being documented as in the 1-2.5 range the 
conversion of the pro drug to the active form would only be facilitated at acidic sites 
of the body i.e. the stomach (Evans et al, 1988).
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Figure 7.9 Reaction mechanism of Lansoprazole under acidic conditions. The
compounds protonate and accumulate in an acid space and undergo an acid-catalysed 
conversion to a tetracyclic sulfenamide, which then reacts with cysteines in the oc 
subunit of the H,K-ATPase that are accessible from the extracytoplasmic surface 
(Adapted from Besancon et «/, 1997)
These two PHOSPHO1 inhibitors were used directly to investigate if they 
influenced calcification of chick growth plate MVs. As shown in figure 7.8B the 
effect of these inhibitors was minimal with only around a 10% decrease in calcium 
detected with each inhibitor. This is not in agreement with the data showing 
Lansoprazole and SCH 202676 causing a 26% and 16% decrease in Pi release from 
MV preparations, respectively. It would have been expected that the calcium 
phosphate deposition from these preparations would also have decreased by a similar 
ratio. However, as the calcification reaction was done at a higher pH (7.6 compared 
to 6.7) it is likely that TNAP activity of these MV preps would be higher thus 
perhaps masking the inhibition of PHOSPHO1 though production of Pi for 
calcification. In an attempt to overcome this, TNAP null MVs were obtained from 
osteoblast cultures (isolated from TNAP null calvaria) and used in an identical assay. 
When the calcification potential of these MV preparations was investigated, and
210
Chapter 7 Discovery and Characterisation ofPHOSPHOl Inhibitors
incubated in the presence of PHOSPHO1 inhibitors, a more profound effect on 
calcification was observed. Although only a very small quantity of calcium 
phosphate was produced from these preparations (11.4x less than the equivalent 
quantity of chick MVs), SCH 202676 caused a 70% decrease in calcification. This 
would indicate that PHOSPHO1 which is sequestered within the lumen of MVs has 
the ability to hydrolyse PEA to increase the intravesicular concentrations of Pi and 
thereby allow mineralisation to occur. This is likely to occur in synergy with 
phosphate and calcium transporters to facilitate the production of seed crystals for 




Figure 7.10 Schematic representation of Ca2+ and Pi accumulation in MVs.
Inhibition of PHOSPHO1 will decrease the Pi pool within the MV lumen thus 
causing a decrease in HA production. BSP, bone sialoprotein; PCho, 
phosphocholine; PEA, phosphoethanolamine; PLC, phospholipase C; A-C, annexin 
complex; Pi-T, phosphate transporter.
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In conclusion the inhibitors, SCH 202676 and Lansoprazole have a certain 
efficacy in the modulation of in vitro mineralisation within MVs. These two 
compounds, in addition to TNAP inhibitors, may allow further investigation into the 
initial stages of calcification through the modulation of MV associated phosphatases.
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8.1 General Discussion
The initiation step of mineralisation is critical for subsequent ordered growth 
of HA crystals for bone development. Although it is now widely regarded that the 
production of apatite seed crystals is orchestrated within the confines of the MV, the 
factors influencing this process are poorly understood. It was originally postulated 
that TNAP was the catalyst for this process, a master enzyme governing the 
production of phosphate for calcium phosphate precipitation, however knockout 
mice lacking functional TNAP displayed mineralised skeletons, and perhaps more 
critically their MVs contained crystals of hydroxyapatite. This discovery triggered 
the investigation of other factors which may influence skeletal mineralisation. This 
work that I present within this thesis concentrated on one protein, PHOSPHO1, 
which may be involved in this pathway. However before I commence any detailed 
discussion of the results presented in this thesis I will briefly describe the main 
findings from this study.
PHOSPHO1 is a phosphatase enzyme which belongs to the HAD superfamily 
of hydrolases. This enzyme is capable of hydrolysing PEA and PCho, compounds 
which form the polar head regions of phospholiphid membranes, with high specific 
activity and favourable kinetics. This would indicate that this reaction is likely to 
occur in vivo and implicates this enzyme in the phosphoglycerolipid metabolism 
pathway. This enzyme, despite its relatively high sequence identity, displays an 
entirely different hydrolysis pattern to PHOSPHO2. PHOSPHO2 is expressed within 
mineralising tissues, as is PHOSPHO1, however out of the tested substrates P5P 
served as the best ligand for this enzyme. This was somewhat surprising, however 
upon analysis of molecular models of both PHOSPHO1 and PHOSPHO2 significant
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differences were observed between the two structures which may cause the 
differences in apparent substrate specificity. The active site of PHOSPHOl was also 
further characterised with residues previously postulated to be involved in substrate 
specific interactions mutated to investigate their involvement in PHOSPHOl 
mediated catalysis.
Previous to this project, localisation studies had been undertaken using a 
chick model, the results of which implicated PHOSPHOl in the mineralisation 
process due to its localisation to every surface of mineralisation in both bone and 
cartilage. It was therefore important to replicate this in the mammalian system thus 
disproving the interpretation that perhaps this protein was merely a caveat of avian 
bone formation. Indeed mammalian PHOSPHOl is localised in the mouse model in 
an identical fashion as previously observed within the chick. Interestingly the protein 
is also present in MVs of both species, furthering the hypothesis that PHOSPHOl is 
involved in the mineralisation process. Further, the mineralisation promoter AA also 
increases the content of PHOSPHOl within MVs indicting a similar regulatory 
pattern to TNAP.
The modulation to PHOSPHOl has an effect on the mineralisation capacity 
of both cells and MVs. Reduction of PHOSPHOl transcript within the MLO-A5 cell 
line through siRNA mediated knockdown reduces the potential for matrix 
mineralisation. In addition, reduction of PHOSPHOl activity through the use of 
newly discovered small molecule inhibitors causes a decrease in the capacity of MVs 
to calcify in vitro. These data both indicate that PHOSPHOl has a role in the 
mineralisation process which is likely to be in the production of Pi for calcium 
phosphate precipitation.
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Collectively these data indicate that PHOSPHO1 is closely associated with 
the mineralisation process and in particular, due to the results presented in chapter 7, 
the generation of Pi for hydroxyapatite production. This is an essential phase of 
mineral formation, not only for the precipitation with calcium but initially to raise the 
Pi/PPi ratio to a degree that is permissive to mineralisation. This, as discussed 
previously, is due to PPi acting as a powerful inhibitor of HA formation. The source 
of substrate for Pi generation by PHOSPHO1 is likely to be that of the MV- 
membrane which is a reservoir of both phosphatidylethanolamine and 
phosphatidylcholine. As discussed previously, Wu et al (2002) have found that the 
phosphatidylethanolamine and phosphatidylcholine composition of the MV 
membrane decreases during mineralisation and that 1,2-diacyl glycerol accumulates 
in MVs, indicative of phospholipase C activity. In addition to this a recent study has 
shown that prostaglandin F2a increases PCho production in murine MC3T3-E1 
osteoblast-like cells (Sakai et al, 2004). The authors suggest that a phospholipase C 
(PLC) is responsible for this increase in PCho production. This combined with the 
localisation of PHOSPHO1 in MVs and the differentiation pattern akin to TNAP 
furthers the initial hypothesis. This would represent a novel means of generating Pj in 
mineralising cells and offer an explanation as to why HA is observed within the MVs 
of TNAP null mice. It is apparent though that this is not a form of enzymatic 
redundancy in the mineralisation process as PHOSPHO1 does not cleave well known 
TNAP substrates such as PPi and P5P, also TNAP is anchored to the outer leaflet of 
MVs and mineralising cells whereas PHOSPHO1 appears to be cytosolic. It is more 
likely that these two enzymes act in a synchronised manner to promote the 
mineralisation process; TNAP would primarily hydrolyse the mineralisation inhibitor
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PPi whereas PHOSPHO1 would produce Pi to facilitate seed crystal deposition. The 
loss of function of either of these enzymes would only serve to impede skeletal 
development. It seems however, that neither of these enzymes are powerful enough 
to cause a complete loss of mineralisation. This is indicated by the data in chapter six 
referring to the use of siRNA to knockdown PHOSPHO1 transcript and that in 
chapter seven concerning the inhibition of PHOSPHO1 in TNAP null MVs. 
Collectively these data strongly suggest that if the function of both enzymes is lost 
mineralisation would be severely retarded.
If correct this would have implications to the manner in which we treat 
mineralisation disorders such as osteomalacia and pathological soft-tissue 
ossification, a process clinically significant in atherosclerosis and heart failure. 
Intervention of these pathological conditions at a stage prior to mineral growth, at the 
point of seed crystal initiation may prove to have an efficacy in the treatment of these 
conditions. Indeed, as it seems from the results presented that bone mineralisation 
requires both PHOSPHO1 and TNAP, the targeted inhibition of these proteins may 
be a potential treatment in these disorders. The discovery of novel small molecule 
inhibitors and the characterisation of the PHOSPHO1 active site may lead to the 
generation of novel reagents with the ability to modulate PHOSPHO1 activity. In 
addition since the discovery that siRNAs can be used to selectively knockdown gene 
expression in vivo (Xia et al, 2002) a novel therapeutic mechanism could potentially 
be developed. I have described within this thesis regions of the PHOSPHO1 RNA 
sequence which can be targeted to ensure knockdown of gene expression, 
information which would ultimately need to be compiled before the development of 
a siRNA therapeutic.
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In conclusion the data presented within this thesis has linked PHOSPHO1 to 
a cellular pathway (phosphoglycerolipid metabolism) and to the mineralisation 
process in the mammalian system. Its elevated expression and localisation in the 
mouse model only serves to strengthen this hypothesis. Its localisation within MVs 
also attributes to this conclusion, as these discrete packages are considered the 
epicentre of mineralisation. A protein that is present within MVs, which is regulated 
so as content increases in line with cellular differentiation, would presumably be 
contributing to the processes which are occurring within.
8.2 Future Work
Although the results described within this thesis give an indication that 
PHOSPHO1 is involved in the bone mineralisation process, to assign true function, a 
model to study PHOSPHO1 in vivo would have to be developed. Knockout 
technology allows the production of mice lacking functional genes; hence by 
generating a mouse deficient in PHOSPHO1 it would be possible to assign function 
through analysis of metabolic abnormalities. This has already been exemplified by 
the wealth of information gained through the study of the TNAP-deficient mouse 
model of hypophosphatasia.
As it has been hypothesised that PHOSPHO1 is closely associated with 
TNAP in the mineralisation process, the PHOSPHO1 null mouse could be compared 
directly to the TNAP null mouse developed by Dr Millan (Burnham Institute, CA). 
In addition, inactivation of both the PHOSPHO1 and TNAP genes simultaneously 
could be investigated by cross breading the two mutants. As it has already been 
shown that TNAP is involved in the second step (phase 2) of mineralisation and as
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PHOSPHOl has been hypothesised to be involved in the first, initiation step it may 
be hypothesised that the knockout of both gene products simultaneously could lead 
to the complete absence of HA crystals. If this were the case, it would clearly 
implicate the function of PHOSPHOl, and of MV-mediated mineralisation, as a 
crucial step in skeletal mineralisation. Alternatively, it may be found that the 
phenotypic changes in the PHOSPHOl/TNAP double mutant mice are not 
significantly different from the osteomalacia observed in the TNAP null mice. This 
would imply either that MV-mediated calcification is not dependent on PHOSPHOl 
function and/or that other phosphatases or pathways may be operating in addition to, 
or instead of, PHOSPHOl. Only upon complete characterisation of bone physiology 
from both the single and double mutant mice could a reasoned evaluation of 
PHOSPHOl function be carried out.
Calvarial osteoblasts could also be grown in culture from these mice and used 
to evaluate phenotypic changes in vitro. These cells could be tested directly, utilising 
mineralisation assays, to investigate differences in their ability to deposit mineral in 
vitro compared to TNAP null cells and also if this ability is restricted further in the 
PHOSPHOl/TNAP double mutant cells. Using techniques described in this thesis it 
could also be investigated whether MVs derived from PHOSPHOl null and TNAP 
null osteoblasts have an impaired ability to calcify in vitro compared with MVs from 
WT cells and also if calcification is further restricted in MVs derived from 
PHOSPHOl/TNAP double mutant osteoblasts. This would further give data which 
could directly be used to assign not only function of PHOSPHOl but also which 
stage of the mineralisation process it is involved in.
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Finally, as PHOSPHO1 has been implicated in the glycerophospholipid 
metabolism pathway changes in phospholipid metabolites of MVs from the single 
and double mutants during calcification could be investigated. As discussed in 
chapter 3 it has previously been demonstrated by Wu et al, 2002 that the 
phospholipid composition of the MV membrane decreases during mineralisation and 
that 1,2-diacyl glycerol accumulates in the MV lumen. Although this is directly the 
result of Phospholipase C activity, the products of the reaction would be PEA and 
PCho, these could be directly monitored using 3 ^-nuclear magnetic resonance 
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Appendix 1: Vector Maps
pBAD-TQPQ (Invitrogen) as used in chapters 3 and 4 for PHOSPHOl and 
PHOSPHO2 expression




Represents covalemly bound topoisomcrase I
Vector Features
Arabinose promoter and regulatory elements: 4-276
pBAD Forward priming site: 208-227
Ribosome binding site: 328-331
Initiation ATG codon: 345-347
Enterokinase recognition site: 363-377
TOPO Cloning site: 387-388
V5 epitope: 402-443
Polyhistidine region: 453-470
pBAD Reverse priming site: 526-543
rrnB Tl and T2 transcription terminators: 576-733
Ampicillin resistance gene: 1013-1873
pBR322 origin: 2018-2691
AraC ORF: 4100-3222 (ORF on the opposite strand)
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pGEM-T-Easv (Promega) as used in chapter 5 for cloning of PHOSPHOl CDS


















































T7 RNA Polymerase transcription initiation site: 1
SP6 RNA Polymerase transcription initiation site: 141
T7 RNA Polymerase promoter (-17 to +3): 2999-3
SP6 RNA Polymerase promoter (-17 to +3): 139-158
Multiple cloning region: 10-128
LacZ start codon: 180
Lac operon sequences: 2996, 166-395
Lac operator: 200-216
Beta-lactamase coding region: 1337-2197
Phage fl region: 2380-2835
Binding site of pUC/M13 Forward Sequencing Primer: 2956-2972
Binding site of pUC/M13 Reverse Sequencing Primer: 176-192
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pSUPER-Nco-GFP (Oligoengine) as used in chapter 5 for shRNA mediated 



















































Ampicillin resistance ORF: 5301-4444
T7 primer binding site (AATACGACTCACTATAG): 627-643 
T3 primer binding site (CTTTAGTGAGGGTTAAT): 3242-3258 
M13(-20) primer binding site (GTAAAACGACGGCCAGT): 600-616 
M13 reverse primer binding site (CATGGTCATAGCTGTT): 3276-3291
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PWGBIO as used in chapter 5 for Mammalian PHOSPHOl expression
pWGB10-PHOSPHO1-HA






pWGBlO contains a phosphoglycerate kinase (PGK) promoter to drive PHOSPHOl 
expression, simian virus 40 (SV40) small t intron/polyA and SV40/Puromycin to 
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CAGAAAAC TCTTTC CAGAATGTC TCAAAATCTTGAGCCTATGGAATATTC TGTTGTAGTTTGGTC C TC 
AGGTGTTGATATAATTTCTCATTTACAATTTCTAATAAAGGATTAA
Nucleotide Sequences of PHOSPHO1 and PHOSPHO2. This CDS was used for 
recombinant protein production, producing prteins with the sequence defined on the 
next page
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Amino acid sequence of recombinant PHOSPHO1 and PHOSPHO2. Red regions 
indicate vector associated amino acids, Blue region the V5 epitope and green region 
































































































































































































































































































































































































































































































































































































































































Appendix 5: Predicted Masses of Tryptic Fragments from Recombinant Human 
PHOSPHO1
Mass Position Peptide Sequence
2702.2741 194-219 LF WGDGANDFCPMGLLAGG DVAFPR
2590.2195 23-44 FLLTFDFDETTVDENSDDSIVR
2578.3472 84-107 DLSAIYEAIPLSPGMSDLLQ FVAK



























PH1 mut(D203 S)F CCTCTTCTACGTGGGC AGCGGCGCC AACGACTTCTGC
PHlmut(D203S)R GCAGAAGTCGTTGGCGCCGCTGCCCACGTAGAAGAGG
PH 1 mut(D43N)F CGTGGACGAAAAC AGC AACGATTCGATCGTGCG
PH 1 mut(D43N)R CGC ACGATCGAATCGTTGCTGTTTTCGTCC ACG
PH lmut(D 123N)F GGTGATTCTCATCTCCAATGCCAACACCTTTGGCG
PH 1 mut(D 123N)R CGCC AAAGGTGTTGGC ATTGGAGATGAGAATC ACC
The sequence of the reverse and forward primers used in the mutagenesis reactions to 
generate the 5 mutant proteins, D32N, D43N, D123N, D123N/D3N and D203N.
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Appendix 7: Hits from Chemical Screen for PHOSPHO1 Inhibitors
LOP AC Library














































pyrrolidine ditfaio c arb amate
SCH-202676 hydrobromide
Tetraethylthiuram disulfideJ
Each hit was reconfirmed manually, (Green = Inhibition > 40%, Blue = Inhibition > 




Structure Initial Inhibition Reconfirmed Inhibition Compound Name
AKLAVINEHYDROCHLORIDE
-N ,P \ Pn :\ v< H ^ ^ /)H M—/
Each hit was reconfirmed manually, (Green = Inhibition > 40%, Blue = Inhibition > 














Initial Inhibition Reconfirmed Inhibition Compound Name
.„ ,, ! ESCULETIN : 50 26 i
45 31 ! FRAXETIN
! i




98 82 2-MERCAPTOBENZOTHIAZOLE !
_ i CHLORANIL 100 100 | i
i
Each hit was reconfirmed manually, (Green = Inhibition > 40%, Blue = Inhibition > 
60%, Red = Inhibition > 80%)
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Human PHOSPH01 exhibits high specific phosphoethanolamine and 
phosphocholine phosphatase activities
Scott J. ROBERTS*, Alan J. STEWART* 1 , Peter J. SADLERf and Colin FARQUHARSON*
*Roslin Institute, Roslin, Midlothian EH25 9PS, U.K. and fSchool of Chemistry, The University of Edinburgh, Edinburgh EH9 3JJ, U.K.
Human PHOSPHO1 is a phosphatase enzyme for which expres­ 
sion is upregulated in mineralizing cells. This enzyme has been 
implicated in the generation of Pj for matrix mineralization, a 
process central to skeletal development. PHOSPHO1 is a member 
of the haloacid dehalogenase (HAD) superfamily of Mg2+ -depen­ 
dent hydrolases. However, substrates for PHOSPHO1 are, as yet, 
unidentified and little is known about its activity. We show here 
that PHOSPHO1 exhibits high specific activities toward phos­ 
phoethanolamine (PEA) and phosphocholine (PCho). Optimal
enzymic activity was observed at approx. pH 6.7. The enzyme 
shows a high specific Mg2+-dependence, with apparent Km values 
of 3.0 nM for PEA and 11.4 /*M for PCho. These results provide 
a novel mechanism for the generation of Pj in mineralizing cells 
from PEA and PCho.
Key words: bone, haloacid dehalogenase (HAD) superfamily, 
mineralization, PHOSPHO1, phosphocholine (PCho), phospho­ 
ethanolamine (PEA).
INTRODUCTION
Matrix vesicle (MV)-mediated mineralization is a process central 
to the formation of bone, cartilage and teeth. Inside the MV, cal­ 
cium phosphate accumulates until sufficient amounts are present 
for precipitation to occur. This is then converted to an intermedi­ 
ate, octa-calcium phosphate, crystals of which are transformed 
into the less soluble hydroxyapatite [1]. The MV membranes 
then breakdown and release preformed hydroxyapatite into the 
extracellular fluid. Calcium accumulation is controlled by Ca2+ - 
binding molecules, such as annexin I and phosphatidylserine [2,3]. 
PI accumulation is associated with the action of alkaline and acid 
phosphatases [4,5]. The most abundant of these being tissue non­ 
specific alkaline phosphatase (TNAP), an isoenzyme of alkaline 
phosphatase expressed in bone, liver and kidney [6]. In addition 
to its structural role, Pj has also been shown to regulate multiple 
genes during osteoblast differentiation, including the immediate 
response gene, Nrf2 [7].
Deficiency of Pj in skeletal tissue (termed hypophosphatasia) 
is highly variable in its clinical expression, ranging from death 
in utero with an unmineralized skeleton to premature loss of 
teeth [8]. Hypophosphatasia is usually attributed to a reduction 
in TNAP activity. In newborn TNAP knockout mice, bone deve­ 
lopment and mineralization appear to be normal, although hypo- 
mineralization and other abnormalities of the skeleton and denti­ 
tion have subsequently been observed [9-11]; failure occurs in 
the propagation of the mineral from the MV to the surrounding 
extracellular matrix [12,13]. Support for this concept comes from 
earlier work [14], which shows that the catalytic activity of TNAP 
decreases in direct proportion to the extent that MVs induce 
mineral formation. TNAP is known to hydrolyse inorganic PPj 
[15], which is a potent inhibitor of hydroxyapatite crystal for­ 
mation [16]. Abnormalities found in TNAP knockout mice are, 
however, not present in TNAP/PC-1 double-knockout mice [9]. 
PC-1 (now known as NPP1) encodes the enzyme, phospho- 
diesterase I in mineralizing cells and generates PP{ from nucleo- 
tide triphosphates [17]. Studies have also shown that TNAP can
be removed from some preparations of MVs without reducing 
their potential to mineralize [18], whilst specific inhibitory studies 
on TNAP provide additional evidence that other phosphatases 
are present within mineralizing chondrocytes [19]. These obser­ 
vations suggest that the primary role of TNAP in skeletal develop­ 
ment is to hydrolyse PPj, preventing its inhibition of mineral 
crystal growth. It therefore appears that TNAP is not essential, at 
least for the initial events leading to MV-induced mineralization 
and implies that other phosphatases are involved.
Recently a novel phosphatase, PHOSPHO1, was identified 
which is expressed at levels approximately 100-fold higher in 
mineralizing chondrocytes than in non-skeletal tissues [20]. Im- 
munolocalization studies have since shown that PHOSPHO1 is 
specifically localized to mineralizing regions of skeletal tissue 
[21]. The amino acid sequence of PHOSPHO1 contains three 
peptide motifs that are conserved within the haloacid dehalogen­ 
ase (HAD) superfamily of Mg2+-dependent hydrolases. Human 
PHOSPHO1 shares approximately 30 % homology at the amino 
acid level with the LePS2 family of phosphatases [22,23]. Mole­ 
cular modelling of human PHOSPHO1, based upon the crystal 
structure of phosphoserine phosphatase from Methanococcus 
jannaschii, shows that all the characteristic features of the cata­ 
lytic site, with regard to the HAD superfamily, are preserved [24]. 
Despite these structural data, little is known about the phosphatase 
activity of PHOSPHO1. We report here a biochemical character­ 
ization of the enzyme and establish its substrate specificity and 
conditions for optimal activity. The data allow us to propose a 
new pathway for the generation of Pj in mineralizing cells that is 
coupled to the degradation of phospholipids.
EXPERIMENTAL 
Materials
SaOS-2 osteosarcoma cells were purchased from the European 
Collection of Cell Cultures (ECACC; CAMR Centre for Applied 
Microbiology & Research, Porton Down, Salisbury, Wilts, U.K.).
Abbreviations used: BAP, brain alkaline phosphatase; CDP-Cho, cytidine 5'-diphosphocholine; CDP-EA, cytidine 5'-diphosphoethanolamine; HAD, 
haloacid dehalogenase; MALDI-TOF-MS, matrix-assisted laser-desorption ionization-time-of-flight mass spectrometry; MESG, 2-amino-6-mercapto-7- 
methylpurine ribonucleoside; MV, matrix vesicle; Ni-NTA, nickel-nitrilotriacetate; PEA, phosphoethanolamine; PCho, phosphocholine; PNPase, purine 
nucleoside phosphorylase; IBS, Tris-buffered saline; TNAP, tissue non-specific alkaline phosphatase.
1 To whom correspondence should be addressed (email alan.stewart@bbsrc.ac.uk).
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Reverse transcriptions were carried out using the Gibco Super- 
Script™ First-Strand Synthesis System for RT-PCR. Custom 
DNA oligonucleotides were purchased from MWG-Biotech UK 
Ltd. (Milton Keynes, U.K.). Plasmid isolation and purification 
was carried out using the Promega Wizard DNA purification kit. 
The chemically competent Escherichia coli TOP 10 cells, the 
pBAD TOPO TA expression kit and the V5 antibody were pur­ 
chased from Invitrogen (Paisley, U.K.). Restriction enzymes 
were purchased from New England BioLabs (Hitchin, Herts., 
U.K.). Thermal cycling was performed using a Hybaid PCR 
Express Thermal Cycler. Nickel-nitrilotriacetate (Ni-NTA)- 
agarose was purchased from Qiagen (Crawley, West Sussex, 
U.K.). Complete® protease inhibitor cocktail was purchased 
from Roche. SDS/PAGE was performed on precast 10% acryl- 
amide mini-gels using a Bis-Tris buffered system (NuPAGE, In­ 
vitrogen). Gels were stained directly for protein using Coomassie 
Brilliant Blue R (Sigma). Tryptic digests and matrix-assisted 
laser-desorption ionization-time-of-flight mass spectrometry 
(MALDI-TOF-MS) were carried out by the Functional Genomics 
Unit at the Moredun Research Institute. BioDesign dialysis tubing 
(8,000 Molecular mass cut-off) was purchased from VWR Inter­ 
national. Human PHOSPHO1 concentrations were determined in 
96-well plates using the Bio-Rad protein assay kit with gam- 
maglobulin as standard. Optical spectroscopy of 96-well plates 
was performed using a Dynatech MR7000 plate-reader unless 
otherwise stated. Ammonium molybdate, L-arabinose, ATP, /J- 
glycerol phosphate, fructose 6-phosphate, glycone phosphate, 
Hepes, imidazole, MgCl2 (99% pure), Malachite Green, NaCl, 
p-nitrophenylphosphate, PCho (phosphocholine), PEA (phospho- 
ethanolamine), phospho-L-serine, phospho-L-tyrosine, pyridoxal- 
5-phosphate, pyrophosphate sodium salt, ribose-5-phosphate and 
Trizma base were purchased from Sigma Chemical Co. CaCl2 , 
CoCl2 , NiCl2 and MnCl2 (all AnalaR grade) were purchased from 
BDH-Merck Ltd. (Lutterworth, Leics., U.K.). ZnCl2 (99.99 % 
pure) was purchased from Acros Organics (Den Bosch, The 
Netherlands).
Production of recombinant human PHOSPH01
RNA was isolated from SaOS-2 osteoblast-like cells by phenol/ 
chloroform extraction and reverse transcribed. cDNA corres­ 
ponding to Met19-Cys267 of human PHOSPHO1 was amplified 
with the specific primers, hs_phosl-fl primer (5'-ATGGCCG- 
CGCAGGGC-3') and hs_phosl-rl primer (5'-GCACGACTTC- 
AGCACCTGTTGC-3'). This strategy was adopted in view of 
the ambiguity concerning the initiation codon of PHOSPHO1 
and, therefore, we expressed a protein containing only the region 
that would be common to all predicted forms. The cDNA fragment 
was subcloned into the pBAD TOPO TA vector. The construct was 
designed to express PHOSPHOl fused to a V5 epitope and 
6 His-tag at the C-terminus. A clone (pBAD-PHOSPHOl) con­ 
taining the PHOSPHOl fragment in the correct orientation was 
identified by restriction digestion of plasmid minipreps. The 
E. coli cells were grown in Luria-Bertani broth (10 litres, 37 °C) 
and recombinant protein expression was induced by treatment 
with 0.1 % (w/v) L-arabinose for 4 h. Bacteria were harvested 
by centrifugation and were resuspended in a lysis buffer con­ 
taining 50 mM potassium phosphate pH 8.0, 300 mM NaCl, 
10 mM imidazole and 1.6 mg/ml of Complete® protease inhibitor 
cocktail. Cells were lysed using a French press (16000 p.s.i., 
16°C). A clarified lysate was prepared by centrifugation at 
20000 g for 1 h. A 5 ml Ni-NTA-agarose column was equi­ 
librated with 50 ml of lysis buffer. Following equilibration, a 
20 ml aliquot of the clarified lysate was applied to the column. 
The column was then washed with 50 ml of Tris-buffered saline
(TBS) pH 8.0 containing 20 mM imidazole, and eluted in 5 ml 
fractions each by addition of a single column volume of TBS, 
pH 8.0, containing 250 mM imidazole. The fraction containing 
the pure recombinant protein was then dialysed three times in 
TBS, pH 7.2 (5 1, 4 °C, 24 h) and stored at 4 °C prior to use.
Western blotting
Following dialysis, 1 pig of purified protein was subjected to SDS/ 
PAGE as described above and transferred to nitrocellulose filters 
using the transfer buffer supplied by the manufacturer. After 
transfer, filters were blocked for 1 h in PBS containing 4 % 
dried milk powder and 20 % horse serum. The filters were then 
incubated in blocking solution containing 1:3000 dilution of 
mouse monoclonal horseradish peroxidase-labelled anti-V5 anti­ 
body and washed three times in PBS. They were then developed 
by incubation in a solution containing 25 mM Tris/HCl, pH 7.2, 
75 mM NaCl, 0.25 mg/ml diaminobenzidine, 0.1 mg/ml CoCl2> 
0.15 mg/ml urea hydrogen peroxide.
Phosphatase assays
The standard discontinuous colorimetric assay used was based 
on that of Baykov et al. [25]. The reactions were measured in 
96-well plates containing 200 //,! of 25 % (w/v) glycerol, 20 mM 
TBS, pH 7.2, 25 ptg/ml BSA, 2.5 mM substrate, 2 mM of the 
corresponding divalent metal chloride salt and 600 ng of purified 
recombinant PHOSPHO1. For investigation of the effect of pH on 
PHOSPHOl activity, 20 mM Mes was used to obtain pH values 
between 5.0 and 6.7, and 20 mM 3-(cyclohexylamino)propane- 
1-sulphonic acid (Caps) for pH 9.0, in place of TBS. The ionic 
strength of each buffer was adjusted to that of 20 mM TBS by 
addition of NaCl. Standard solutions containing known concen­ 
trations of KH2PO4 were included in each plate. Reactions were 
allowed to proceed for 15 min at 37 °C then stopped by the 
addition of 50 n\ of 3.75 M sulphuric acid containing 3 % ammo­ 
nium molybdate, 0.2 % Tween 20 and 0.12 % Malachite Green. 
The absorbance of each well at 630 nm was measured and the spe­ 
cific activity was calculated in units of activity per mg of enzyme, 
where 1 unit of activity represents the hydrolysis of 1 nmol of 
phosphate per min.
The continuous spectrophotometric assay was performed 
using the EnzChek® Phosphatase Assay Kit (Molecular Probes, 
Eugene, OR, U.S.A.), which is based upon the purine nucleoside 
phosphorylase (PNPase)-coupled assay reported by Webb [26]. 
The reactions were measured in 96-well plates containing 25 % 
(w/v) glycerol, 20 mM Mes, pH 6.7, 500 mM NaCl, 2 mM 
MgCl2 , 0.2 unit PNPase, 200 t^M MESG (2-amino-6-mercapto- 
7-methylpurine ribonucleoside) and 144 ng of purified recom­ 
binant PHOSPHOl at 37 °C. PNPase and MESG concentrations 
were optimized to ensure that the phosphatase activity was rate- 
limiting. PHOSPHOl substrate concentrations were varied ac­ 
cordingly. Absorbances were measured continuously at 355 nm 
using a VICTOR HTS plate-reader.
RESULTS
Purification of recombinant human PHOSPH01
Recombinant His-tagged PHOSPHOl protein in fractions eluted 
from a Ni-NTA-agarose column was assayed by SDS/PAGE. 
Typically, fraction 2 yielded a single band of the expected mass 
(32 kDa) consistent with >99% purity (Figure 1A). The final 
yield of protein was approx. 35 mg per 10 litres of culture. 
Western blotting of the purified protein yielded a band of expected
© 2004 Biochemical Society
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Figure 1 SDS/PAGE and Western analysis of purified recombinant human 
PHOSPH01
(A) The cell lysate (L) and the flow-through (FT), wash (W) and eluted fractions 1 and 2 (F1 
and F2) from each stage of Ni-NTA purification were subjected to SDS/PAGE under reducing 
conditions and visualized by Coomassie Blue staining. Molecular mass standards are also 
shown (M). (B) Western blot (WB) of the purified protein (1.2 ^g) with anti-V5 antibody, which 
recognizes the V5 epitope tag fused to the recombinant protein near its C-terminus.
Table 1 Substrate specificity of recombinant human PHOSPH01
Recombinant human PHOSPH01 (3 /ig/ml) was incubated with each substrate and assayed 
for phosphatase activity by the discontinuous assay at 37 °C. The 200 n\ reaction mixture 
contained 25% (w/v) glycerol, 20 mM TBS, pH 7.2, 25 /xg/ml BSA, 2.5 mM substrate and 
2 mM MgCI2 . The results are the means ± S.E.M. of triplicate assays.



















size and showed the presence of the V5-epitope tag (Figure IB). 
The purified protein was also confirmed as recombinant 
PHOSPHO1 by MALDI-TOF MS of tryptic fragments (results 
not shown).
Catalytic properties of recombinant human PHOSPH01
Twelve phosphate compounds were investigated as potential 
substrates for human PHOSPHO1. The resultant specific activities 
are shown in Table 1. PHOSPHO1 was found to have the highest 
specific activities toward PEA and PCho, with PEA being hydro- 
lysed approx. 1.5 times faster than PCho. Six of the potential 
substrates tested (PPj, phospho-L-serine, glycone phosphate, fruc­ 
tose 6-phosphate, phospho-L-tyrosine and ATP) yielded no 
detectable phosphatase activity.
The concentration of MgCl2 was varied between 2 /zM and 
200 mM and activity was found to be maximum at 2 mM MgCl2 .
56789
pH
Figure 2 The pH optimum for activity of recombinant PHOSPH01
Enzymic activity was measured in the presence of 3 /xg/ml enzyme and 2 mM Mg2+ by the 
discontinuous assay (as described in the Experimental procedures) for phosphoethanolamine 
(solid line) and phosphocholine (broken line).
In the presence of 2 mM Mg2+ at 37 °C, the recombinant enzyme 
exhibited a pH optimum around 6.7 for both PEA and PCho 
(Figure 2). High catalytic activity (>70% of maximum) was 
observed between pH 6.0 and 7.2. This high level of activity 
extends up to at least pH 7.5 for PEA but begins to decline signi­ 
ficantly for PCho at pH values higher than pH 7.2. The kinetic 
constants of recombinant PHOSPHO1 were determined for PEA 
and PCho using the continuous coupled assay in the presence of 
2 mM Mg2+ at 37 °C. The enzyme exhibited Michaelis-Menten 
kinetics for both substrates (Hill coefficients = 1.00). A plot of 
reaction rate versus substrate concentration for PEA and PCho 
and also Lineweaver-Burke plots, allowing the calculation of Km 
arid Vmax values, are shown in Figure 3. PHOSPHO1 displayed an 
apparent Km of 3.0 /^M and a &cat of 2.27 s~' for PEA, and a Km 
of 11.4 /j,M and a kM of 1.98 s" 1 for PCho.
Requirement for metals
To investigate the requirement of metal ions for the recombinant 
enzyme, the purified enzyme solution was extensively dialysed 
against metal-free buffer to remove any weakly bound metal ions. 
The effect of different metal ions on the hydrolysis of PEA and 
PCho was assessed by addition of 2 mM concentrations of various 
metal salts. As controls, reactions were also carried out in buffers 
without added metal ions. The results are shown in Figure 4. 
The phosphatase activity was approximately 80-fold higher for 
both substrates in the presence of Mg2+ compared with the metal- 
free control. Co2+ , Mn2+ and Ni2+ also stimulated activity but to 
a lesser extent than Mg2+ , whereas the presence of Ca2+ and 
Zn2+ had no significant effect on activity compared with the 
control (Mg2+ > Co2+ > Mn2+ > Ni2+ > Ca2+ = Zn2+ = no metal). 
Interestingly, PHOSPHO1 has a higher activity toward PCho than 
to PEA in the presence of Co2+ and Mn2+ . This is most probably 
due to an allosteric effect caused by a difference in the metal- 
binding properties of each enzyme-substrate complex.
DISCUSSION
The results presented here show that PHOSPHO1 has activity 
which is typical of most enzymes within the HAD superfamily, 
with a strong Mg2+ -dependence and a pH optimum within the 
acid-to-neutral pH range [27-29]. A high level of activity extends 
to pH values at least as high as pH 7.5 for PEA but begins to de­ 
cline significantly for PCho at pH values higher than pH 7.2. The 
pH of the extracellular fluid of growth plate cartilage is close 
to pH 7.6 [30] and so the activity of PHOSPHO1 may be restricted
© 2004 Biochemical Society
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Figure 3 Kinetic analysis of the hydrolysis reactions catalysed by recombinant PHOSPH01
Kinetic activity toward (A) PEA and (B) PCho, measured using a method based upon the purine nucleoside phosphorylase-coupled assay [26] as described in the Experimental procedures. Shown 
are the reaction velocities (V) as a function of substrate concentration. Insets, Lineweaver-Burke plots from which Km and ^max values were calculated.
mainly to PEA at this region. Overall, PHOSPHO1 has a high spe­ 
cific activity toward PEA and PCho compared with the other phos- 
phomonoesters investigated. The results are highly significant for 
the mineralization process in cells. Both PCho and PEA are pre­ 
sent in mineralizing cells and are the two most abundant phos- 
phomonoesters in cartilage [31]. The very low Km values for both 
PEA and PCho Ou-M range) suggest that they would be half- 
saturated at levels of 3 and 11.4 ^M, respectively. This indicates 
that under the reported conditions both substrates would be rapidly
hydrolysed. These compounds are therefore likely to be natural 
substrates of PHOSPHO1.
The hydrolysis of PEA and PCho is known to occur in vivo, 
although the enzyme responsible has not been identified pre­ 
viously. It has been hypothesized that PEA is a natural substrate 
for TNAP [8,32] due to an increase in its urinary excretion in 
patients diagnosed with hypophosphatasia [33]. However, this 
appears unlikely following examination of kinetic data for the 
TNAP-catalysed hydrolysis reaction at physiological pH, with
© 2004 Biochemical Society
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Figure 4 Metal requirement for activity of recombinant PHOSPH01
Enzyme activity toward phosphoethanolamine (filled bars) and phosphocholine (open bars) was measured in the presence of the indicated metal ions (final concentration 2 mM). The activity of the 
apoenzyme was measured in the absence of added metals (No Metal). Inset, concentration dependence of apoenzyme activation by Mg2+ for PEA (solid line) and PCho (broken line); enzyme activity 



































Scheme 1 Human PEA and PCho metabolism
Proposed metabolic pathways for the generation of PEA and PCho. The basis of the diagram is information from the Kyoto Encyclopedia of Genes and Genomes (KEGG) [41].
reported high Km values at millimolar concentrations [34-36]. 
It is therefore possible that the genetic defect assumed to be 
caused by a loss of TNAP in hypophosphatasia is actually due to a 
loss or defect of PHOSPHOl. Brain alkaline phosphatase (BAP), 
an isoenzyme of TNAP, is reported to have PCho phosphatase 
activity [37]. However, the specific activity of BAP toward PCho 
in the reported study was measured under alkaline conditions 
(pH 8.5) and is likely to be much lower at physiological pH. 
PCho hydrolysis has been studied in hamster heart and is not
catalysed by alkaline phosphatase, but by a separate unidentified 
enzyme [38]. It has also been shown that the hydrolysis of PEA 
and PCho is due to the action of an acid phosphatase in a variety of 
tissues, including bone and teeth [39], a study which agrees well 
with our present finding that PHOSPHOl displays high activity 
toward both substrates between pH 6.0 and 7.2.
PEA and PCho are metabolites in the cytidine 5'-diphospho- 
ethanolamine (CDP-EA) and cytidine 5'-diphosphocholine (CDP- 
Cho) pathways respectively (Scheme 1). These are the main
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pathways involved in the formation of phosphatidylcholine and 
phosphatidylethanolamine [40], which are involved in the meta­ 
bolism of complex glycerolipids, glycosylphosphatidylinositol- 
anchors, prostaglandins, leukotrienes and the amino acids glycine, 
serine and threonine [41]. These pathways are also implicated 
in the pathogenesis of Alzheimer's and Huntington's disease 
[42,43]. Therefore the identification of a phosphatase with speci­ 
ficity toward PEA and PCho is highly significant. Conversely, 
phosphatidylethanolamine and phosphatidylcholine may be hy- 
drolysed by phospholipase C to form PEA and PCho respectively 
[44]. The synthesis of phosphatidylcholine from choline by the 
CDP-Cho pathway in mineralizing cells has previously been 
investigated. PCho accumulation is much decreased in neo-natal 
rat calvaria compared with the liver of the same animal [45]. PCho 
concentration is usually determined by the relatively higher activ­ 
ity of choline kinase compared with that of phosphate cytidylyl- 
transferase 1. However, the low PCho accumulation in mineral­ 
izing compared with non-mineralizing cells may be due to the 
upregulation of PHOSPHO1. PHOSPHO1 is highly expressed at 
sites of mineralization [21], and as a consequence will reduce the 
levels of PCho and PEA in chondrocytes and osteoblasts. P( may 
be scavenged from PEA and PCho during the mineralization 
process in order to generate the concentration required for hy- 
droxyapatite crystal formation.
The MV-membrane is a rich source of both phosphatidylethan­ 
olamine and phosphatidylcholine and may act as a pool for PEA 
and PCho in MVs. Wuthier et al. have found that the phospha­ 
tidylethanolamine and phosphatidylcholine composition of the 
MV membrane decreases during mineralization and that 1,2- 
diacyl glycerol accumulates in MVs, indicative of phospholipase 
C activity [46]. However, in the absence of any kinetic data relating 
to phosphatidylethanolamine or phosphatidylcholine degradation 
in MVs it is impossible to say at this time whether such a mech­ 
anism exists as a viable means of generating PEA or PCho. Ca2+ 
and PJ are present at high levels in MVs even before induction 
of mineral formation, and are derived from cellular activity prior 
to MV formation [47]. Since the ambient concentration of Pj in 
the extracellular fluid is close to 2 mM [48], it is doubtful that 
the amount of Pj released from MV lipids would be sufficient to 
increase the overall level of extracellular Pj. However, the local 
effect of this limited release may be sufficient to facilitate mineral 
formation.
In conclusion, these results show for the first time that human 
PHOSPHO1 is a phosphoethanolamine and phosphocholine phos­ 
phatase. PHOSPHO1 is known to be upregulated in mineralizing 
cells, these findings therefore provide a novel means of generating 
Pi in mineralizing cells and may have implications for the diag­ 
nosis of hypophosphatasia and treatment of bone mineralization 
abnormalities such as osteomalacia and pathological soft-tissue 
ossification, a process clinically significant in atherosclerosis and 
heart failure.
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Abstract
PHOSPHO1, a phosphoethanolamine/phosphocholine phosphatase, is upregulated in mineralising cells and is thought to be involved in 
the generation of inorganic phosphate for bone mineralisation. PHOSPHO2 is a putative phosphatase sharing 42% sequence identity with 
PHOSPHO1. Both proteins contain three catalytic motifs, conserved within the haloacid dehalogenase superfamily. Mutation of Asp32 and 
Asp203, key residues within two motifs, abolish PHOSPHO1 activity and confirm it as a member of this superfamily. We also show that 
Asp43 and Asp 123, residues that line the substrate-binding site in our PHOSPHO1 model, are important for substrate hydrolysis. Further 
comparative modelling reveals that the active sites of PHOSPHO1 and PHOSPHO2 are very similar, but surprisingly, recombinant 
PHOSPHO2 hydrolyses phosphoethanolamine and phosphocholine relatively poorly. Instead, PHOSPHO2 shows high specific activity 
toward pyridoxal-5-phosphate (Tmax of 633 nmol min" 1 mg" 1 and Km of 45.5 uM). Models of PHOSPHO2 and PHOSPHO1 suggest subtle 
differences in the charge distributions around the putative substrate entry site and in the location of potential H-bond donors. 
© 2005 Elsevier B.V. All rights reserved.
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1. Introduction
Human PHOSPHO1, a phosphatase with upregulated 
expression in mineralising tissue [1], is localised to the 
mineralising regions of bone [2] and has been implicated in 
the generation of inorganic phosphate for matrix minera­ 
lisation. PHOSPHO1 has been identified in a number of 
vertebrates including humans, mice, chickens, zebrafish and
Abbreviations: CD, circular dichroism; HAD, haloacid dehalogenase; 
MESG, 2-amino-6-mercapto-7-methylpurine ribonucleoside; A//PSP, phos- 
phoserine phosphatase from Methanococcus jannaschii; Ni-NTA, nickel- 
nitrilotriacetate; P5P, pyridoxal-5-phosphate; PCho, phosphocholine; PEA, 
phosphoethanolamine; PNPase, purine nucleoside phophorylase; TBS, Tris- 
buffered saline 
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puffer fish [3,4] and has recently been shown to exhibit high 
specific phosphohydrolase activity toward phosphoethanol­ 
amine (PEA) and phosphocholine (PCho) substrates [5]. 
PEA and PCho are involved in the biosynthesis of 
phosphatidylethanolamine and phosphatidylcholine, respec­ 
tively, and form the polar headgroups of phospholipids in 
biological membranes. Both PEA and PCho levels are 
controlled in vivo by the expression of CTP-dependent 
cytidyltransferases, which catalyse the formation of CDP- 
ethanolamine and CDP-choline, respectively [6,7]. Both 
PEA and PCho are known to accumulate in mineralising 
cells. Indeed these compounds have been shown to be the 
two most abundant phosphomonoesters in cartilage [8]. The 
discovery of PHOSPHO1 provides a close link between 
PEA and PCho accumulation and the generation of 
inorganic phosphate in mineralising cells. PHOSPHO1 is 
therefore a potential target in the design of new therapeutics 
toward diseases such as osteopetrosis and craniosynostosis,
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which lead to skeletal abnormalities characterised by excess 
or premature mineral formation [9]. Inhibition of PHOS­ 
PHOl may also be of benefit in the treatment of vascular 
calcification, a process that shares many similarities with the 
mineralisation of bone and is clinically significant in 
atherosclerosis and heart failure [10].
Enzymes of the haloacid dehalogenase (HAD) super- 
family catalyse the hydrolysis of C-C1, C-OP and C-P bonds 
from a wide range of substrates and demonstrate great 
functional diversity from a single protein fold. The ammo 
acid sequence of PHOSPHOl contains three motifs that are 
conserved within the HAD superfamily. These motifs form 
the active site of this group of enzymes, which includes a 
variety of magnesium-dependent phosphatases [11]. In 
motif 1, DXDX(T/V), both Asp residues coordinate to the 
catalytic Mg2+ ion, and the first Asp also forms a phospho-
protein intermediate during hydrolysis [12]. In motif 2, (S/ 
T), the conserved serine or threonine is involved in 
hydrogen bonding to a phosphoryl oxygen. Motif 3, 
K(X), 8 _ 30(G/S)(D/S)XXX(D/N), is also involved in phos­ 
phoryl oxygen hydrogen bonding and coordination to the 
Mg2+ ion [12,13].
A search for homologous proteins to PHOSPHOl 
revealed the sequence of PHOSPHO2, a putative human 
phosphatase that shares 42% sequence identity with human 
PHOSPHOl. Analysis of expressed sequence tags (ESTs) in 
dbEST indicates that PHOSPHO2 is expressed in a wide 
range of tissues. Orthologous proteins to PHOSPHO2 were 
also found. Fig. 1 shows a sequence alignment of 
PHOSPHOl and PHOSPHO2 proteins from a number of 
species. Analysis of sequences with the program SignalP 
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TrPHOSl FYIBDGMIDVCPSLALGPRDTTFPRRGFPMHVLLCS ———— EATFKANWPWRGEDIVDCLKKWEER- 264
HSPHOS2 VnK)G6IB)VCPVTFLKNPDVAHPRKGYTLQKTLSRH— SCWLEPHEYSVWMSSGVDIISHLCyLIKD— 241
AtePHOS2 VYI6DGCM)VCPVTFLKKNDVAHPREGYTLHRTLAKH~SCNLEPHESSIVVWSSGVEIISHL<»'LIKH~ 241
XnPHOS2 VYICDGGM)VCPVTFLKKNDVAMPREGYTLHRTLIiKM~SCNLEPHASSIWWSSGMEIISHLQFLIQH— 241
G0PHOS2 AYI6DG6IB)LCPVHFLKKGDVAMPRHGYTLEKKISQL— SRDFCPIECSVLVGHLLLKLHSYLKLLIKEQ- 242
DrPHOS2 CXIGDG6M)FCPVKELTEGDIAMPRKGFTLEKLLRKG-ISEGSNELRAKIHPaTSAKEIL(a:LRALIE —— 241
TrPHOS2 FWra>OeiB)LCPTSCLRGHDVAHPRRGYTLEKLLAKLGKQKr)NHCLKAKWrWSSGSDILC£LKASLQ —— 242
Fig. 1. Alignment of the amino acid sequences of PHOSPHOl proteins with PHOSPHO2 and its homologues. The three catalytic motifs are highlighted in 
grey. The white on black letters denotes residues which are proposed to be involved in substrate specific interactions. The following sequences are used 
(accession numbers are shown in parentheses): HsPHOSl, human PHOSPHOl (Q8TCT1); MmPHOSl, mouse PHOSPHOl (Q8R2H9); flnPHOSl, rat 
PHOSPHOl; GgPHOSl, chicken PHOSPHOl (O73884); 7>PHOS1, puffer fish PHOSPHOl; HsPHOS2, human PHOSPHO2 (Q8TCD6); MmPHOS2, mouse 
PHOSPH02 (Q9D9M5); RnPHOS2, rat PHOSPHO2 (XP_230005); GgPHOS2, chicken PHOSPHO2 (XP_422006); DrPHOS2, zebrafish PHOSPH02 
(ENSDARP00000004689); 7rPHOS2, puffer fish PHOSPHO2 (SINFRUPOOOOO 138420). "*"=identical or conserved residues in all sequences in the 
alignment, ":"= indicates conserved substitutions and "."= indicates semi-conserved substitutions.
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the PHOSPHO1 or PHOSPHO2 proteins suggesting both 
enzymes are cytosolic. Closer inspection of the amino acid 
sequence of PHOSPHO2 protein revealed that all three 
catalytic motifs are conserved. Also conserved are Asp 19 
and Asp99, which correspond to two residues (Asp43 and 
Aspl23) previously postulated to be involved in substrate- 
specific interactions in PHOSPHO1 [4]. These two residues 
were found to line the substrate-binding pocket in a 
structural model of PHOSPHO1, and are the only residues 
in this region that are conserved between orthologous 
proteins from other species, but not in phosphoserine 
phosphatases (PSPs), which are a closely related group of 
enzymes within the HAD superfamily. In contrast, in PSP 
with bound substrate (PDB: 1L7P; AspllAsn mutant), 
Glu20, Met43, Phe49 and Arg56 have been shown to be 
involved in phospho-L-serine binding, and these residues 
are fully conserved in PSPs, but not present in PHOSPHO1 
or PHOSPHO2 [12]. These observations have led to the 
suggestion that PHOSPHO1 and PHOSPHO2 might utilise 
the same, or highly similar substrate. If true, this would 
intimate functional redundancy between PHOSPHO1 and 
PHOSPHO2 in vivo.
hi this study, we have used site directed mutagenesis to 
confirm PHOSPHO1 as a member of the HAD superfamily 
and also to ascertain the importance of Asp43 and Asp 123 
residues for the catalysed hydrolysis of PEA and PCho. The 
activity of PHOSPHO2 protein toward PEA and PCho as 
well as a range of other potential substrates is investigated. 
In addition, we present structural models of PHOSPHO1 
and PHOSPHO2 based upon the X-ray crystal structure of 
phosphoserine phosphatase from Methanococcus jannaschii 
and examine potential enzyme-substrate interactions using 
in silico ligand docking experiments.
2. Materials and methods
2.1. Site-directed mutagenesis of human PHOSPHO1
DNA corresponding to Metl9-Cys267 of human PHOS- 
PHO1 was amplified and cloned into the pBAD TOPO TA 
vector (Invitrogen) as described [5]. Oligonucleotide-direc- 
ted mutagenesis was used to prepare cDNAs encoding the 
PHOSPHO1 mutants. Mutagenesis was performed using the 
QuikChange Site-Directed Mutagenesis kit (Stratagene). 
Five mutants were prepared (D32N, D43N, D123N, 
D203S and a double mutant D43N/D123N). Clones con­ 
taining the desired mutation(s) were identified commercially 
(The UK Centre for Functional Genomics in Farm Animals 
(ARK-Genomics), Roslin, UK) by nucleotide sequence 
analysis across the mutation site. The Escherichia coli cells 
with transformed mutated plasmids were grown in Luria- 
Bertani broth containing 100 fig/ml ampicillin (1 1, 37 °C) 
and recombinant protein expression was induced by treat­ 
ment with 0.1% (w/v) L-arabinose for 4 h. Bacteria were 
harvested by centrifugation and were lysed in CellLytic™
B-II lysis reagent (Sigma) containing 1.6 mg/ml of 
Complete® protease inhibitor cocktail (Roche), 50 mg/ml 
lysozyme (Sigma), 5 ug/ml DNase I (Sigma), 500 mM NaCl 
and 10 mM imidazole. Clarified lysates were prepared by 
centrifugation at 20,000 xg for 1 h. A 5 ml Ni-NTA-agarose 
column was equilibrated with 50 ml of lysis buffer (Tris- 
buffered saline (TBS; 20 mM Tris-HCl, 500 mM NaCl, pH 
8.0) containing 10 mM imidazole. Following equilibration, 
a 20 ml aliquot of each clarified lysate was applied to each 
column. The columns were washed with 50 ml of TBS, pH 
8.0 containing 20 mM imidazole and eluted in 5 ml fractions 
each by addition of a single column volume of TBS, pH 8.0 
containing 250 mM imidazole. The secondary structures of 
the mutants were compared to that of wild type recombinant 
PHOSPHO1 using circular dichroism (CD) to confirm that 
in each case, the mutation(s) had not affected the overall 
fold of the enzyme. CD spectra were recorded on a JASCO 
J-600 spectropolarimeter by using 0.5 mg/ml solutions of 
the recombinant PHOSPHO1 proteins in 20 mM potassium 
phosphate, pH 7.2, 130 mM sodium sulfate. The SELCON 
procedure [15] was used for secondary structure analysis. 
The CD spectra of the mutants were similar to the native 
protein (data not shown) showing that the mutations did not 
cause any significant changes in secondary structure.
2.2. Production of recombinant PHOSPHO2 protein
DNA corresponding to PHOSPHO2 was amplified from 
human genomic DNA as the whole coding sequence was 
found to be on the same exon. The DNA fragment was 
subcloned into the pBAD TOPO TA vector. The construct 
was designed to express PHOSPHO2 fused to a 6-His tag at 
the C-terminus. A clone (pBAD-PHOSPHO2) containing the 
PHOSPHO2 fragment in the correct orientation was identi­ 
fied by restriction digestion of plasmid minipreps. The E. coli 
cells were grown in Luria-Bertani broth (10 1, 37 °C) and 
recombinant protein expression was induced by treatment 
with 0.1% (w/v) L-arabinose for 4 h. Bacteria were harvested 
by centrifugation and were resuspended in a lysis buffer 
containing 20 mM Tris-HCl, pH 8.0,500 mM NaCl, 10 mM 
imidazole and 1.6 mg/ml of Complete® protease inhibitor 
cocktail (Roche). Cells were lysed using a French press 
(16,000 psi, 16 °C). A clarified lysate was prepared by 
centrifugation at 20,000 xg for 1 h. Purification of the 
PHOSPHO2 enzyme was carried using the same method as 
that described for the recombinant PHOSPHO1 mutant 
protein. The fraction containing the pure recombinant protein 
was then dialysed three times in TBS, pH 7.2 (5 1,4 °C, 24 h) 
and stored at 4 °C prior to use.
2.3. Phosphatase assays
Phosphatase assays were carried out as described pre­ 
viously [5] in order to provide a direct comparison with 
human PHOSPHO1. The standard discontinuous colorimet- 
ric assay is based on that of Baykov et al. [16]. The
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reactions were measured in 96-well plates containing 200 ul 
of 25% (w/v) glycerol, 20 mM respective buffer, 25 ug/ml 
bovine serum albumin, 2.5 mM substrate, 2 mM MgC^ and 
600 ng of purified recombinant enzyme. Buffers used were 
20 mM MES, pH 6.7 for the PHOSPHO1 and mutants 
assays and 20 mM Tris-HCl for the PHOSPHO2 experi­ 
ments to allow the direct comparison with previous results. 
Standard solutions containing known concentrations of 
KH2PO4 were included in each plate. Reactions were 
allowed to proceed for 15 min at 37 °C then stopped by 
the addition of 50 ul of 3.75 M sulphuric acid containing 3% 
ammonium molybdate, 0.2% Tween 20 and 0.12% mala­ 
chite green. The absorbance of each well at 630 nm was 
measured and the specific activity was calculated in units of 
activity per mg of enzyme, where 1 unit of activity 
represents the hydrolysis of 1 nmol of phosphate per min. 
The continuous spectrophotometric assay was performed 
using the EnzChek® Phosphatase Assay Kit (Molecular 
Probes). The reactions were measured in 96-well plates 
containing 25% (w/v) glycerol, 20 mM MES, pH 6.7 (20 
mM Tris, pH 7.2 for PHOSPHO2), 500 mM NaCl, 2 mM 
MgC\2, 0.2 units purine nucleoside phosphorylase 
(PNPase), 200 uM 2-amino-6-mercapto-7-methylpurine 
ribonucleoside (MESG) and 650 ng of PHOSPHO1 or 10 
ug PHOSPHO2 at 37 °C. The concentration of PEA was 
varied from 2 uM to 100 uM for PHOSPHO1 and from 2 
uM to 150 uM for PHOSPHO2. PNPase and MESG 
concentrations were optimised to ensure that the phospha- 
tase activity was rate-limiting. PHOSPHO1 substrate con­ 
centrations were varied accordingly. Absorbances were
measured continuously at 355 nm using a VICTOR HTS 
plate-reader.
2.4. Structural modelling and ligand docking
The protein sequence of PHOSPHO2 was subjected to 
homology modelling as described previously for PHOS- 
PHO1 [4]. Submitting the protein sequence of human 
PHOSPHO2 to the 3D-PSSM fold recognition server [17] 
revealed the high resolution (1.8 A) X-ray structure of 
phosphoserine phosphatase (A//PSP) from Methanococcus 
jannaschii (PDB code: 1F5S) [18] as the most suitable 
template for homology modelling. A pairwise alignment 
between the target and template sequence was manually 
adjusted, taking into consideration multiple sequence align­ 
ments, structural alignments and the continuity of secondary 
structure elements (Fig. 2). Twenty models were built using 
MODELLER v6.2 [19], keeping the active site Mg2+ and its 
bound phosphate and water molecules in the positions found 
in the template. A disulfide bridge was introduced between 
Cysl52 and Cysl85, both of which are conserved within the 
PHOSPHO1/PHOSPHO2 multiple sequence alignment 
(Fig. 1), since these residues were found in close proximity 
to each other in the structural model. Non-identical side- 
chains between template and target were optimised using 
SCWRL [20].
Hydrogen atoms and bonds between Mg2+ and its 
coordinating amino acids were introduced in SYBYL 
v.6.9 (Tripos Associates, St. Louis). The resulting pdb files 






















































Fig. 2. Alignment of//^PHOSPHOl, HsPHOSPHOl and the scaffold protein MjPSP, showing the secondary structure for PSP and secondary structure 
prediction for PHOSPHO2. The following sequences are used (accession numbers are shown in parentheses): HsPHOSl, human PHOSPH01 (Q8TCT1); 
//sPHOS2, human PHOSPHO2 (Q8TCD6); A#PSP, phosphoserine phosphatase from Methanococcus jannaschii (Q58989). Secondary structure elements for 
PHOSPHO2 (secPHOS2) and MjPSP (secPSP) are denoted as h=a-helix, e=(J-strand. Black shading indicates identical, and grey shading highly similar 
amino acid residues.
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Table 1
Specific activities of recombinant human PHOSPHOl mutants














Wild-type recombinant human PHOSPHOl and the five mutants (3 ug/ml) 
were incubated with 2.5 mM PEA or PCho and assayed for phosphatase 
activity by the discontinuous assay at 37 °C. The 200-ul reaction mixture 
contained 25% (w/v) glycerol, 20 mM TBS, pH 7.2, 25 ug/ml BSA, 2.5 
mM substrate and 2 mM MgCl2 . The results are the averages of triplicate 
assays.
previous findings [4], the active sites were defined manually, 
and included the Mg2+ ion, the two water molecules, the 
residues 32,34,43,60, 64,71 and 123 for PHOSPHOl, or 8, 
10, 19, 36, 40, 47 and 99 for PHOSPHO2, plus a 2.9-A 
margin around these residues. Substrate starting structures 
(PEA, PCho, and pyridoxal-5-phosphate) were built and 
energy-minimised in SYBYL v6.9. As our initial homology 
models were necessarily generated without a substrate in the 
active site, it appears as if the sidechain of Arg60 (or Arg36) 
is trying to fill the "empty space" of the active site. 
Therefore, for subsequent FlexX runs, the side-chain of this 
residue was manually adjusted. Thirty docked structures 
were generated for each protein, and the best was selected 
based on the overall FlexX score. The resulting protein - 
substrate complexes were energy-minimised in SYBYL v6.9 
applying 50 steps of minimisation, restricted to the substrate, 
the Mg2+ ion, and Arg60 for PHOSPHOl or Arg36 for 
PHOSPHO2 and their immediate surroundings, followed by
100 steps of energy minimisation applied to the entire 
protein. The minimisation protocol used the Powell algo­ 
rithm and an improved version of the Tripos force-field. The 
validity of the resulting model was assessed using PRO- 
CHECK v3.5 [22] and WHAT IF v4.99 [23], which are 
available on-line at the "Biotech validation suite" at http:// 
biotech.embl-ebi.ac.uk. The validity of this approach was 
tested by docking phospho-L-serine into A//PSP (PDB code: 
1F5S). The resulting docked model corresponded well with 
the structure of the DUN mutant of A//PSP with bound 
substrate (PDB code: 1L7P).
3. Results
3.1. PEA and PCho phosphatase activity in PHOSPHOl 
mutants
Phosphatase activities toward PEA and PCho were 
assayed using the standard discontinuous assay for the five 
PHOSPHOl mutants. The resultant specific activities are 
shown in Table 1. No detectable phosphatase activity was 
observed with either of the two active site mutations (D32N 
and D203S). Mutations of Asp43 (D43N) and Asp 123 
(D123N) dramatically decreased the reactivity toward both 
substrates when compared with the wild-type enzyme, the 
D123N mutation reduced activity ~ 20-fold for PEA and 
~60-fold for PCho. The D43N mutation reduced activity 
~ 60-fold for PEA, whilst no activity was observed with 
PCho. No activity was detected with the double mutant, 
D43N/D123N-PHOSPHO1, with either substrate.
The reaction with PEA catalysed by the D43N mutant 
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Fig. 3 Kinetic analysis of the hydrolysis reactions catalysed by recombinant PHOSPHOl D123N mutant. Plot of the reaction velocity (K) as a function of 
substrate concentration. Inset, Lineweaver-Burke plot from which Km and Fmax values were calculated. Kinetic activity toward phosphoethanolamine was 
measured using a method based upon the PNPase-coupled assay [5] as described under Materials and methods.
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Fig. 4. Specific activities of PHOSPHO2 and PHOSPHO1 in the presence 
of a range of substrates. PHOSPHO1 data were taken from ref [5]. 
Activities for PHOSPHO2 were determined using the same method and 
under the same conditions as described previously to allow a direct 
comparison with the previously published results for PHOSPHO1.
parameters. However, the kinetic constants were determined 
for recombinant D123N-PHOSPHO1-catalysed hydrolysis 
of PEA in the presence of 2 mM Mg2+ at 37 °C. The 
reaction exhibited Michaelis-Menten kinetics. A plot of
reaction rate versus PEA concentration and also a Line- 
weaver-Burke plot for the D123N-PHOSPHO1-catalysed 
reaction are shown in Fig. 3. The enzyme displayed 
apparent ATm, Fmax and kcM values of 9.5 uM, 175 nmol 
min" 1 mg" 1 and 0.094 s" 1 , respectively.
3.2. Substrate specificity of recombinant PHOSPHO2 
protein
Eleven phosphate compounds were investigated as 
potential substrates for human PHOSPHO2. A comparison 
of the resultant specific activities with those previously 
reported for human PHOSPHO1 [5] is shown in Fig. 4. Of 
the phosphate compounds tested, pyridoxal-5-phosphate 
(P5P) was hydrolysed by PHOSPHO2 with the highest 
specific activity (464.1 ±19.5 units/mg), which was approx­ 
imately 3 times higher than that towards ATP and phospho- 
L-serine. PHOSPHO2 also hydrolysed pyrophosphate, PEA, 
phospho-L-tyrosine, fructose-6-phosphate, /7-nitrophenyl 
phosphate, p-glycerophosphate and PCho. No hydrolysis 
of ribose-5-phosphate was observed in the presence of 
PHOSPHO2. PHOSPHO1 has previously been shown to 
have high specific activities toward PEA and PCho 
(4600 ±582 and 2980±335 units/mg, respectively). Five of 
the potential substrates that previously yielded no detectable 
phosphatase activity with PHOSPHO1 showed activity with 
PHOSPHO2 (pyrophosphate, phospho-L-serine, fructose-6- 
phosphate, phospho-L-tyrosine and ATP).
Kinetic constants were determined for recombinant 
PHOSPHO2-catalysed hydrolysis of P5P in the presence 
of 2 mM Mg2+ at 37 °C. The reaction exhibited Michaelis- 









V,_ = 633 nraol" 1 min"' mg" 1
fftttX




20 40 60 80 
[P5PJ (MM)
100 120 140 160
Fig. 5. Kinetic analysis of the hydrolysis reactions catalysed by recombinant PHOSPHO2. Plot of the reaction velocity (V) as a function of substrate 
concentration. Inset, Lineweaver-Burke plot from which Km and V^^ values were calculated. Kinetic activity toward pyridoxal-5-phosphate was measured 
using a method based upon the PNPase-coupled assay [5] as described under Materials and methods.
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concentration and also a Lineweaver-Burke plot for the 
PHOSPHO2-catalysed reaction are shown in Fig. 5. The 
enzyme displayed apparent Km, Vmm and £cat values of 45.5 
uM, 633.3 nmol min" 1 mg~' and 0.34 s" 1
3.3. Homology model ofPHOSPHO2
, respectively.
In the absence of structural data for PHOSPHO2, a three- 
dimensional model was built based on the X-ray crystal 
structure coordinates of M/PSP (PDB: 1F5S). Sequence 
identity between A//PSP and PHOSPHO1 is 19.4% whilst 
identity between A//PSP and PHOSPHO2 is 18.0%. Despite 
the low sequence identity, fold recognition strongly suggests 
that PHOSPHO2 (and PHOSPHO1) and PSPs belong to the 
same fold (alignment shown in Fig. 2), therefore allowing us 
to build a meaningful structural model (Fig. 6). The protein 
model consists of two domains: the catalytic a/p domain 
and a four-helix-bundle. The a/(3 domain forms a Rossman 
fold structure consisting of a six-stranded parallel (5-sheet, 
surrounded by six a-helices.
3.4. Ligand docking
The homology models of PHOSPHO2 and PHOSPHO1 
were subjected to in silico docking calculations, a model of 
PHOSPHO2 incorporating P5P as substrate is presented in 
Fig. 6, compared to the structure of the DUN mutant of 
A//PSP (PDB:1L7P). In this model, a hexadentate Mg2+ ion 
is bound in an octahedral geometry via three Asp residues 
(Asp8, Asp 10 (backbone oxygen) and Asp 179), O-ligands 
are also provided by the phosphate group of P5P and two 
water molecules.
Previous modelling studies of PHOSPHO1 suggested 
that as well as Asp43 and Asp 123, two additional residues, 
Arg60 and Tyr71, also line the substrate-binding pocket [4]. 
A comparison of this region in both the PHOSPHO1 and
Fig. 6. Comparison of the PHOSPHO2 model structure (A) with the crystal 
structure of phosphoserine phosphatase from Methanococcus jannaschii 
with bound phospho-L-serine (B; MjPSP; PDB code: 1L7P). Pyridoxal-5- 
phosphate was modelled into the catalytic site of PHOSPHO2 as this was 
found to be the best substrate for PHOSPH02 of those tested.
PHOSPHO2 models is shown in Fig. 7. The active sites of 
PHOSPHO1 and PHOSPHO2 in our models are very 
similar. Apart from the conserved Mg2+-binding site (side- 
chains of Asp8 and Asp 179, backbone-CO of Asp 10 in 
PHOSPHO2), and phosphate-binding site (backbone-NH of 
Phe9, side-chains of Ser98, Lysl53 and Asnl82; PHOS- 
PHO2), residues in or close to the predicted substrate pocket 
are: Asnll, Asnl7, Asp 19, Thr20, Arg36, Tyr39, Arg40, 
Phe47, Tyr54, Asp99, and SerlOO in PHOSPHO2 (corre­ 
sponding to Glu35, Asn41, Asp43, Asp44, Arg60, Tyr63, 
Arg64, Tyr71, Tyr78, Asp 123 and Alal24 in PHOSPHO1 
respectively).
4. Discussion
Mutation of active-site residues Asp32 (D32N) and 
Asp203 (D203S) of PHOSPHO1 resulted in a complete 
loss of activity toward PEA and PCho. This observation is a 
hallmark for HAD superfamily proteins [24-28], and 
confirms PHOSPHO1 as a member of this family. PHOS- 
PHO1-induced hydrolysis of PEA and PCho is therefore 
likely to be catalysed by the same Mg2+-dependent 
mechanism as other HAD-like phosphatases. The substitu­ 
tions D32N and D203S are likely to have dramatically 
reduced the affinity of Mg2+ towards the site, whilst the 
D32N mutation would also prevent the formation of a 
phospho-protein intermediate during the reaction.
The mutations D43N and D123N also greatly affected 
PHOSPHO1 activity towards PEA and PCho. Both muta­ 
tions reduced the specific activity, by varied degrees toward 
PEA and PCho, with D43N having the more pronounced 
effect. The double mutant, D43N/D123N, exhibited no 
activity toward either PEA or PCho. Kinetic analysis 
revealed that PEA hydrolysis by the D123N mutant is 
reduced by a factor of 24 compared to wild type 
PHOSPHO1 under the same conditions [5]. This suggests 
that Asp 123 is important for hydrolysis of PEA. The 
mutation of Asp 123 has only a moderate effect on substrate 
binding (reduction of Km by a factor of ca. 3). The Km value 
is, under true Michaelis-Menten conditions, an estimate for 
the dissociation constant of enzyme and substrate. A 
probable explanation for these kinetic data is that Asp 123 
of PHOSPHO1 does not interact directly with the substrate 
but plays a similar role to that of Glu20 in MjPSP, which 
stabilises an attacking nucleophilic water molecule during 
phosphoserine hydrolysis and is conserved in all known 
PSPs [12]. Such a role for Asp 123 during the reaction would 
account for the relatively larger difference in Vmax and kcal 
values and small difference in Km value observed between 
the D123N mutant and wild type enzyme. The D43N 
mutation has a much more dramatic effect than D123N. No 
activity toward PCho was observed with the D43N mutant 
and activity toward PEA was reduced ~ 60-fold compared to 
wild type. This suggests that Asp43 is a more likely 
candidate than Asp 123 to directly interact with the substrate.
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Fig. 7. Models of the active sites of PHOSPHO1 without and with phosphoethanolamine (A and C) and PHOSPHO2 with pyridoxal-5-phosphate (B and D), 
respectively. Key residues around the sites likely to be involved in substrate binding and catalysis are shown. Amino acid residues are coloured according to 
type: negatively charged (red), positively charged (blue), hydrophilic uncharged (green), aromatic (violet) and hydrophobic (grey). Atoms of the ligands are 
coloured as follows: hydrogen (cyan), carbon (grey), nitrogen (blue), oxygen (red), phosphorus (orange); the magnesium ion is shown in purple.
Such an interaction would presumably be more important 
for the binding of the bulkier choline moiety of PCho than 
the smaller ethanolamine moiety of PEA as our results 
suggest.
Recombinant PHOSPHO2 protein was assayed for 
phosphatase activity in the presence of a number of 
phosphomonoesters. Surprisingly, activities toward PEA 
and PCho were -100 times lower for PHOSPHO2
compared to PHOSPHO1 under the same conditions [5]. 
The highest activity corresponded to the hydrolysis of P5P 
(ca. 464.1 ±19.5 nmol min" 1 mg" 1 ). This activity is ~10- 
fold less than that measured for PHOSPHO1 catalysed 
hydrolysis of PEA under the same conditions. The relatively 
low Km (ca. 45.5 uM) suggests that this molecule may be 
hydrolysed by PHOSPHO2 in vivo, however the existence 





Fig. 8. Electrostatic potential surfaces for PHOSPHOl (left) and PHOSPHO2 (right). Negative and positive potentials on the surface of each protein are shown 
in red and blue, respectively. The models suggest that a large difference in potential exists between the two proteins around the entrance to their catalytic sites. 
The large negative charge at this region of PHOSPHOl is partly due to Glu65, which corresponds to a positively charged Lys41 in PHOSPHOl.
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These results show that despite the overall high level of 
identity (ca. 42%), PHOSPHO1 and PHOSPHO2 are 
distinct enzymes with different substrate specificities. Even 
though high sequence similarity in proteins with distinct 
functions is well documented [29], it is surprising that two 
related enzymes that share such close similarity outwith the 
catalytic motifs have such different specificities.
We have modelled the human PHOSPHO2 protein based 
on the crystal structure of A^/'PSP to better understand why 
these two proteins are functionally distinct. The model shows 
that the characteristic features of the catalytic site found in the 
HAD superfamily are all preserved. This includes all residues 
involved in the recognition of the phosphate group in MjPSP, 
with the exception of GlylOO (in PSP), which is replaced by 
Asp99 (in PHOSPHO2). Considering that only the backbone 
oxygen of this residue is involved in substrate binding in PSP, 
the modelled catalytic site in PHOSPHO2 closely resembles 
the catalytic site in MjPSP [18]. The models including bound 
substrate molecules have been generated by in silico docking. 
The conformation shown for each substrate is just one of 
many possible, but is probably a reasonable representation of 
the general orientations of the molecules. Although no 
restraints were used during the docking procedure, the 
interactions between the phosphate group and the amino 
acid side-chains (Serl22, Lysl77, Asn206 for PHOSPHO1 
or Ser98, Lysl53 and Asnl82 for PHOSPHO2) agree very 
well with those observed in the X-ray structures of related 
phosphatases [12,18,30]. The situation is slightly more 
complicated for the remainder of the binding pocket, as the 
residues defining the "non-phosphate" moiety of the 
substrate-binding site are not conserved between our 
template and the two target proteins. Although it is therefore 
not possible to predict reliably the orientation of the side- 
chains of these residues, the models allow us to define the 
residues lining the binding pocket and to predict some of the 
interactions likely to define substrate specificities. In the 
theoretical PHOSPHO1/PEA model, the negatively charged 
side-chains of Asp34, Asp43, and Asp 123 are all in the 
vicinity of the positively charged ammonium group of PEA, 
potentially providing both a highly negatively charged 
pocket as well as H-bond acceptor atoms. These interactions 
are consistent with the decrease in activity for the D43N, the 
D123N, and the D43N/D123N mutants. Residues in or near 
the substrate pocket that are not highly conserved between 
PHOSPHO2 and PHOSPHO1 are Asnll/Glu35, Thr20/ 
Asp44, SerlOO/Alal24 and Phe47/Tyr71. Of these, only 
Thr20/Asp44 and SerlOO/Alal24 are fully conserved within 
the two subfamilies. With the exception of chicken PHOS- 
PH01, Glu35 is also conserved within the PHOSPHO1 sub­ 
family; PHOSPHO2 proteins carry either an Asn or a His 
residue at this position. In the case of Tyr71, there does not 
appear to be any specific conservation within sub-families. 
Clearly, the binding site of PHOSPHO1 is more negatively 
charged than that of PHOSPHO2, and there are subtle 
changes in the location of potential H-bond donors. In 
addition, the surface charges of the putative entry sites are
also different (Fig. 8): whilst Glu65 in PHOSPHO1 renders 
the surface rather negative, the respective Lys41 residue in 
PHOSPHO2 has the opposite effect. Again, these amino 
acids are fully conserved within their respective sub-families. 
Changes in surface charges are likely to contribute to the rate 
of both ligand binding and product release.
Our experimental findings clearly demonstrate that the 
two enzymes, PHOSPHO1 and PHOSPHO2, have different 
substrate specificities. Structural modelling has helped to 
identify subtle differences inside the substrate-binding 
pockets and on the surfaces of the active sites. Given the 
overall high similarity between PHOSPHO1 and PHOS- 
PHO2, it was important to elucidate whether or not the 
enzymes had similar activities. PHOSPHO1 is associated 
with high levels of expression at mineralising regions of 
bone and cartilage. The discovery of another phosphatase 
with comparable PEA and PCho phosphatase activity would 
have given rise to serious questions regarding a role in 
mineralisation for PHOSPHO1 as gene expression studies 
carried out in chicken and EST analysis in mammals have 
shown that PHOSPHO2 expression is not specific to bone 
(data not shown) and is indeed expressed in a wide range of 
soft tissues. In addition, functional redundancy would likely 
complicate future gene knockout and inhibitory experi­ 
ments. Furthermore, this is the first investigation of human 
PHOSPHO2 structure and activity, providing a platform for 
the further study of this enzyme.
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Abstract
PHOSPHO1 is a phosphoethanolamine/phosphocholine phosphatase that has previously been implicated in generating inorganic phosphate 
(Pi) for matrix mineralization. In this study, we have investigated PHOSPHO1 mRNA expression during embryonic development in the chick. 
Whole-mount in situ hybridization indicated that PHOSPHO1 expression occurred prior to E6.5 and was initially restricted to the bone collar 
within the mid-shaft of the diaphysis of long bones but by El 1.5 expression was observed over the entire length of the diaphysis. Alcian blue/ 
alizarin red staining revealed that PHOSPHO1 expression seen in the primary regions of ossification preceded the deposition of mineral, 
suggesting that it is involved in the initial events of mineral formation. We isolated MVs from growth plate chondrocytes and confirmed the 
presence of high levels of PHOSPHO1 by immunoblotting. Expression of PHOSPHO1, like TNAP activity, was found to be up-regulated in MVs 
isolated from chondrocytes induced to differentiate by the addition of ascorbic acid. This suggests that both enzymes may be regulated by similar 
mechanisms. These studies provide for the first time direct evidence that PHOSPHO1 is present in MVs, and its developmental expression pattern 
is consistent with a role in the early stages of matrix mineralization. 
© 2006 Elsevier Inc. All rights reserved.
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Introduction
Matrix mineralization is a biphasic process that occurs in the 
matrix surrounding terminally differentiating chondrocytes, 
osteoblasts and ondontoblasts and is the mechanism by which 
growth plate cartilage, bone and tooth formation occurs by each of 
these cell types, respectively [1,2]. The initial phase concerns the 
formation of Ca2+ ions and inorganic phosphate (P;) within matrix 
vesicles (MVs) [3,4]. The accumulation of Ca2+ is controlled by 
calcium binding molecules such annexins, phosphatidylserine 
and bone sialoprotein [5-7], however, the source of P; is less clear. 
It has long been speculated that the generation of P; results from 
the action of phosphatases, the most abundant being tissue non­ 
specific alkaline phosphatase (TNAP), an isozyme of alkaline
* Corresponding author. Fax: +44 131 440 0434.
E-mail address: colin.farquharson@bbsrc.ac.uk (C. Farquharson). 
1 Both authors contributed equally to this work.
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phosphatase expressed in bone, liver and kidney [4]. Once suf­ 
ficient, levels of Ca2+ and P; have accumulated within the MVs, 
calcium phosphate precipitates, before the formation of insoluble 
hydroxyapatite [8]. The second phase involves the breakdown of 
the MV membranes, which expose the preformed hydroxyapatite 
to the extracellular fluid.
Generation of P, for mineralization does not appear to be 
entirely due to the activity of TNAP as, in newborn TNAP knock­ 
out mice, bone development and mineralization appear normal. 
Hypomineralization and other abnormalities do subsequently ap­ 
pear [9-11] but have been shown primarily to be due to a build up 
of inorganic pyrophosphate (PPj), a known substrate of TNAP [12] 
and a potent inhibitor of hydroxyapatite crystal formation [13]. 
However, hypomineralization is greatly reduced in TNAP/PC-1 
double-knockout mice and only observed in the long bones and 
not the vertebrae or cranium [11,14]. PC-1 encodes the enzyme, 
phosphodiesterase I, which generates PPS from nucleotide tripho- 
sphates [15]. Additional studies have shown that TNAP can be 
removed from MVs without reducing their potential to mineralize
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[16], while specific inhibitory studies on TNAP provide further 
evidence that other phosphatases are required for P; generation [17]. 
PHOSPHO1 is a phosphatase with up-regulated expression in 
avian growth plate chondrocytes [18] and is localized to 
mineralizing regions of chick bone [19]. Since its identification 
in the chicken, PHOSPHOl orthologues have also been 
identified in a number of other species including, humans, 
mice and zebrafish [20,21]. Analysis of PHOSPHOl sequences 
using the web-based program SignalP vl.l [22] predicts the 
absence of a signal peptide. This suggests PHOSPHOl to be a 
soluble cytoplasmic phosphatase. We have recently shown that
human PHOSPHOl exhibits high specific activity toward the 
phospholipid metabolites, phosphoethanolamine and phospho- 
choline [23]. It has been demonstrated that phosphoethanola­ 
mine and phosphocholine are the two most abundant 
phosphomonoesters in cartilage [24]. In addition, the propor­ 
tions of membrane phospholipids containing these groups 
decrease in MVs during mineralization, while 1,2-diacyl 
glycerol has been shown to accumulate, indicative of phospho- 
lipase C activity [25]. This gives rise to the possibility of a novel 
mechanism whereby phosphate locked within the plasma 
membrane may be unleashed through the action of PHOSPHOl
H
Fig. 1. Whole-mount in situ hybridization showing PHOSPHOl mRNA expression in the long bones. (A) Metatarsi from chicken embryos (E9.5) incubated with 
antisense (above) and sense (below) PHOSPHOl oligonucleotides. The staining can be seen only around the ossification center (or bone collar) of the bone from the 
embryo incubated with the antisense probe. (B-D) PHOSPHOl expression in metatarsi from embryos (E6.5, E9.5 and El 1.5, respectively). The region of PHOSPHOl 
expression extends from the mid-shaft region to the tips between these stages. (E and F) PHOSPHOl expression pattern in front limb (E9.5) and hind limb phalange 
(11.5), respectively. (G and H) Alcian blue/alizarin red staining showing the presence of cartilaginous matrix/mineral in front limb (E9.5) and hind limb phalange 
(11.5), respectively. Magnification bars represent 1 mm.
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and phospholipase C to contribute to the Pj concentration inside 
theMV.
Despite the localization of PHOSPHOl to mineralizing 
regions of bone in chicks, little is known about its expression 
in relation to the onset of mineralization during embryonic
B
development or in adult bone. More importantly, it has also yet 
to be demonstrated whether PHOSPHOl is present within 
MVs. In the present work, we investigate PHOSPHOl ex­ 
pression from the initial stages of skeletal formation in chick 
embryos to adult and assay for the presence of PHOSPHOl in
AJ. Stewart et al. /Bone 39 (2006) 2000-1007 1003
MVs isolated from the growth plate and primary chondrocyte 
cultures.
Materials and methods
Whole-mount in situ hybridization
A 750 bp DNA fragment corresponding to the third exon of the chicken 
PHOSPHO1 gene was obtained via PCR amplification of cDNA derived from 
RNA isolated from chick growth plate chondrocytes using primers F; 
ATGGCAGCTCCCGGC and R; GCAGTTCTTGAGGAGCTCCG and cloned 
into a pGEM-T Easy vector (Promega, Southampton, UK). Digoxigenin (DIG)- 
labeled sense and anti-sense RNA probes were synthesized by in vitro 
transcription of the DNA template in the presence of ribonucleotides using the 
DIG-labeling mix (Roche, Lewes, UK) with SP6 and T7 RNA polymerases (both 
from Roche), respectively. Embryos (E6.5, E9.5 and El 1.5) were fixed in 4% 
paraformaldehyde/phosphate-buffered saline (PBS) overnight and dehydrated in 
methanol. One milliliter of 50% methanol/50% DMSO was added on ice, then 
0.25 ml of 10% Triton X-100 was added and incubated at room temperature for 
30 min. Embryos were then washed three times in PBT (PBS plus 0.1% Tween 
20), pre-hybridized for 1 h (67°C) then hybridized at 67°C for 4 days with 5.0 ug/ 
ml of each respective probe. Following hybridization, the embryos were washed 
twice in 2x SSC (300 mM NaCl, 30 mM sodium citrate, pH 7.0) at 70°C, three 
times in 2x SSC/0.1% CHAPS (3-[3-cholamidopropyl)dimethylamrnonio]-l- 
propanesulfonate) at 70°C, three times in 0.2 x SSC/0.1% CHAPS at 70°C and 
twice with KTBT (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 10 mM KC1, 1% 
Triton X-100) at room temperature. Embryos were blocked in 20% heat- 
inactivated fetal calf serum/KTBT for 3 h. Alkaline-phosphatase-conjugated 
mouse anti-DIG antibody (Roche) was added (1:1000 dilution) and allowed to 
react overnight at 4°C. The next day, the embryos were washed five times with 
KTBT and incubated overnight at 4°C. The embryos were washed twice in 
NTMT (100 mM NaCl, 100 mM Tris-HCl, pH 9.5, 50 mM MgCl, 0.1% Triton 
X-100) then a solution containing 3.5 ul/ml;7-nitrotetrazolium blue, 3.5 ul/ml 5- 
bromo-4-chloro-3-indoyl-phosphate in NTMT was added for color detection. 
This reaction was carried out in the dark and was stopped by addition of 4% 
formal saline.
Aldan blue/alizarin red staining
The embryos (E9.5 and El 1.5) were fixed in 90% ethanol, and prior to 
staining, skin and viscera were removed. Alcian blue solution (0.01% alcian 
blue, 3% acetic acid) was added to the embryos and left for 3 days. The embryos 
were rehydrated in increasing dilutions of ethanol. Embryos were then placed in 
1% KOH for 2 days to clear and then in alizarin red solution (0.001% alizarin 
red, 1% KOH) for 3 days. Embryos were washed with 1% KOH and stored in 
100%glycerol.
Immunohistochemistry and calcein labeling
Tibiae were removed from female chickens aged 1 day, 3 weeks and 2 years 
and E6.5 and E.9.5 embryonic chickens. The mineralized tissue was briefly 
immersed in 5% polyvinyl alcohol (Sigma, Poole, UK) and chilled in an n-
hexane freezing bath at -70°C [26]. In some cases, the tibiae were decalcified in 
10% EDTA at 4°C for up to 14 days before. Sections were cut (10 urn thickness), 
fixed in ice-cold acetone and stored at - 80°C until required. Immunolocalization 
of PHOSPHO1 was performed using a standard immunoperoxidase procedure 
which included an overnight incubation at 4°C with affinity purified antiserum 
diluted to 4 fig/ml of IgG in PBS containing 5% fetal bovine serum (FBS) or 4 ug/ 
ml of normal sheep IgG as control (Sigma). In some cases, DAB peroxidase 
substrate tablets containing cobalt chloride (Sigma) were used. All sections were 
mounted without counterstaining. The antiserum to PHOSPHO1 was raised in 
sheep against recombinant chicken PHOSPHO1 as previously described and shows 
specificity with avian tissues only [19]. For calcein labeling, 3- and 24-week-old 
female chickens were injected with 10 mg/kg calcein and culled by cervical 
dislocation 3 days after injection. The presence of calcein stain in sections of tibiae 
was visualized by fluorescence microscopy. Some sections were stained with 
hematoxylin and eosin or von Kossa using standard protocols to identify mineralizing 
regions.
Matrix vesicle isolation
Three-week-old chickens were culled by cervical dislocation and the tibias 
removed. The growth plate was dissected from the overlying and underlying 
tissue and diced into small pieces (1 mm3). Cartilage pieces were incubated at 
37°C in the presence of 0.1 % trypsin type II (Sigma) in HBSS (Hank's buffered 
salt solution) for 30 min. The tissue was washed in HBSS and incubated in 0.07% 
collagenase at 37°C for 3 h. The cell suspension was passed through a sieve 
(45 um) to remove remaining tissue fragments and spun (lOOOxg for 5 min) to 
pellet the cells. Supematants were subjected to differential centrifugation. 
Briefly, the supernatant from the chondrocytes was spun at 30,000xg for 20 min 
to remove sub-cellular debris and finally at 100,000 x g for 1 h to pellet MVs. To 
obtain primary chondrocyte cultures, cartilage pieces were digested by 
collagenase and hyluronidase as previously described [27]. Chondrocytes were 
seeded in T25 culture flasks at a density of 1 x 1Q6 cells/cm2 in Dulbecco's 
modified eagles medium containing 10% FBS, 2 mM L-Glutamine. Following 
cellular attachment, the cells were treated with or without ascorbic acid (100 ug/ 
ml) and cultured for up to 12 days (37°C, 5% CO2). When harvesting the cells, 
the monolayer was washed with HBSS and incubated in 0.07% collagenase type 
II solution at 37°C for 90 min. The mixture was then subjected to differential 
centrifugation as described above.
TNAP activity was assayed using the ALP bio-assay kit (Thermo Electron, 
Melbourne, Australia). MVs activity was determined by measuring the cleavage 
of />-nitrophenyl phosphate (pNPP) at 405 nm, pH 10.7. Total TNAP activity 
was expressed as nmol pNPP hydrolyzed/min/mg of total protein.
Immunoblotting
The resultant MVs were analyzed for the presence of PHOSPHO1 by immu- 
noblotting. LDS sample buffer was added to the MV lysate extracted from the 
primary chondrocyte culture, while MVs extracted directly from chick cartilage 
were lysed in lithium dodecyl sulfate (LDS) sample buffer prior to electrophoresis. 
Samples corresponding to 10 ug total protein were incubated at 70°C for 
10 min before loading. Samples were run on a 10% Bis-Tris NuPAGE gel and 
electroblotted to nitrocellulose, which were then blocked in 5% non-fat milk in 
Tris-buffered saline with 0.1% Tween 20 (TBST). The membranes were then
Fig. 2. (A) Immunohistochemical staining of the bone collar (arrows) and chondrocytes with affinity purified antibodies to PHOSPHO1 in a cross-section of a tibia 
from E6.5 chick embryo. (B) Immunohistochemical staining of longitudinal tibial section from E6.5 embryo showing positive staining is present in the bone collar of 
the mid-section of the diaphysis (arrows). The area delineated by the box is shown at higher magnification in (C) where the staining is present in the bone collar 
(arrows), periostea! osteoblasts (arrow heads) and chondrocytes (*). (D) Control longitudinal section of E6.5 chick incubated with normal sheep IgG. The bone collar 
(arrows) and chondrocytes (*) are unstained. (E and F) Hematoxylin and eosin-stained sections showing trabecularized morphology of the developing cortical bone in 
longitudinal (E) and cross-section (F) of E9.5 chick tibia. (G and H) Immunohistochemical staining of longitudinal tibial section from E9.5 embryo. Panel (H) shows 
the box in panel (G) at higher magnification. Staining is limited to the bone forming surfaces (arrows) and is not present on all mineralized bone surfaces. (I) von Kossa 
staining of mineral in longitudinal section of E9.5 chick tibia. Immunohistochemical staining of PHOSPHO1 in sections of tibia from (J) 1-day-old, (K) 3-week-old 
and (L) 2-year-old chickens and calcein fluorescence showing (M) mineralization within the periosteum and primary osteons of cortical bone in 3-week-old chick and 
(N) mineralizing surface of medullary bone in 24-week-old chickens. MB, medullary bone; CB, cortical bone. Staining within the cortical bone (J and K) was limited 
to the osteoid layer of the periosteum and the bone forming surfaces of the primary osteons (arrows) and mirrored that of the calcein fluorescence (M), with no staining 
present in the fibroblastic or osteogenic layers. No immunostaining was observed within the cortical bone of the adult (L). DAB peroxidase substrate tablets containing 
cobalt chloride giving a gray/black end product were used in B, C, G and H. Magnification bars represent 0.1 mm in A-I and 0.2 mm in J-N.
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probed with 2 ng/ml sheep-anti-PHOSPHOl antibody in blocking solution [19] 
and washed three times with TBST. Blots were then incubated with mouse anti- 
sheep/goat IgG-peroxidase (DAKO, Cambridgeshire, UK) diluted 1:2000 in 
blocking solution followed by three washes in TBST. The immune complexes were 
then visualized by enhanced chemiluminescence. Finally, the proteins on the blot 
were stained with India ink after alkali pre-treatment, as described by Sutherland 
and Skerrit [28]. Briefly, the membranes were washed in TBST before incubation 
with 0.2 M NaOH for 5 min. The membrane was then submerged in 10% India ink 




PHOSPHO1 mRNA expression during embryonic develop­ 
ment was investigated in the chick using whole-mount in situ 
hybridization, staining was seen in embryos incubated with the 
antisense oligonucleotides corresponding to PHOSPHO1 gene 
expression at the ossification centers of the long bones. No hy­ 
bridization was observed in any other tissues or in embryos 
incubated with the sense oligonucleotides (Fig. 1 A). PHOSPHO1 
expression began prior to E6.5 around the mid-shaft of metatarsi 
and by El 1.5 had spread to the ends of the diaphysis (Figs. 1B- 
D). The unmineralized cartilaginous ends of the bones remain 
unstained.
The temporal expression ofPHOSPHOl in relation to depo­ 
sition of mineral was also investigated in the chick embryos. 
Figs. IE and F show PHOSPHO1 staining of the front limb
bones (E9.5) and hind phalange (E 11.5), respectively. The entire 
diaphysis of the front limb bones appeared to be stained, whereas 
staining had a more restricted location within the diaphysis of the 
hind phalanges of the older mice. This developmental feature 
was confirmed by alcian blue and alizarin red staining. Between 
E9.5 and El 1.5, these bones consisted primarily of a 
cartilaginous matrix with alizarin red staining of mineral 
restricted only to a small region around the center of the bones 
in the front limb by E9.5 (Fig. 1G) whereas the phalanges at 
El 1.5 show a complete lack of mineralization (Fig. 1H). 
Immunohistochemical staining of frozen sections of tibia from 
embryonic chicks (E6.5 and E9.5) mirrored that of the in situ 
hybridization and revealed that the PHOSPHO1 staining was 
localized to the osteoid (bone collar) and associated periosteal 
osteoblasts within the mid-diaphyseal region (Figs. 2A-C). 
There were also indications that some chondrocytes within the 
rudiment also stained positively (Fig. 2C). At this developmental 
stage, the PHOSPHO1 stained osteoid and the matrix of the 
differentiating chondrocytes were not mineralized as assessed by 
von Kossa staining (data not shown). Control sections in which 
the primary antibody was substituted with normal sheep IgG 
showed no positive staining (Fig. 2D). By developmental stage 
E9.5, cortical bone formation had began and had a trabecularized 
appearance (Figs. 2E and F), which was distinct from osteonal 
bone present in post-hatch birds (Figs. 2J-L). PHOSPHO1 
staining was limited to the bone forming surfaces within cortical 
bone (Figs. 2G and H) and not on pre-existing mineralized 
surfaces as visualized by von Kossa staining (Fig. 21).
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Fie 3 (A 1) Immunoblot showing PHOSPHO1 expression in MVs isolated from the tibial growth plates of 3-week-old chicks. (B) Immunoblots examining 
PHOSPHO1 expression in MVs isolated from primary chondrocytes cultured in the presence or absence of 100 ug/ml ascorbic acid. (C) India ink staining of MV 
immunoblot demonstrating equal loading in each lane. (D) TNAP activity of MVs isolated from primary chondrocyte cultures.
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PHOSPHO1 in growing and adult bone
Strong immunoreactivity was observed at the periosteum 
and also the bone forming surfaces of the primary osteons 
situated within the cortical bone (Figs. 2J and K) of the 1-day- 
old and 3-week-old chicks. All osteons within the cortical bone 
of the 1-day-old chick were immunoreactive, whereas only 
those within the periosteal area of the 3-week-old bone were 
positive. Staining within the periosteum of the 1-day-old and 3- 
week-old chicks was limited to the osteoid layer and mirrored 
that of the calcein fluorescence (Fig. 2M), with no staining 
present in the fibroblastic or osteogenic layers. In the 3-week- 
old chicks, closed osteons were negative and staining was also 
absent from the endosteal surface and the cells within the 
marrow cavity. PHOSPHO1 immunostaining was also present 
on medullary bone surfaces (Fig. 2L) but not within the 
periosteum or osteons of a 2-year-old adult chicken. At this age, 
bone apposition has ceased and no mineralization within 
osteons or at the periosteal surface takes place. Mineralization 
in medullary bone of adult female birds was observed by 
calcein fluorescence (Fig. 2N).
PHOSPHO1 in isolated matrix vesicles
The presence of PHOSPHO1 was examined in MVs isolated 
from chick growth plate cartilage. Two forms of PHOSPHO1 
(30.4 and 28.6 kDa) were detected in MVs isolated directly 
from the tibial growth plates of 3-week-old chicks (Fig. 3 A) and 
from primary cultured chondrocyte cells (Fig. 3B). PHOSPHO1 
expression in the MVs isolated from the primary cells was 
found to increase with time in culture and appeared to be much 
greater in the presence of ascorbic acid after 12 days in culture. 
Equal loading of the samples was confirmed by India ink 
staining of the membrane (Fig. 3C). No overt signs of matrix 
mineralization were noted in these cultures. TNAP activity in 
the presence of ascorbic acid was found to double after 5 days in
culture and was 4 times that of the control after 12 days but was 
not found to alter significantly with time in the control cultures 
(Fig. 3D).
Discussion
In the embryo, bones begin as condensations of mesenchy- 
mal cells that act as models (anlages) for further development. 
In the developing long bone, capillary invasion of the perichon- 
drium coincides with a switch in perichondrial cell differenti­ 
ation to the osteoblast lineage. These cells secrete a primary 
bone collar, which is a thin layer of mineralized bone, lying 
around the outside of the mid-section of the bone. The bone 
collar maintains the structural integrity of the bone that is 
weakened by osteoblasts eroding the internal calcified cartilage 
scaffold. The ossification process begins at the mid-diaphyseal 
region and progresses towards the bone extremities [29,30].
PHOSPHO1 has previously been shown to be localized to 
mineralizing regions of chick bone [19] and has therefore been 
implicated in the generation of P; for mineralization. If this 
hypothesis is true, then developmental expression of PHOSPH01 
should precede the deposition of mineral and follow the same 
pattern. Whole-mount in situ hybridization indicated that PHOS 
PHO1 expression occurred prior to E6.5 and was present within the 
bone collar within the mid-shaft of the diaphysis of the long bones. 
This was confirmed by immunohistochemistry where both the non- 
mineralized bone collar and associated periosteal osteoblasts, 
which first appear at E6.5-7 [31], stained strongly. The matrix 
staining of PHOSPHO1 on bone forming surfaces may reflect the 
presence of the enzyme in osteoblast derived MVs, which are 
deposited within newly formed osteoid [32]. The expression of 
PHOSPHO1 preceded the mineralization of the osteoid which is 
known not to occur until E7.5 in the chick [29]. Furthermore, the 
appearance of PHOSPHO1 in the cartilage rudiment at E6.5 is 
coincident with chondrocyte hypertrophy in the mid-diaphysis [33] 




Fig. 4. Schematic representation of Ca2+ and Pi accumulation in MVs. BSP, bone sialoprotein; PCho, phosphocholine; PEA, phosphoethanolamine; PLC, 
pbospholipases C; A-C, annexin complex; Pj-T, phosphate transporter.
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expressed by hypertrophic chondrocytes prior to them mineralizing 
Iheir extracellular matrix [19].
By El 1.5, expression was observed over the entire length of 
the diaphysis. In addition, mRNA expression preceded the depo­ 
sition of mineral as revealed by alcian blue/alizarin red staining. 
The absence of PHOSPHO1 immunoreactivity on the surface of 
existing mineralized cortical bone is in accord with previous 
observations by us where PHOSPHO1 immunoreactivity was 
absent from terminally differentiated chondrocytes situated deep 
in the mineralized zone [19]. This suggests that PHOSPHO1 is 
required for the de novo formation of the inorganic phase but not 
for the continued crystal growth of hydroxyapatite. It is therefore 
likely that PHOSPHO1 has a pivotal role in first phase of the 
mineralization process during embryonic development.
By the time of hatching, the chick skeleton is essentially 
mineralized but continues to grow by periosteal apposition until 
adulthood. Expression of PHOSPHO1 was observed in all 
osteons within the cortical bone of the 1-day-old chick but only 
those situated in the periosteal region of the 3-week-old chick. 
This difference in PHOSPHO1 distribution reflects the vastly 
different bone apposition rates between the two ages of birds and 
is similar to TNAP protein localization, which has previously 
been shown to be present at the surface of growing osteons but 
absent in closed osteons where mineralization is complete [34]. 
Further compelling evidence that PHOSPHO1 plays a role in 
mineralization comes from the observation that it is present in 
medullary bone but not cortical bone of adult chicks. In adults, 
bone apposition has ceased and no mineralization at the 
periosteum takes place. However, medullary bone in adult 
female birds constantly undergoes remodeling [35] as illustrated 
by calcein fluorescence.
Previous studies by us have shown that 30.4 and 28.6 kDa 
forms of PHOSPHO1 exist in growth plate chondrocytes, 
corresponding to transcripts derived from alternative start sites 
in the PHOSPHO1 gene [19]. The amino acid sequences of both 
putative transcripts contain all three of the catalytic motifs 
found within the HAD enzyme superfamily [36], and so both 
forms are likely to be catalytically active. It is unknown whether 
each form has a distinct physiological significance. Both forms 
of PHOSPHO1 were found to be present in MVs providing 
strong evidence that PHOSPHO1 is involved in the first phase 
of the mineralization. Primary chondrocytes were cultured in 
the presence and absence of ascorbic acid. The addition of 
ascorbic acid was found to increase both PHOSPHO1 levels and 
TNAP activity in isolated MVs. Ascorbic acid is a known 
stimulant for osteogenesis and mineralization in vitro [37,38]. 
This suggests that PHOSPHO1 expression and TNAP activity 
are both influenced by the state of differentiation and may be 
controlled by similar mechanisms within growth plate 
chondrocytes.
Ca2+ and Pj are known to be present at high levels in MVs 
even before induction of mineral formation [39]. The action of 
PHOSPHO1 in MVs will contribute to the Pj generated, although 
the extent of this contribution is unknown. As well as its generation 
inside MVs, it is also clear that some P; is imported from the 
extracellular matrix with at least two types of P; transporter known 
to be present in growth plate chondrocytes [40-43]. The ambient
concentration of PI in the extracellular fluid is close to 2 mM [44]. 
This may be due to TNAP, which is GPI-anchored to the outer MV 
membrane [45], as its proposed role in the bone matrix is to 
generate the P; needed for hydroxyapatite crystallization [46-48]. 
However, TNAP has also been hypothesized to hydrolyze the 
mineralization inhibitor PP; [13] to facilitate mineral precipitation 
and growth [12,49,50]. It is therefore doubtful that the amount of P; 
released from MV lipids would be sufficient to increase the overall 
level of extracellular Pj. However, the local effect of PHOSPHO1 
within MVs may be sufficient to facilitate mineral formation. A 
schematic representation of this process is shown in Fig. 4.
In conclusion, PHOSPHO1 is expressed at the primary regions 
of ossification in developing embryonic bone prior to deposition 
of mineral and is thus likely to play a role in the initial events 
leading up to mineralization. We also show for the first time that 
PHOSPHO 1 is enriched in MVs. This study provides further 
evidence that PHOSPHO 1 expression is associated with skeletal 
mineralization and indirectly supports our hypothesis that PHOS 
PHOl is involved in generating P; within MVs for mineralization.
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